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Abstract
This thesis investigates the order and timing of changes in the splenic microarchitecture 
and the lifespan and kinetics of B cells and plasma cells during primary acute 
P. chabaudi infection, and the length of chronic P. chabaudi infection. Infected red 
blood cells can be seen in the spleen as soon as 1 hour post infection, alterations in the 
splenic microarchitecture begin at day 5 post-infection with the movement of dendritic 
cells and the merging of B and T cell zones. Macrophages and B cells of the marginal 
zone are lost from this location by day 10 post-infection, however there is no alteration 
in the location of red pulp macrophages. Large numbers of plasma cells can be seen in 
the spleen from day 8 post-infection, when they switch from IgM+ to IgG+. The 
adhesion molecule MAdCAM-1 is more widely expressed, although not on reticular 
fibroblasts or red pulp endothelial cells. The significance of these alterations, and the 
mechanisms responsible, are discussed. Chronic, subpatent parasitaemia in P. chabaudi 
infection is cleared by 3 months post-infection in C57BL/6 mice, and 2 months in 
BALB/c mice.
Most changes in B cell and plasma cell formation occur during the acute infection, and 
are resolved by 6 weeks post-infection. The number of B cells in the bone marrow is 
reduced, and plasma cell production in the spleen is high during acute infection. Plasma 
cell migration to the bone marrow is consistently lower in infected mice than naive 
mice. The majority of B cells and plasma cells produced throughout the acute and 
chronic infection are short-lived, with little evidence of production of long-lived cells.
B cell and plasma cell formation is still elevated at 12 weeks post-infection, indicating 
that B cells and plasma cells during this period may be maintained by continuous 
turnover rather than production of long-lived cells.
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Chapter 1
Introduction
Malaria today
Malaria is one of the most prevalent transmissible human diseases, with around 300 million 
infections and 1 million deaths annually, with the majority of those deaths being children 
between the ages of 6 months and 5 years living in endemic areas [1]. Endemic areas 
include sub-Saharan Africa, south east Asia and the Indian subcontinent, Central America 
and northern parts of South America (Figure 1 A). Of those areas, the highest transmission 
intensity is in central Africa (Figure IB). It is no accident that the countries most affected 
by malaria are some of the poorest countries in the world. Malaria is currently estimated to 
restrict economic growth by up to 1.3% per year [2], and is estimated to cost African 
countries up to $12 billion per year in lost GDP [3], even though the provision of mosquito 
nets is a cheap and easy way to reduce the incidence of disease [4].
History o f malaria
The name malaria comes from the Italian male d'aria or bad air, so called because of its 
association with noxious smelling swamp land that provided good breeding grounds for the 
mosquito vector. The disease acquired this name sometime in the 16th century, becoming 
maVaria in the 17th century and finally dropping the apostrophe in the early 19th century to 
become the word we know today. Despite this relatively recent nomenclature, malaria has 
plagued mankind for millenia. Physical evidence of malaria infection such as enlarged 
spleens of Egyptian mummies and anaemia in human bones, as well as literary references
A)
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Figure 1. World incidence of malaria (A) and transmission intensity (B)
From the World Health Organisation [5, 6]
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from Chinese and Mesopotamian medical writings, goes back to 4000 B.C. [7]. Modem 
thinking on the history of malaria suggests that Plasmodium vivax, Plasmodium ovale and 
Plasmodium malariae have been with us even longer, evolving with us as Homo sapiens 
became a distinct species [8]. Plasmodium falciparum is suggested to have crossed the 
species barrier from avian malaria relatively recently, dating back only as far as the 
beginning of agriculture. This is suggested both by its increased virulence in comparison to 
other species, and by comparing genetic identity to other malarial species [8,9].
As well as the current effects on the global population, malaria has also played a significant 
role throughout history. It is thought that the presence of malaria around Rome, and the 
Romans’ partial immunity to it, helped to protect the heart of the Roman Empire for many 
years [7]. The incidence of malaria decreased in Europe over time, in all likelihood due to 
increased use of the land leading to loss of mosquito breeding grounds, however it 
continued to exert an effect outside Europe. Malaria created a serious obstacle for armies 
in both World War I and World War II [7], and it is estimated that in the Vietnam war up to 
half of the American soldiers were at some point incapacitated due to malaria [10, 11]. 
Malaria has also been linked to post-traumatic stress disorder during conflict [12]. On a 
more positive note, two of the most effective current drugs to treat malaria, mefloquine and 
artemisinin, were both discovered during the Vietnam war. Given such profound effects of 
the disease during conflict, it is staggering to contemplate its effect on the lives of those 
who still live daily with malaria, and to think of the immense beneficial effect that control 
or eradication of the disease could bring.
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Biology o f malaria
The malarial disease is caused by a Protozoan parasite of the genus Plasmodium. The four 
species that infect humans are Plasmodium vivax, Plasmodium ovale, Plasmodium 
malariae and Plasmodium falciparum, with P. falciparum being responsible for the most 
severe forms of the disease. The Plasmodium parasite was first discovered in 1880 by 
Alphonse Laveran, with its cyclical development and rupture of red blood cells associating 
with fever being described by Camillo Golgi in 1885. Although non-erythrocytic forms 
were described in 1893, it was not until 1948 that they were shown to develop in liver cells. 
Transmission of the parasite by mosquitoes was demonstrated by Ronald Ross in 1897, and 
the fourth species of human parasites, Plasmodium ovale, was identified in 1922 with its 
life cycle completed in 1955 [7] (Figure 2).
Human malaria is only transmitted by female mosquitoes of the Anopheles genus, with 
Anopheles gambiae being considered the most efficient vector [13]. Other species of 
malaria can be transmitted by mosquitoes of a different genus, including Mansonia and 
Aedes. P. falciparum is capable of developing in Mansonia mosquitoes, however natural 
transmission with this vector has never been demonstrated (review [14]). On feeding, the 
mosquito injects an estimated 25-50 sporozoites per infective bite [15], however some of 
these remain in the dermis and some migrate through the lymphatic system to the lymph 
node, where they are degraded [16]. Sporozoites that reach the blood stream migrate to the 
liver where they undergo a 5-15 day replication phase in human malarias [15], 42-72 hours 
in rodent malarias [17], before releasing merozoites back into the blood. P. vivax and P. 
ovale can both persist as hypnozoites, a dormant phase in the liver, re-emerging months or 
years after clearance of blood-stage parasites as can the primate malaria P. cynomolgi
23
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Figure 2. Generalised Plasmodium life cycle in mammals
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[15,18,19], and the rodent malaria P. yoelii [17].
The merozoites invade red blood cells, mature through ring and trophozoite stages to 
become schizonts, which then rupture the red blood cells and release merozoites to invade 
more erythrocytes. It is this erythrocytic schizogony that is associated with the cyclical 
fevers that are the classical symptoms of malarial disease. It is interesting to note that 
while thousands of merozoites per infected liver cell are released compared to a maximum 
of 32 merozoites per erythrocyte [15,18], there are no clinical symptoms associated with 
liver-stage schizogony.
At some point during the erythrocytic cycle the formation of male and female gametocytes 
is triggered, and it is these forms that are transmitted back into the mosquito. The exact 
trigger for gametogenesis is unknown [15]. Zygote formation and maturation to ookinetes 
occurs in the mosquito midgut and may be aided by the mosquitos’ own defence 
mechanisms or metabolic waste products [20,21] (review [22]). Ookinetes then cross the 
peritrophic matrix and midgut epithelium where they become oocysts. These mature for 
approximately another 10 days, before releasing sporozoites 14-16 days after the blood 
meal, which migrate to the salivary gland for transmission to the mammalian host (review 
[23]).
Treatment o f malaria
The first effective treatment for malaria was ingestion of the bark of the cinchona tree, 
which comes from South America, of which quinine is the active ingredient. This was first 
introduced to England in 1650, although quinine as a drug was not produced until 1820. 
Despite the long history of malaria infections, it is likely that this remedy was not 
discovered sooner because in all probability malaria was introduced to South America from
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Europe. The introduction of malaria to South America by the slave trade is suggested by 
the lack of genetic mutations protecting against malaria in the native South American 
genome, as well as by the limited number of parasites and vectors in comparison to Asia, 
the purported origin of malaria [7,24]. The first synthetic anti-malarial drug was 
chloroquine, produced in Germany in 1937 [7]. It is still in use today, although growing 
parasite resistance has limited its use. Many other anti-malarial drugs have since been 
produced, including mefloquine (Larium™), atovaquone/proguanil (Malarone™), 
doxycyline, primaquine and artemisinin [25], however resistance to these is also 
continually developing.
Models o f malaria
The main barriers to the study of malaria in the human population are the availability of 
appropriate tissue samples, most studies having access only to peripheral blood, and the 
lack of control over timing of infection and re-infection. Although it is possible to plan 
careful studies around transmission seasons, there will always be certain questions that 
cannot be answered by a study of human infections.
The closest model system to humans is primates. The natural non-human hosts of malaria 
in Asia are largely primates of the genus Macaca, which are infected by P. inui inui, P. 
cynomolgi cynomolgi, P. c. bastianelli, P. coatneyi, P. i. shortii, P. knowlesi, P. k. edesoni, 
P. fragile, P. semiovale, P.fieldi (review [26,27]). Addition species in Asia, P. hylobati 
and P. eylesi are parasite of gibbons (Hylohates) [14]. In Africa, P. gonderi infects the 
Cercocebus (mangabeys) and Mandrillus (drill) primates, P. reichenowi and P. rodhaini 
infect the chimpanzees Pan satyrus and Pan troglodytes, whilst in South America P.
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brasilianum infects Cebus, Ateles, Saimiri, Lagothrix, Alouatta and Cacajao genii and P. 
simium infects the howler monkeys {Alouatta fused) [9,24].
P. knowlesi and P. cynomolgi in rhesus monkeys (Macaca mulatto) are the best studied 
primate malarias. The rhesus monkeys are not a natural host for these Plasmodia and 
therefore the infection is much more severe than in the natural host, P. knowlesi being a 
lethal infection in this rhesus monkeys [26]. P. knowlesi has been used as a model for 
cerebral malaria, whilst P. cynomolgi has been used as a model for P. vivax. These models 
do not exactly replicate the human infection however, rhesus monkeys show little sign of 
illness during infection even with high parasitaemias, despite the ultimately fatal outcome 
of infection [26]. Due to difficulties obtaining primate hosts and the ethical considerations 
involving the use of primates for experimentation, other models have been more widely 
utilised although some work on malaria in non-human primates continues [28].
Prior to the discoveiy of rodent malarias, the alternative models to primate malarias were 
avian malarias. The mostly widely used avian malaria model is P. gallinaceum in chicks, 
which was discovered in 1935 [29], others include P. relictum and P. cathemerium in 
canaries, P. lophurae in ducks P. circumflexum and P. elongatum in sparrows [17,29]. 
Rodent malarias were first discovered as sporozoites during dissection of Anopheles dureni 
millecampsi by Vincke and Comte d’Ursel in 1943. Entomological studies in the following 
year revealed that this mosquito fed on animals, and in 1948 malaria parasites were isolated 
from one of their their natural hosts, the African thicket rat Grammomys surdaster by 
Vincke and Lips [17]. Although Plasmodium spp. are thought to have been introduced to 
the Americas, the fact that they are found only in African, and not in Asian, rodents is 
intriguing. The first described was P. berghei, followed by P. vinckei in 1952, P. chabaudi
in 1965 and P. yoelii was described as a polytypic species encompassing three subspecies 
of P. bergheiAike parasites in 1974. P. yoelii was for a long time considered a subspecies 
of P. berghei, but is now classified as a separate species [17]. Work on these species was 
limited however, until the successful establishment of the firsts, d. millecampsi and G. 
surdaster colonies in 1963 [17]. Laboratory mice are permissive hosts for rodent malarias, 
however mice are not their natural hosts and therefore the course of infection can be 
expected to be somewhat different. For example, the number of schizonts produced per 
merozoite is reduced in mice compared to the natural host. Likewise, other vectors such as 
Astephensi may transmit malaria in a laboratory environment although invasion of 
sporozoites into the salivary glands is reduced [17].
In immunologically intact mice malaria can be either a lethal or a self-limiting infection.
P.yoelii 17XNL produces sterile immunity after a single infection, and a secondary 
infection of P.c.chabaudi (AS) produces a much reduced peak parasitaemia of only 1% or 
less infected erythrocytes [30] (Figure 3B). This is in contrast to human malaria, where 
repeated infections are required to produce immunity [18], and to the natural host, which 
has recurring recrudescences of parasitaemia throughout life [17]. In addition to the 
differing memory responses, higher parasitaemia is required to produce clinical symptoms 
of disease in mice than in humans [13]. Many aspects of malaria infection can however be 
studied perfectly adequately in laboratory mice.
Infections in the natural host would be more similar to human infection, however such 
work has been limited due to the difficulty of maintaining thicket rat colonies and the lack 
of reagents available. Even in the natural host, in an experimental environment infections 
are limited to less than 6 months, possibly due either to the lack of re-infection, or to this
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Figure 3. Diagrammatic illustration of a typical course of infection with 
Plasmodium chabaudi chabaudi (AS)
A) Primary infection with 105 pRBC in C57BL/6 mice
B) Secondary infection with 105 pRBC in C57BL/6 mice
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environment discouraging the development of liver hypnozoites [17]. For a thorough 
investigation of chronicity of infection, the natural host would still be the best. For 
example, temperature has been shown to affect many aspects of the malaria life cycle. The 
development of oocysts and sporozoite infectivity may be reduced if the temperature the 
mosquitoes are kept at is either too low or too high. Likewise, cold temperatures have been 
used to induce the development of exoerythrocytic schizonts, which may be hypnozoites 
[17].
The three main rodent malaria species used in laboratory studies today are Plasmodium 
chabaudi, Plasmodium yoelii, and Plasmodium berghei. These can be further divided into 
subspecies, for example Plasmodium chabaudi chabaudi and Plasmodium chabaudi adami. 
Of these species there are different strains such as P. c. chabaudi (AS), (AJ), (CB), (ER) and 
others [31]. Classification of malaria parasites has been difficult as species that we now 
recognise as distinct are difficult to distinguish under the microscope. The classical 
definition of a species is a group that is reproductively isolated yet, as Plasmodium sexual 
reproduction occurs in the mosquito vector, this is difficult to test. Early classification was 
further hindered by the fact that many isolates were in fact mixed infections of different 
species, as are most natural infections [17]. Much of the current classification comes from 
examination of isoenzymes, and it has been suggested that rodent malaria species are still in 
active evolution [17]. As the African landscape continues to change, geographical barriers 
may occur to hasten speciation.
Strains differ in virulence and in lethality, for example P.c.chabaudi (ER) being more 
virulent than P.c.chabaudi (AJ), which is in turn more virulent than P.c.chabaudi (AS)
[31]. Plasmodium berghei (ANKA) is used as a model for cerebral malaria [15]. Virulence
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also depends on the host, with P.c.chabaudi being a self-limiting infection in C57BL/6 
mice, but lethal in A/J mice, with resistance to death being associated with 4 major 
susceptibility loci (review [32]) [33-36]. Virulence is also affected by gender, specifically 
testosterone levels, with female mice being more resistant than male mice [37,38].
The model system used in this study is P.c.chabaudi (AS) in female C57BL/6 and BALB/c 
mice, the natural host being Thamnomys rutilans [17]. The course of infection in both 
mouse strains is almost identical, although BALB/c mice have an increased tendency to die 
at higher doses of infection (107 parasitised red blood cells, unpublished observations). The 
common infective dose used in our laboratory is 10s parasitised red blood cells (pRBC) and 
a typical course of parasitaemia in C57BL/6 mice is shown in Figure 3 A. Peak 
parasitaemia o f20-30% occurs around day 8 of primary infection with an infective dose of 
105 pRBC, around day 7 with an infective dose of 106 pRBC, day 9 for infection with 104 
pRBC, etc. [39]. Parasitaemia falls below detection limits around day 30 in P.c.chabaudi 
infection, with P.yoelii infections being eliminated earlier [40]. Chronic, low-level 
parasitaemia persists for some weeks before final clearance. In a secondary infection, 
parasitaemia becomes visible around day 5, with peak parasitaemia of less than 1% 
occuring around day 8, falling below detection limits around day 12 (Figure 3B) [41].
The immune system
The immune system can be divided into two parts, the innate immune system and the 
adaptive immune system. The innate immune system is considered to be the ancestral 
immune system, from which the adaptive immune system evolved. The main difference 
between them is that the responses of the innate immune system remain the same on
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subsequent encounters with the same pathogen. By contrast, the adaptive immune system 
is capable of memory responses [42].
The innate immune system is the first line of defence against foreign bodies. It consists of 
anatomical barriers (e.g. skin), physiological barriers (e.g. non-permissive temperature, 
gastric acid), phagocytes (e.g. macrophages), leukocytes (e.g. granulocytes and NK cells) 
and serum factors (e.g. complement, acute phase proteins, histamine and antibacterial 
proteins) [42,43]. The innate immune system works in concert with adaptive immunity, 
providing antigen presentation and cytokine signals. Conversely, the adaptive immune 
system helps the innate immune system, for example by antibody opsonisation of antigens 
for phagocytosis. The adaptive immune system can be subdivided into humoral (antibody- 
mediated) and cellular immunity. The components of the adaptive immune system are 
lymphocytes -  B cells and T cells.
There are two methods of distinguishing pathogens. The first is recognition of specific 
pathogen ligands or pathogen-related molecular patterns (PAMPs) by pattern recognition 
receptors (PRRs) such as protein kinase R, C-type lectins (review [44]) and Toll-like 
receptors (TLRs) [45]. The Toll receptor was first discovered in Drosophila by Hashimoto, 
Hudson & Anderson in 1988 [46]. TLRs were subsequently discovered in humans in 1997 
by Medzhitov, Preston-Hurlburt & Janeway [47], and recognise molecules such as bacterial 
endotoxin (LPS) [48], bacterial and viral DNA and RNA [45,49] (review [50]). Such 
receptors are considered to be the bridge betweeen the innate immune system and the 
adaptive immune system [51]. The expression of multiple TLRs and convergent signalling 
pathways allows for increased flexibility in the cell’s response, and cytokines produced by 
other cells may also modulate the expression of TLRs [50].
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TLRs recognise distinct molecular signatures from pathogens and form a basis for targeting 
specific immune responses to specific infections [45]. TLR ligation can induce dendritic 
cell maturation and up-regulation of the co-stimulatory molecules necessary to induce T 
cell activation [45]. Dendritic cell maturation can also be triggered by cytokines, however 
this is not full activation, and does not lead to full activation of T cells. PRR signalling is 
still required for priming of a T cell response [52]. Although TLRs are expressed on many 
different cell types, their function has been best studied in dendritic cells. Such studies are 
complicated however, because TLR function is not always conserved between human and 
mouse, expression patterns differ and not all TLRs are currently known to have functional 
homologues in the other species (Table 1) [45,53].
The other method of antigen recognition is recognition by cells of the adaptive immune 
system. Foreign antigenic peptides are recognised by T cells when the peptides are 
associated with self major histocompatibility complex (MHC) molecules, of which there 
are three classes. MHC Class I molecules are expressed on nearly every nucleated cell type 
and present antigens from inside the cell, while MHC Class II antigens are expressed only 
on antigen-presenting cells and present exogenous antigens that have been endocytosed 
[43]. The MHC is also referred to as the human leukocyte antigen (HLA) complex in 
humans, and the histocompatibility (H-2) complex in mice. MHC genes are present on 
chromosome 6 in humans and chromosome 17 in mice. They code for MHC Class I 
molecules of three major subgroups (HLA A, B, C in humans, H-2 K, D & L in mice) and 
MHC Class II molecules of 2-3 subgroups (HLA DR, DP & DQ in humans, H-2 A & E in 
mice) [43]. Ancestors of MHC molecules can be found as far back in evolution as worms, 
crustaceans and insects [42].
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Table 1. Expression of Toll-like receptors on dendritic cell subsets in human and mouse
Human blood 
mononuclear 
cells
Mouse spleen dendritic cells
CD1 lc+ pDC CD4+CD8+CD11 c+ CD8+CD4CDllc+ CD4*CD8'CD1 lc+ pDC
TLR1 +++ ++ ++ ++ ++ ++
TLR2 ++ +/- ++ ++ ++ ++
TLR3 +++ - + +++ ++ +/-
TLR4 ++ - + + + +
TLR5 ++ +/- +++ + ++ ++
TLR6 ++ + +++ ++ ++ ++
TLR7 + ++ ++ - + +++
TLR8 + - ++ ++ ++ ++
TLR9 - +++ ++ -i- i- -KI­ +++
TLR10 ++ +/- ND ND ND ND
t l r it - - +/? +/? +/? ND
Adapted from [45]
ND = not determined
Human TLR11 contains stop codons that are thought to produce a truncated, non-functional protein. TLR11 
is expressed on mouse dendritic cells, however its expression on specific subsets has not been defined.
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Proteins from within the cell are degraded in the proteasome into small peptides (8-13 
amino acids), transported into the endoplasmic reticulum by the TAP transporter protein, 
where they are loaded into the antigenic groove of MHC Class I molecules that are then 
transported to the cell surface for antigen presentation [43]. These MHC-peptide 
complexes are recognised by CD8+ T cells, which form a surveillance system throughout 
the body. Presentation of foreign (e.g. viral or tumour) antigens in the context of MHC 
Class I leads to the activation of CD8+ T cells and their differentiation into effector 
cytotoxic lymphocytes (CTLs). These then proceed to kill the infected cell by activation of 
death receptors or release of cytotoxic mediators such as perforin [43].
Specialised antigen-presenting cells (APCs) also express MHC Class II molecules. APCs 
take up foreign antigens and break them down to peptides of 13-18 amino acids in 
endosomes and lysosomes [43]. These endosomes then fuse with vesicles containing MHC 
Class II molecules, which are transported to the cell surface for presentation to CD4+ T 
cells. Recognition of a wide variety of antigens is achieved by a large number of alleles of 
MHC genes, with polymorphism mainly within the peptide binding site, which interact 
with T cell receptors that undergo gene rearrangment to generate diversity during T cell 
development [43]. Activation of naYve T cells, however, requires engagement of co­
stimulatory receptors by molecules on the surface of antigen presenting cells, as well as 
MHC-peptide complex recognition. Without appropriate stimulation by both of these 
signals, T cell anergy or apoptosis can be induced instead of activation (review [54]). 
Unfortunately for the immune response to malaria, mature red blood cells do not express 
any MHC molecules, therefore recognition of malarial antigens requires the phagocytosis 
of pRBCs, and the presentation of malaria antigens on MHC Class II molecules.
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MHC Class III molecules, while being encoded within the third region of the MHC, are 
secreted molecules that have no role in antigen presentation. They do however have roles 
in the immune response, as they include components of the complement pathway, tumour 
necrosis factor a  (TNFa) and lymphotoxin a  (LTa) [43].
Dendritic cells
Dendritic cells (DCs) are the only antigen-presenting cells responsible for presenting 
antigens to naTve T cells. B cells and macrophages are also capable of antigen presentation, 
however they present more efficiently to antigen experienced rather than naive T cells.
DCs are required to initiate an acquired immune response, and are also involved in the early 
innate immune response (review [55]) [56]. They are highly phagocytic cells that 
constitutively take up antigens, process them into peptides in the endosome and then 
present those peptides to T cells in the context of MHC Class II (review [54]). Different 
types of DCs are found throughout the body, some residing in tissues and others 
recirculating in the blood and lymphatic system [55]. When immature DCs in peripheral 
tissues encounter antigen they migrate through the blood and lymphatic system to 
secondary lymphoid organs, upregulating co-stimulation molecules and MHC molecules 
[55, 57]. Maturing DCs also undergo conformational changes, acquiring characteristic 
long, branching processes known as dendrites [55,58]. Mature DCs present antigen to T 
cells, thereby initiating the adaptive immune response [58,59].
Some DCs are resident within secondary lymphoid organs. In the mouse spleen, immature 
or non-activated DCs are found mostly in the MZ and red pulp, with a few mature DCs in 
the T cell zone [60,61] (Chapter 4, Figure 23). Upon encounter with antigen, DCs migrate 
into the T cell zone for antigen presentation to T cells [45,62]. DCs are defined by their
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expression of a panel of cell surface molecules, many of which are not exclusive to DCs 
and their expression levels may also alter depending on the activation state of the cell.
There are three main types of dendritic cells in mice, which are derived from 
haematopoietic precursors; the Langerhans cells in the skin, the conventional DCs and 
plasmacytoid DCs in the blood and lymphoid organs. Most types of DCs express the cell 
surface molecule CD1 lc (a integrin associated with fc integrin CD 18), although levels of 
expression vary. The main DC types can be further divided into subsets based on 
expression of other cell surface molecules, although it is not yet clear which of these 
subdivisions have functional significance [63].
Langerhans cells are present in the dermis, where they phagocytose antigens. Upon antigen 
encounter, they migrate to the draining lymph node where they present antigens to T cells 
[55]. Langerhans cells may have a role in immunity to malaria sporozoites which traffic 
through the skin. Whilst immunity to pre-erythrocytic stages may have a substantial effect 
on the development of blood-stage malaria, Langerhans cells have not been investigated in 
this thesis and will therefore not be discussed further.
There are two main subsets of conventional DC in the mouse spleen, distinguished by 
expression of CD8. These can be further subdivided by expression of CD4, CD205 and 
CD1 lb [64] (Table 2). Human DCs express CD4 but not CD8, and although they express 
varying levels of other surface markers, distinct populations comparable to mouse CD8+ 
and CD8' subsets have not yet been shown [64].
Some researchers have proposed that CD8+ and CD8' subsets are part of a single population 
at different stages of development [65], whilst others maintain they are discrete populations 
[66]. Both CD8+ and CD8' DCs can be derived from either common lymphoid or myeloid
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Table 2. Cell surface molecules used for identification of dendritic cell subsets
Cell
surface
molecules
expressed
Dendritic cell populations
Langerhans cells Plasmacytoid 
dendritic cells
Conventional dendritic cells
Human Mouse Human Mouse Human Mouse
CDllc +/- int +/low low low + - + + + +
CD8 - - - +/- + - -
CD4 + + +/- +/- - - +
CDllb - - - - + - - + +
CD14 - - - + - -
CD13 - +
CD33 - +
CD34 + - + +
Lin - -
IL-3Ra + - + - - +
CD1 + -
120G8 +
BDCA-2 +
BDCA-4 +
PDCA-1 +
CD45
RA
+ + +/- +
CD45
RB
+ - - -
CD45
RO
+ low
Ly6C + -
DEC-205 +/- + +
Langerin + +
Compiled from [49, 55,64,67,68] 
Blank spaces indicate not determined
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progenitors (review [64]) [69,70], although a larger number of myeloid progenitors mean 
that most DCs are derived from this line [69]. The CD8+ and CD8‘ DC subsets are, 
however, still considered to be separate developmental lineages (review [71]). The 
existence of regulatory DCs (CD1 lclow) has recently been described, although these are not 
yet well characterised and may be further subdivided into functionally distinct groups [53, 
72, 73].
There has been much debate as to whether subtypes of DCs are pre-programmed to induce 
a particular type of immune response [74,75] (review [76,77]). Recent work, however, 
has shown that DCs exposed to two different antigens concurrently can induce separate 
immune responses to each antigen [78]. Current thinking suggests that DCs are a very 
plastic population and that each subtype may induce any type of immune response, 
although certain DC subtypes may have a predisposition towards inducing a particular type 
of immune response. The immune response they induce is highly dependent upon the type 
and strength of signal they receive and the local cytokine environment where T cell 
activation takes place [79,80] (review [64]). This does not, however, preclude DC subsets 
from having differing roles in the induction of immune responses. For example, CD8+ DCs 
are thought to specialise in the phagocytosis of apoptotic cells and the cross-presentation of 
antigens from these cells [63].
In addition to antigen-presentation on MHC Class II molecules, APCs are also capable of 
presenting exogenous antigens on MHC Class I molecules, a phenomenon termed cross­
presentation. There are thought to be two mechanistic pathways for cross-presentation, one 
involving TAP-dependent transport of exogenous antigens out of endosomes and into the 
cytosol, the other involving fusion of phagocytic vesicles with vesicles containing MHC
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Class I molecules (review [81]). This process would enable the activation of CTLs specific 
for foreign antigens. Both the CD8+ and CD8' dendritic cell subsets of APCs are believed 
to be capable of cross-presentation, although only one subset (CDS'*) is suggested to do so 
constitutively [82]. Macrophages can also cross present antigens, however they do so with 
much lower efficiency than dendritic cells (review [54]).
Plasmacytoid DCs (pDCs) express low levels of CD1 lc and do not express CD1 lb (Mac-1, 
a  integrin partner of integrin). Human pDCs also express CD4, the CD45 antigen 
CD45RA and the IL-3 receptor CD123 (CDllclowCDl 1 b'CD4+CD45RA+CD 123+). Mouse 
pDCs do not express those molecules, but instead express the CD45 antigen B220 and the 
Ly6C molecule (CD1 lclowCDl lb'B220+Ly6C+). Human pDCs specifically express the 
cell surface molecules BDCA-2 (a C-type lectin) and BDCA-4 (neuropilin-1) (review [83]). 
Mouse pDCs can also be specifically identified by the monoclonal antibodies 120G8 or 
PDCA-1, the ligands for which are currently unknown [80].
pDCs can be derived from either common lymphoid or myeloid progenitors under the 
influence of the cytokine Flt-3 ligand (review [83]) [84]. pDCs are immature cells that 
become dendritic cells upon antigen encounter. They are less phagocytic and less efficient 
at antigen presentation to naTve T cells than conventional DCs, but can promote efficient 
proliferation of antigen experienced T cells [67] and induce a Thl like response 
characterised by IFNy and IL-10 production [85]. The average lifespan of pDCs outside the 
bone marrow is 2 weeks. pDCs are thought to be important in viral infections as they are 
the only cell type to produce high levels of interferon a  (IFNa, 200-1,000 times more than 
any other cell type) in response to viruses (review [67]) [80, 86]. In keeping with this 
function, they express only those TLRs which are required for viral DNA and RNA
recognition -  TLR7 and TLR9 [67], and are progressively lost during HIV infection [86]. 
Viral recognition, however, triggers differentiation as well as IFNa production [85], 
causing pDCs to become more efficient antigen-presenting cells and reduce production of 
IFNa [86]. Importantly the by-product of Plasmodium breakdown of haem, haemozoin, 
has been shown to activate DCs via TLR9 [87].
In addition to their production of type IIFN, pDCs have also been shown to require IFNa 
for full maturation and migration to the T cell zone of the spleen [80]. IFNa and |$, the 
type I IFNs, mediate a range of anti-viral effects. IFNa can enhance cytotoxicity of natural 
killer (NK) cells and CD8+ T cells, induce IFNy secretion and promote plasma cell 
differentiation [67]. Type I IFNs have also been proposed to act as immune regulators by 
modulating DC function, IFNy and IL-12 expression (review [80]). pDCs act 
synergistically with conventional DCs for the activation of NKT cells [88], but have also 
been suggested to induce the formation of CD8+IL-10 producing regulatory T cells (review
[89]). Pelayo and colleagues [68] recently described two distinct subsets of pDCs in mice, 
distinguished by expression (or lack of expression) of recombinase-activating gene-1 (Rag- 
1). Only Rag-1' pDCs produced IFNy and IL-12, whilst only T cells stimulated by Rag-1+ 
cells, however expressed IL-4. Rag-1' cells also produced higher levels of IFNa than Rag- 
1+ cells.
Dendritic cells have been shown to be important for immunity to liver stages of malaria
[90], but their role in blood stage infection is still being elucidated [91]. The role of 
plasmacytoid DCs in malaria infection is currently being investigated.
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There are three different types of T cells, a (3 T cells, yb T cells and NK T cells. The most 
numerous of these are the T cells, ap and yb T cells are named for the type of T-cell 
receptor (TCR) chains they express, either the TCR a  and p chains or the y and 6 chains, 
whilst NK T cells express both the TCR and NK cell-specific molecules NK1.1 and DX5. 
All types of T cell develop in the thymus gland.
ap T cells are divided into two subsets based on expression of the surface markers CD4 
and CD8 that, along with the associated signalling complex, are co-receptors for the T cell 
receptor. The T cell receptor binds to MHC-peptide complexes presented by APCs. TCRs 
are highly diverse and this diversity is one of the mechanisms the adaptive immune system 
uses in order to recognise a wide variety of antigens.
CD8+ T cells are also known as cytotoxic T cells (CTLs) in their effector phase. They 
circulate throughout the body looking for foreign antigens presented on MHC Class 1 
molecules. They are important for immune responses to intracellular pathogens, viruses 
and tumours. Upon activation they may develop into CTLs, release mediators such as 
perforin and granzymes, which kill target cells. They can also bind receptors on target cells 
(e.g. Fas ligand) to initiate apoptosis [42]. CD8+ T cells can be divided into two subsets 
(Tel and Tc2) based on the expression of different cytokines, however the functional 
significance of these subsets is unclear [92]. CD8+ T cells are crucial for immune 
responses against intracellular pathogens such as liver-stage malaria, Leishmania, and 
viruses [93, 94] (review [95-98]). Mature mouse and human RBC express only low levels 
of MHC Class I molecules, although immature reticulocytes express higher levels. 
Expression of MHC Class I molecules on reticulocytes is thought to cause reduced
virulence of reticulocyte preferring parasites (e.g. P. vivax, non-lethal P. yoelii) compared 
to erythrocyte preferring parasites (e.g. P. falciparum, lethal P. yoelii) [99]. In P. chabaudi 
infection, CD8+ T cells appear to have little role in controlling the acute peak of 
parasitaemia, although they do assist in the clearance of parasites later in the infection 
[100].
CD4* T cells are known as helper T cells because they help B cells to produce antibodies, 
through contact dependent receptor-ligand interactions (e.g. CD40 on B cells with CD40 
ligand on T cells) and production of cytokines. CD4+ T cells also stimulate proliferation 
and differentiation of cytotoxic T cells, and activate macrophages to produce reactive 
oxygen species (ROS). T helper (Th) cells can be broadly divided into two main subsets 
depending on the cytokines they produce (Figure 4). Whilst both subsets produce certain 
cytokines (e.g. GM-CSF, IL-2, IL-3), only Thl cells produce the inflammatory cytokine 
interferon y (IFNy) that is important for cell-mediated immune responses against 
intracellular pathogens (e.g. viruses, Leishmania) involving cytotoxic T cells and 
macrophages. Th2 cells produce IL-4, IL-5, IL-6, IL-9 and IL-13, which are important for 
B cell and antibody mediated responses, immune responses to extracellular pathogens (e.g. 
helminths) and allergic reactions. There is some overlap in function, as production of 
certain antibody isotypes are associated with Thl responses and Th2 cells can also activate 
macrophages [101,102]. Whilst immune responses tend to be dominated by one or the 
other type of response, they are not mutually exclusive. The malaria infection is 
characterised by an early Thl-type response followed by a switch to a Th2-type response 
[28, 103,104].
Recently a third set of CD4+ T cells have been described, IL-17 producing T cells, that are
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Figure 4. Development of Thl and Th2 responses
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induced by IL-23 [105]. These cells may be more closely related to Thl than Th2 cells, as 
they express low levels of IFNy, however IL-17 producing cells are highly pathogenic and 
are essential for the development of autoimmunity in the central nervous system. The 
origin of these cells is unclear, as IL-23 does not act on naYve T cells [106].
Regulatory T cells (Treg), which produce high levels of IL-10, are thought to act as negative 
regulatory cells to prevent pathological immune responses (review [107]). Treg cells can be 
further divided into “natural” regulatory cells, and inducible regulatory Th3 and Trl cells. 
“Natural” Tregs express the surface markers CD4 and CD25, as do activated T helper cells. 
Their defining characteristic is expression of the transcription factor FoxP3 (review [108]). 
The effects of regulatory T cells are associated with increased production of IL-10 and 
TGFp, anti-inflammatory cytokines that can inhibit activation of NK cells and 
downregulate production of TNFa and IFN-y [109,110]. Natural Tregs work in mostly non- 
contact dependent, antigen non-specific fashion.
During malaria infection, natural Tregs are associated with faster parasite growth, while 
depletion of Tregs protects mice from death upon infection with a lethal strain of P. yoelii, 
and reduces parasitaemia in P.berghei infection [107,111,112]. Whilst production of 
TGFp from day 5 post infection is associated with resolution of parasitaemia, earlier 
production (day 1) of TGFp is associated with lethality [110]. Natural Tregs have also been 
shown to have a role in Helicobacter, Listeria monocytogenes, Leishmania, Schistosoma 
and viral infection, including HIV [107].
Whilst natural regulatory T cells can produce both IL-10 and TGFp, inducible Tregs 
primarily produce either IL-10 (Trl) or TGFp (Th3) [113]. Trl cells may be again 
subdivided into those that produce only IL-10 and those that additionally produce Thl and
Th2 cytokines (IFNy and IL-5), though the significance of such a division is unclear [114]. 
Trl cells act in an antigen-specific fashion and are thought to function in the control of 
auto-immunity [115]. Th3 cells are induced in response to antigens in the digestive tract, 
and function in a mostly antigen non-specific fashion [115]. Different subsets of regulatory 
T cells have been suggested to be induced by different dendritic cell subsets [89]. CD8+ 
Treg (CD28+ and CD28' subsets), CD4+CD25‘ Treg, NK Treg and Breg populations have also 
been described, however little work has been done on these as yet [115,116].
B cells
The major function of B cells is antibody production. B cells develop in several discrete 
stages in the bone marrow, the first of which is a progenitor B cell (pro-B cell). B cell 
developmental stages can be defined by surface markers, or by the state of re-arrangement 
of their immunoglobulin genes [117-119] (Figure 5). Antibodies are made up of light 
chains and heavy chains. Antibody genes are made up of constant (C), variable (V), 
diversity (D) and joining (J) chain segments. The V, D and J chain segments must be 
correctly rearranged and expressed on the cell surface with the C chain segments during B 
cell development in order for viable B cells to be exported from the bone marrow (review 
[120]). Heavy chain DJ rearrangment occurs in pro-B cells, and a surrogate light chain is 
expressed at this stage. Once DJ rearrangement is complete, heavy chain V genes are 
rearranged to join the D and J chains. Once an in-frame rearragement of the heavy chain 
has occurred, this is expressed on the cell surface together with the surrogate light chain as 
the pre-B cell receptor, and the cell becomes a pre-B cell (review [121]). Pre-B cells 
undergo a number of proliferation cycles, then light chain rearrangment can occur and, as 
the cell becomes an immature B cell, IgM is expressed on the cell surface.
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Figure 5. Diagrammatic representation of the stages of B cell development 
B cells develop in the bone marrow from pro-B cells to pre-B cells to immature B cells, 
which are released into the circulation. Immature B cells develop from transitional type 1 
(Tl) B cells to transitional type 2 B cells (T2) in secondary lymphoid organs. T2 B cells 
develop into either marginal zone B cells or follicular B cells, either of which can form 
extra-follicular plasma cells or germinal centres. Germinal centre B cells can differentiate 
into memory B cells or long-lived plasma cells. Most long-lived plasma cells are found in 
the bone marrow, however some can also be found in the gut and the spleen.
B1 B cells reside in the peritoneal cavity. It is not known at what developmental stage 
these cells separate from the rest of the B cells (B2 B cells)
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The cell leaves the bone marrow as a transitional B cell, expressing high levels of IgM and 
low levels of IgD (IgMhighIgDdun) (review [122]). There are two types of transitional B 
cells, T1 and T2. T1 B cells are IgMhi8hIgDdun, non-cycling cells that are precursors of T2 
and mature B cells. T2 B cells express high levels of IgM, but also moderate levels of IgD, 
CD21 (complement receptor) and CD23 (FceRII) (IgMhi8hIgD+CD21+CD23+) and are in 
cell cycle (review [123,124]). T1 cells are an intermediate stage of development that 
cannot respond to antigen. These cells die upon BCR ligation, whereas T2 cells proliferate 
and differentiate [120]. Differentiation from T1 to T2 B cells occurs in approximately 48 
hours, with another 24-48 hours for differentiation into mature B cells to occur [123]. 
Mature, recirculating B cells express lower, variable levels of IgM, high levels of IgD and 
also express CD21 and CD23 (IgM+IgDhighCD21+CD23+). Development of mature B cells 
from T2 B cells requires BCR signals, allowing the cell to become long-lived and circulate 
through the blood, spleen, bone marrow and lymph nodes [124].
B IB  cells first appear during foetal life, before the more conventional B2 B cells can be 
found, express little IgD, but high levels of IgM and also express CD5. B1 B cells are 
found primarily in the peritoneal cavity, where they are a self-renewing population (review 
[125]). They respond primarily to carbohydrate antigens, and do so faster than 
conventional B cells. They are thought to be an earlier, ancestral form of B cell as they do 
not usually undergo class switching to IgG but produce low-affinity IgM antibodies. 
Expansion of B1 cells occurs during P.chabaudi infection, earlier expansion of B1 cells 
occurs in mice more resistant to infection [126] and mice deficient in B1 cells suffer more 
severe infections, associated with defects in the anti-malaria IgM response [99].
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Marginal zone (MZ) B cells are a different line of development, thought to differentiate 
from conventional B cells between the T1 and T2 B cell stages [57,127]. They express 
high levels of IgM but little IgD, express moderate levels of CD21 but low levels of CD23 
(IgMhlgh IgDdull/'CD21 +CD23k>) [128,129]. They share many characteristics of B1 cells in 
that they can also respond to carbohydrate antigens, have a lower threshold for activation 
than conventional B cells and as such are important for responses for T cell-independent 
type II antigens [130,131]. CD21/35 is the complement receptor CR1/2, and is expressed 
at higher levels on MZ B cells than on follicular B cells [129,132]. Through complement 
(C3 & CR1/2), polysaccharide antigens are specifically targeted to MZ B cells [131]. As 
well as their involvement in responses to T cell-independent antigens, MZ B cells can also 
participate in responses to T cell dependent antigens. Upon activation they migrate into the 
B cell follicle, can present antigens to CD4+ T cells, and are fully capable of forming 
germinal centres, undergoing somatic hypermutation and antibody isotype switching 
(review [129]) [133].
There are two methods of B cell activation, thymus dependent (TD) and thymus 
independent (TI) responses. TI responses can be further divided into two types (TI-I and 
TI-II). TI-I antigens include the bacterial cell-wall component lipopolysaccharide (LPS). 
TI-I antigens are mitogens that can activate B cells through receptors not including the 
specific B cell receptor (e.g. TLRs) [43]. Both TI-I and TI-II antigens can also generate 
memory B cells and secondary antibody responses [134, 135], although TI-II memory B 
cells may have a slightly different phenotype to TI-I and T-D antigen induced memory B 
cells [135]. TI-II antigens are multivalent antigens that activate B cells by cross-linking B 
cell receptors (BCRs) [136], however they activate only mature B cells and inactivate
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immature B cells [43]. TI responses are also not completely T-cell independent, as T cells 
or cytokines such as IFNy are still required for efficient proliferation and antibody class- 
switching [137, 138].
Most infectious agents include TD and TI antigens, with the majority of immune responses 
being to TD antigens. T cell help is mostly MHC restricted (i.e. cognate - the helping T 
cell must be specific for the same antigen presented by the helped B cell) and mediated by 
effector T cells. It requires both cell-contact, the interaction of CD40 and ICOS ligand 
(ICOS-L) on B cells with CD40 ligand (CD40L) and ICOS on T cells, and cytokine 
production (e.g. IL-4 & IL-21) (review [136]) [43, 139]. In certain conditions, however, T 
cell help may be non-cognate or bystander without involvement of the B cell receptor [139, 
140]. Although germinal centres may form in the absence of cognate help, T cell help is 
required for the exit of cells from germinal centres and prevention of apoptosis [141].
TD antigens bind to the B cell receptor (BCR), which is part of a complex of molecules 
including CD 19, CD21 and CD81. Any signal received through the BCR is modified and 
amplified by the co-receptor complex, and the co-receptor complex is required for correct 
formation and progression of the germinal centre reaction [142] (review [143]). Antigen 
binding leads to increased expression of MHC Class II and T cell co-stimulatory molecules 
on the B cell surface. The T cell receives signals from the MHC Class II and co­
stimulatory molecules on the B cell and expresses its own co-stimulatory molecules. Either 
BCR or co-stimulatory signals from activated T cells can activate B cells to proliferate, and 
the BCR can bind either membrane-bound or soluble antigen [144, 145]. T cell derived 
cytokines (e.g. IL-4, IL-6), however, are also required for full B cell activation and 
germinal centre formation [144]. Germinal centre formation is reduced, although not
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completely abrogated, in IL-4'7' mice [146], and paradoxically enhanced in a secondary 
response in IL-4'7’ mice [147], possibly indicating more of a regulatory role, rather than an 
essential requirement, for IL-4 in germinal centre development.
Activated B cells proliferate then follow one of two further developmental pathways. Some 
move straight to antibody production, producing low-affinity IgM antibodies (i.e. 
extrafollicular plasma cells), but the majority of these cells are short-lived [148,149] 
(review [150]). Whilst both early antibody-producing cells and germinal centre cells may 
be derived from the same proliferating cell, most activated B cells enter the germinal centre 
pathway of development [151].
Initiation o f immune responses
Primary T and B cell responses are not initiated at the site where the antigen enters the 
body. Instead dendritic cells, as part of their activation process, migrate away from the site 
of antigen encounter to the secondary lymphoid organs, the draining lymph nodes and 
spleen [152] (review [55]). Here they can interact with antigen-specific T cells and B cells, 
causing their activation, proliferation and differentiation into effector cells. Effector T cells 
migrate out of the secondary lymphoid organs, towards the site of antigen encounter. 
Effector B cells (i.e. plasma cells) produce antibodies that circulate through the blood 
stream. Plasma cells also migrate to the bone marrow, which has a larger capacity for 
supporting long-lived plasma cells than the spleen. Migration is controlled primarily by 
upregulating and downregulating receptors for certain signalling molecules, thereby 
altering the cell’s responsiveness to tissue-specific signals (review [153]).
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Chemokines
Chemokines are small, 8-14 kDa secreted proteins that are involved in cell trafficking and 
migration. Four subtypes of chemokines have been identified, based on the number and 
spacing of cysteine residues -  C, CC, CXC and CX3C, CC and CXC being the major ones 
(review [154]). They play a crucial role in the formation of secondary lymphoid organs 
during ontogeny, and in the migration of all lymphocytes throughout the body. Chemokines 
act by attaching to the extracellular matrix and forming signal gradients that allow several 
different cell types to respond to the same signal. The chemokines CXCL13 (binds 
CXCR5), CCL19 and CCL21 (bind CCR7) are important for formation and maintenance of 
the splenic microarchitecture (review [155]). Chemokines are also important in ongoing 
immune responses, e.g. controlling the migration of dendritic cells into secondary lymphoid 
organs and the organisation of germinal centres [56,156-159].
Many different cell types can produce chemokines, including dendritic cells and stromal 
cells. Some chemokines are expressed constitutively, others can be induced in an immune 
response to allow cells to infiltrate inflammatory sites. Alterations in the expression of 
chemokine receptors allow cells to home to specific sites at different stages of 
development. For example, cutaneous memory T cells express CCR4 for homing to the 
skin, whilst plasma cells express CXCR4 for homing to the bone marrow (review [154]) 
[160]. At least 40 chemokines have now been described, although not all of their receptors 
and mouse/human homologues have been identified (review [161]). The role of 
chemokines in migration is the best characterised, however other roles for chemokines are 
beginning to be elucidated, for example chemokine receptors have been suggested to act as 
PRRs in co-operation with TLRs (review [45]). Their receptors have also been shown to be
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crucial in infection with HIV, virus tropism being determined by chemokine receptor 
expression (review [162]).
Tumour necrosis factor a  and lymphotoxin
The cytokines tumour necrosis factor a  (TNFa), lymphotoxin a  (LTa) and lymphotoxin p 
(LTp) are crucial for the correct formation of the splenic microarchitecture [163]. The 
relative importance of each cytokine in the formation of splenic architecture is difficult to 
decipher. Splenic formation still occurs in the absence of all three of these cytokines, 
indicating that they are not required for splenic ontogeny, however the microarchitecture of 
the spleen is radically altered in mice lacking all three cytokines, and to a lesser extent in 
mice lacking only one of these cytokines [164].
The most common form of TNFa is the secreted form, however it also exists in a 
membrane bound form anchored to the cell membrane by a hydrophobic domain [165]. 
Lymphotoxin is a trimer, made up of a combination of subunits a  and p. The cytokine 
referred to as LTa is the 03 form which is soluble (review [166]). LTp is in fact LTa,p2, is 
membrane bound by the p subunit [165], and LIGHT is another, membrane bound, member 
of this cytokine family, whose role in the formation of the splenic microarchitecture is as 
yet unknown [121]. LIGHT may have a role in autoimmunity [167], allorecognition and 
tumour regression (review [168]). The lymphotoxin, TNFa and LIGHT molecules and 
receptor combinatons are illustrated in Figure 6, and their signalling pathways are shown in 
Figure 7.
TNFa, LTa and LTp are each expressed by several different cell types. TNFa is primarily 
expressed by macrophages, whereas LTa and p are mainly produced by T cells, B cells and 
NK cells [165,169]. This production may be constitutive, but is more often induced upon
Figure 6. Diagrammatic representation of the subunit combinations and the ligand- 
receptor combinations of TNFa, lymphotoxin and LIGHT.
LTa ( ■ ) and p (■ ) subunits combine to form LTa3, LTa,{32, LTa2p, and possibly LTp3 
TNFa, lymphotoxin and LIGHT bind to the LTp receptor ( ), TNFRI ( ■ ), TNFRII ( ■ ) 
and HVEM ( )
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Figure 7. Diagrammatic representation of TNFa, lymphotoxin and LIGHT signalling 
pathways
LTp ( ■ ), LIGHT ( ■ ), TNFa ( ■ ) and LTa ( ■ ) are represented with the LTpR ( ■ ) and 
TNFRI ( ■ )
Downstream pathways of the LTpR ( ■ ) and TNFRI (■ ) are also represented, as are 
chemokine receptors CXCL13 ( ) and CCR7 ( ■ )
TNFa and LTa induce CCL19 and CCL21 expression by stromal cells through the NFkBI 
pathway, while LTp induces CXCL13 expression through the NFkB2 pathway
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activation by mitogens, anti-CD3 (T cells), antigen or IL-2 (T and NK cells) [165]. 
Approximately 60% of LTp expression in the spleen is on B cells (review [170]), and 
expression of LTa on B cells but not on T cells, is required for generation of follicular 
dendritic cell (FDC) networks and formation of B cell follicles [171].
There are three receptors for these cytokines, TNFRI (p55), TNFRII (p75) and LTpR.
TNFa signals through TNFRI and TNFRII as does LTa. Many of the in vivo effects 
ascribed to TNFa may therefore be caused by LTa [172], and there is functional 
redundancy between the two [173]. LTc^pi binds TNFRI and TNFRII, but expression is 
limited and the biological function of this form has not been defined. Likewise, LTp3 has 
never been described (review [174]). LTp and LIGHT both bind to the LTpR, and both 
LTa and LIGHT can also bind to the Herpes virus entry mediator (HVEM), expressed on T 
cells, which is thought to be a co- stimulatory T cell molecule, but has also been suggested 
to be a negative regulator of T cell responses [168,175].
The receptors for these cytokines are expressed on stromal cells [176] (review [154]). They 
are also expressed on other cells of the immune system, however this is not relevant for 
maintenance of splenic microarchitecture. Upon receptor-ligand interaction, the stromal 
cells secrete chemokines which form a gradient that is ultimately responsible for formation 
of the splenic microarchitecture. TNFa and LTa, through TNFRI, induce the production of 
CCL19 and CCL21 while LTp-LTpR interaction induces the expression of CXCL13 [177]. 
The receptor for CCL19 and CCL21 is CCR7, which is expressed on T cells, dendritic 
cells, follicular dendritic cells, marginal zone macrophages and lymphatic endothelium 
[154,178,179]. There are actually two forms of CCL21, differing by a single amino acid. 
However, they both bind the same receptor so the functional significance of the two forms
is unclear [161]. The receptor for CXCL13 is CXCR5, which is expressed on follicular 
dendritic cells, a subset of T cells, follicular B cells and marginal zone B cells [154,155, 
158].
Whilst the TNFRI and LTpR signalling pathways appear to act synergistically for 
formation of B cell follicles, T cells zones and FDC networks, at other times they act 
antagonistically. For example, LTp signalling is required for the presence of the marginal 
zone, however in the absence of TNFRI or CXCR5 signalling the marginal zone is enlarged 
[180,181]. Signalling through TNFRI is also required for the expression of MAdCAM-1 
on the sinus endothelium [181], but T and B cell LTp knockout mice have increased 
expression of MAdCAM-1 over the splenic white pulp [170].
Secondary lymphoid organs
Lymph nodes are made up of three concentric regions -  the outer cortex, the central 
paracortex and the inner medulla (Figure 8A) [43]. The cortex contains the B cell follicles, 
while the T cells reside in the paracortex. The medulla consists of medullary cords and the 
medullary sinus, and contains mostly macrophages and plasma cells (review [163]).
Lymph entering the lymph node drains into the marginal sinus at the edge of the lymph 
node, between the cortex and the capsule. It then filters through the lymph node and drains 
into the efferent lymphatic vessel. Blood enters through the lymphatic artery and drains 
through the lymphatic vein. Unlike the spleen, lymph nodes have a closed circulation in all 
species [182], therefore antigen can only enter via the afferent lymphatic vessels [43]. B 
cells and T cells may enter the lymph node by migration through high endothelial venules 
in the paracortex, next to the junction with the cortex. They then traffic through the 
paracortex and medulla, exiting through the efferent lymphatic vessel. Dendritic cells are
Figure 8. Structure of the spleen
A) Gross structure of lymph nodes showing cortex, paracortex and medulla. 
Reproduced from [43]
B) Gross structure of the human spleen showing red pulp and white pulp. Reproduced 
from [43]
C) Microarchitecture of the spleen showing B and T cell zones, germinal centres, 
marginal zone and extrafollicular foci of plasma cells
61
centers
CjtpMlIc
CtHK'X
(terminal
center*
l\ Irm pliocytcs 
Lymphatic artery
Lymphatic vein
Efferent lymphiie 
vessel
Afferent 
hntphatie _
Medulla flt \esse l*  (terminal
B h iiip hocytes
Purt capillary 
vcnulr
Primary 
lymphi >nl
foffide
< apsule i . i iw  section post* 
capillary venule
Red pulp
Primary 
follicle
Marginal 
zone
Periarterial 
lymphatic 
sheath (PALS)
Germinal center 
Artery
Capsule
Vascular
White pulp
62
3325
c Microarchitecture of the spleen
Marginal 
zone
•  2 populations of 
macrophages
•  Marginal 
zone B cells
•  Some 
dendritic 
cells
Germinal 
centre
•  Somatic 
hypermutation
# Affinity selection
Central
arteriole
T cells
•  Support B 
cell activation
Extrafollicular foci of 
antibody-containing 
ceils
•  Proliferating 
plasmablasts
•  Antibody secreting 
plasma cells
Follicular B cells
•  Naive
•  Recirculating
63
thought to enter through the lymphatic system, and transit through the paracortical cords for 
encounters with T cells (review [163]).
The spleen is a secondary lymphoid organ composed of two main regions, the red pulp and 
the white pulp, which can be readily distinguished (Figure 8B) [43]. The white pulp is 
centred around the central arteriole, and is divided into the inner T cell zone and the outer B 
cell follicle, which are collectively known as the periarteriolar lymphatic sheath (PALS). 
The outer surface of follicles are separated from the red pulp by the marginal zone (Figure 
8C). The architecture of human and rodent spleens differs somewhat, in that the T cell 
zone does not form such a complete ring around the central arteriole in humans as it does in 
rodents, and more than one arteriole may run through the same follicle [183]. There are 
also functional differences between the species, for example the mouse spleen is an 
erythropoietic organ, while human erythropoiesis predominantly occurs in the bone marrow 
[183]. Splenomegaly in mouse malaria is largely due to increased erythropoiesis [184], 
with a 20-30-fold increase in the number of splenic erythroblasts during malaria infection 
[185].
The marginal zone region also differs between the two species. In rodents the marginal 
zone contains two rings of specialised macrophage types, an inner ring of marginal 
metallophilic macrophages (MMM), and an outer ring of marginal zone macrophages 
(MZM). Marginal zone B cells, which derive from a separate lineage from follicular B 
cells, are closely associated with MZM in the outer ring of the marginal zone (see Figure 
29; [186]). Marginal metallophilic macrophages are not present in the human spleen, at 
least not in the marginal zone [183]. Staining for sialoadhesin (CD 169 in the mouse,
64
expressed on MMM) however, picks up macrophages surrounding sheathed capillaries in 
the perifollicular zone.
The perifollicular zone is a region outside the marginal zone that is sometimes identified as 
part of the marginal zone, however it contains a high concentration of erythrocytes [183]. 
Neither the perifollicular zone nor the sheathed capillaries are present in rodent spleens. 
Interestingly, the centre section of the sheathed capillaries is surrounded by two layers of 
macrophages, the inner of which is sialoadhesin negative [183]. It is possible that the 
macrophage populations found in the marginal zone of the rodent spleen are the same cells 
surrounding the sheathed capillaries in the perifollicular zone of the human spleen, but this 
could only conclusively be tested by a functional study on these cells. It has been 
postulated that the perifollicular zone in humans serves much the same function as the 
marginal zone in rodents [183].
The exact path of blood circulation through the spleen is unclear. Both human and rodent 
spleens contain splenic cords and sinuses, however there are some structural differences 
which may affect circulation. There are areas where blood is contained within endothelium 
and areas where is is not in human and rodent, with a network of fibroblasts that may tend 
towards being contractile myofibroblasts that aid in circulation. Blood enters the spleen 
through the central arteriole, which in rodents opens out into the marginal zone and red 
pulp. The rodent spleen is described as having both “open” and “closed” circulation. The 
red pulp is made up of irregularly shaped blood vessels, the splenic sinuses, and the cell- 
filled spaces between them, the splenic cords, which form the “closed” and “open” portions 
of the splenic circulation respectively [183,187].
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The splenic cords are composed of a network of fibroblasts supporting B and T cells, 
erythrocytes, thrombocytes, granulocytes and plasma cells. The central arteriole opens into 
the splenic sinus, at the inner edge of the marginal zone. Here these cells can interact with 
the blood, which then drains into the splenic vein. Branches from the central arteriole carry 
blood through the marginal zone to the red pulp cords, and empty out into the cord spaces. 
Blood then drains back into the sinuses through slits in the sinus walls [183]. The arterial 
system in the human spleen is more elaborate than in the rodent spleen, and contains 
structures such as the sheathed capillaries which are entirely absent in rodents.
Nevertheless, blood also opens out into the splenic cords and perifollicular zone, where it is 
no longer constrained within an endothelial layer but moves through a fibroblastic network 
to re-enter the splenic sinuses [183].
Splenic microarchitecture
B cell follicles are mostly made up of recirculating, mature B cells. On encounter with 
antigen germinal centres are formed within follicles, where B cells undergo somatic 
hypermutation and affinity selection (Figure 8C) [188]. Cells exiting the germinal centre 
reaction then differentiate into plasma cells, or memory B cells in the MZ. The marginal 
zone contains two populations of macrophages, marginal zone B cells and memory B cells. 
The marginal zone macrophages (MZM) are located on the outer rim of the MZ, closest to 
the red pulp, and interact with marginal zone B cells. The marginal metallophilic 
macrophages (MMM) are located on the inner edge of the MZ next to the white pulp. The 
sinus lining endothelial cells lie between the two populations [186]. Mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1) is expressed on the sinus-lining endothelial cells in the 
marginal zone [189], The role of MZM and MMM in infection is thought to be mostly
phagocytosis of pathogens (review [190]), however they have been shown to produce IFNa 
in response to viral infection [191].
Follicular dendritic cells
Follicular dendritic cells (FDCs) are present within B cell follicles and have numerous 
dendrites that when associated with immune complexes are known as iccosomes. Little is 
known about these cells, which are not true dendritic cells, are not phagocytic and do not 
present antigens to naYve T cells (review [192]). Their origin is uncertain, they have not 
been thought to be of hematopoietic origin, as they are radio-resistant and have several cell 
surface molecules in common with fibroblasts (review [193]), however recent work has 
found donor-derived FDCs after adoptive transfer [194], and derived FDC-like cells from 
monocyte precursors [195]. They do not express MHC Class II molecules on their surface, 
although they do bind microvesicles containing MHC Class II and other membrane-bound 
proteins, and therefore cannot present antigens directly to T cells [196].
FDCs activate B cells, inducing proliferation and preventing apoptosis and are required, 
along with T cells, for germinal centre formation [197,198]. They bind antigen-antibody 
complexes on their surface, which provide a basis for affinity maturation of germinal centre 
cells, and express other co-stimulatory molecules for B cell activation [199,200].
Although the role of FDCs in the germinal centre reaction and the maintenance of memoiy 
has been questioned, mice lacking immune complexes on FDCs still have severely reduced 
antibody responses (review [192]) [201]. In addition to presenting antigen on immune 
complexes, FDCs also secrete cytokines such as IL-6 and IL-15, which induces antibody 
production and enhances terminal differentiation of B cells [192,202]). Finally, FDCs can
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retain antigen-antibody complexes on their surface for months, and may therefore be 
important in maintaining antigen-dependent memory cells (review [192]).
Germinal centres
Antigen entering the secondary lymphoid organs from the blood encounters B cells in the 
marginal zone. Upon activation, MZ B cells migrate into the B cell follicle and may 
transport antigen to FDCs [203]. Both MZ B cells and activated follicular B cells can 
interact with antigen-specific T cells to form either germinal centres (GCs) or plasma cells, 
although whether MZ B cells or follicular B cells do so faster is debatable [121,204]. 
Germinal centres become visible in B cell follicles from day 4 after antigen exposure [151]. 
Germinal centres are formed from as few as 3 B cells, which undergo rapid proliferation, 
with a cell cycle time of approximately 6-7 hours (review [188]) [205]. They fill the centre 
of the B cell follicle within 3-4 days of antigen exposure, pushing the follicular B cells out 
to form a follicular mantle, then they divide into two zones, the dark zone and the light 
zone [205].
The dark zone contains the proliferating centroblasts, while the light zone contains the non- 
proliferating centrocytes that are undergoing selection on the basis of their affinity for 
antigen held on follicular dendritic cells (review [188]). Selection requires the centrocytes 
to be activated through the B cell receptor -  i.e. to compete for antigen binding with 
antibody in immune complexes, eventually replacing this antibody with higher affinity 
antibody (review [206,207]). Centrocytes may also internalise some of this antigen and 
present it on MHC Class II molecules in order to interact with Ag-specific T cells, as a 
requirement for memory B cell survival [208].
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The classical model of germinal centre reactions is that cells undergo several cycles of 
centroblast division and mutation in the dark zone, followed by centrocyte selection in the 
light zone and differentiation into high affinity plasma cells or memory B cells. However, 
the spatial separation of these two processes in germinal centres of the spleen has been 
questioned. It has been suggested that the separation of centroblasts and centrocytes is 
temporal rather than spatial (review [209]). In any case, the dark and light zone structure is 
no longer seen by 3 weeks after antigen exposure [205], although germinal centres may still 
be visible up to 100 days after immunisation [210].
The processes that occur in the germinal centre; somatic hypermutation, affinity maturation 
and isotype class-switching, are well characterised. Somatic hypermutation is the mutation 
of antibody variable (V) regions in centroblasts in order to produce cells of differing 
affinity for antigen (review [211]). Whilst this mutation is specifically directed at the 
variable regions, and does not involve the constant regions, base-pair substitutions are 
random [208]. This allows for production of specific antibodies to any antigen, however it 
also necessitates the death of many centrocytes producing high affinity self-reactive 
antibodies (review [212,213]). Somatic hypermutation can first be seen 8 days after 
immunisation and peaks at 14 days post-immunisation [151].
Affinity maturation is the selection and survival of those centrocytes that have greatest 
affinity for the antigen bound to follicular dendritic cells (review [214]). Although the 
germinal centre reaction is necessary for these processes to take place, some affinity 
maturation continues after the germinal centre reaction has finished [215]. Antibody 
affinity has been shown to remain high for up to 12 months after intra-muscular
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immunisation, although affinity declines over the same time period after oral immunisation 
[216].
Antibody isotype switching from IgM to IgG, IgA or IgE commonly takes place during the 
germinal centre reaction, however it can also occur in extrafollicular foci of plasma cells 
[151]. Isotype switching often occurs with affinity maturation during the germinal centre 
reaction, however it is also possible for isotype switching to occur without affinity 
maturation and vice versa (review [217]). Different antibody isotypes are defined by their 
Fc portion, which enables them to perform different functions. For example IgA is 
produced mostly at mucosal surfaces, IgE is involved in allergic responses (review [218]), 
IgD is mostly found bound to the cell surface, where it functions as part of the B cell 
receptor (review [219]), and IgG is the only isotype to be secreted across the placenta 
(review [220]).
IgM is the first class of antibody to be produced during a primary immune response as it is 
the “default” isotype that is expressed by newly formed B cells. “Natural” antibodies, that 
are germline-encoded and are produced by a host that has never been exposed to antigen, 
are also of the IgM isotype. IgM is thought to be specifically involved in immune 
responses to bacterial infection, and may also be involved in immune responses to viruses 
[221].
IgG is the most abundant antibody isotype in the serum, approximately 80%, and in most 
cases is the isotype produced after antibody class switching. IgG can be divided into 
several subclasses -  IgG 1-4. IgG2 can be further subdivided into IgG2a and 2b in mice, 
while IgG4 exists in humans but not in mice [222].
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The different subclasses each have different activities, e.g. human IgG3 is the most 
effective IgG subclass for activating complement, whilst IgGl and IgG3 are the most 
effective at mediating opsonisation [43].
Human and mouse antibody isotypes differ in IgG subclasses, the functions of different 
subclasses do not exactly correspond. Human IgG2 is thought to be equivalent to mouse 
IgG3, and human IgGl and IgG3 to mouse IgG2a and IgG2b [223]. Different cytokines 
have been implicated in the selection of different antibody isotypes, e.g IFN-y is thought to 
be required for switching to IgG2a and IgG3 in mice [138,224], IL-4 for switching to IgGl 
[225], IL-4, IL-13 and CD40 for switching to IgE (review [218,226]). Isotype switched 
germinal centre cells and plasma cells become visible from 6-8 days after immunisation 
[151,227].
Plasma cells and memory B cells
Cells that survive the germinal centre reaction become either plasma cells or memory B 
cells. Some long-lived plasma cells are retained in the spleen, however the spleen has a 
finite capacity to support plasma cells [228]. The majority migrate to the bone marrow, 
which can support a larger number [229] (review [230]). In this location they may persist 
for life [231-233] (review [234]), although it has been suggested that in fact there is 
continual turnover of plasma cells maintaining the long-term antibody responses [235]. 
Memory B cells do not constitutively produce antibodies, although they are capable of 
producing high affinity, isotype switched, antibody much faster than naiVe B cells upon 
restimulation with antigen. Memory B cells can also be found, together with MZ B cells, in 
the marginal zone of the spleen [236]. Human memory B cells may express CD27 [237], 
however it has not been shown to be expressed on memory B cells in mice. Instead, CD27
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ligation may inhibit plasma cell development and induce memory B cell differentiation 
[238,239], or accelerate germinal centre formation [240]. It has also been suggested that 
CD27* B cells in humans are not memory B cells but are in fact circulating MZ B cells 
[241]. Although MZ B cells do not recirculate in rodents [242], they have been suggested 
to do so in humans [183].
The study of memory B cells in mice therefore remains difficult. They can be identified by 
functional assays and antigen binding, or as non-GC, non-antibody producing somatically 
mutated B cells. Of these methods antigen binding, by ELISPOT or flow cytometry, 
provides the best way to look at memory B cells in large numbers (e.g. the memory B cell 
population of the spleen).
The mechanism of B cell memory persistence is still somewhat controversial (review [243- 
248]. A true memory response should remain after the clearance of antigen, however it has 
been hypothesised that B cell memory cannot persist without residual amounts of antigen.
It has also been suggested that bystander activation of memory B cells may serve to 
maintain them, and specific plasma cells, in the absence of antigen [235]. Memory to 
smallpox vaccination has been used as a useful example of memory maintenance in humans 
without the possibility of re-exposure to specific antigen. While this does not rule out non­
specific polyclonal stimulation as a mechanism for the maintenance of memory, the data 
does demonstrate a stable pool of memory B cells and long-lived plasma cells persisting for 
up to 75 years [249,250]. Antibody-secreting B cells have been shown to be important for 
the maintenance of CD4+ T cell memory [251], however the importance of T cells in the 
maintenance of B cell memory is not known. CD8+ T cell memory maintenance appears to 
be independent of persisting antigen (review [243]).
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Immune responses to primary malaria infection
The immune response to experimental malaria infection in animal models indicates a role 
for both T and B cells, with CD4+ and CD8+ T cells critical for the immune response to 
liver stages of the parasite [96,252,253], whilst CD4+ T cells and B cells are critical for 
immune responses to blood stages [254-257].
CD4+ T cells are required for clearance of the acute erythrocytic infection, with CD4 
knockout mice or mice depleted of CD4* T cells being unable to control the acute infection 
[100,254,258,259] (review [260]). Depletion of CD4+ T cells from immune mice renders 
them fully susceptible to re-infection [258]. Transfer of either naive or immune CD4+ T 
cells allows T cell deficient nu/nu mice to clear an otherwise lethal P.berghei, P.c.adami or 
P.c.chabaudi malaria infection, with transfer of immune cells clearing parasitaemia ealier 
than transfer of naTve cells [255,256,261]. The relative importance of different elements 
of the immune system depends, however, on the parasite species, as transfer of CD4+ T 
cells from immune to naYve mice does not protect the recipient against P.vinckei infection 
[258], but does protect against P.berghei infection [256]. Transfer of immune T cells alone 
into combined T and B cell deficient SCID or Ragv‘ mice protects them from death, but 
does not allow them to clear a P.c.chabaudi infection [255,262]. Transfer of both B and T 
cells is protective however, and this protection is increased if B cells are activated with 
malaria antigens before transfer [255, 262]. T cells alone can therefore protect against 
death from infection, although they cannot produce sterile immunity without B cells and 
preferably antigen as well.
Other cell types that have been shown to have a role in immune response to malaria include 
y6 T cells, NK cells and NK T cells. y6 T cells contribute to the control of both acute [263]
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and chronic parasitaemia (review [264]) [259,265]. NK cells are activated by malaria 
infection [266], and their role in immunity to malaria is both production of IFNy [267] and 
cytotoxicity [268] (review [269]). NK T cells have a role in both the acute and chronic 
phases of malaria infection, produce high levels of both IFNy and IL-4, and may enhance 
the B cell and antibody response [249,270-272].
There are two phases of the immune response to erythrocytic P.chabaudi infection. The 
initial phase, during the first 14 days, is characterised by high levels of cytokines such as 
IFNy, early production of which is critical for control of acute parasitaemia [273,274] and 
protection against cerebral malaria [275]. These cytokines are produced by Thl-type CD4+ 
T cells, and also by cells of the innate immune system, such as yd T cells and NK cells 
[265,267,276-278] (review [279]). The second phase of the response, during the low level 
chronic parasitaemia, is a Th2 type response with low levels of IFNy production in 
P.chabaudi, P.cynomolgi and P.knowlesi infection [28, 104,280] that provides very 
effective help for malaria-specific antibody production. There are conflicting reports on the 
timing and importance of a Th2 response in P.falciparum infection in humans [281,282], 
whilst in P.vinckei infection in mice, the Th2 response appears to be less important that in 
P.chabaudi infection [283]. In P.berghei infection, a low Th2 response with decreased IL- 
4 and TGFp and increased IFNy in suceptible mice compared to resistant mice, has been 
associated with development of cerebral malaria [284].
The trigger for this Thl to Th2 switch is unknown, although it may be induced by B cells or 
antibody as B-cell deficient mice maintain a Thl type response [285-287]. It does not, 
however, require the production of IL-4 [288], which can be secreted by Th2-type CD4+ T 
cells, as well as non-B, non-T cells that increase dramatically in number in the spleen
between days 9 and 23 post-infection [289]. It has been suggested that the trigger for IL-4 
production by these cells is stimulation with IL-3 from an unknown source, and/or cross 
linking of Fey receptors [289]. The importance of IL-5 and IL-13 in malaria infection has 
not been determined.
Pathology o f malaria infection
Malaria disease is associated with fever (in humans), hypothermia (in mice), anaemia and 
cerebral pathology. Whilst some of these symptoms may be caused in part by the parasite 
(e.g. schizogony, sequestration), most are thought to be due to excessive responses by the 
host. The cytokine TNFa is critical for protective immune responses in the acute infection 
[151], however too much TNFa has been associated with increased pathology and cerebral 
malaria in particular in human infections [290]. In rodent malaria infection, elevated 
production of TNFa occurs in mice susceptible to P.berghei (ANKA) cerebral malaria 
[284], but also in mice resistant to P.berghei (ANKA) cerebral malaria [291]. In P.yoelii 
infection, increased levels of TNFa were found in lethal infection compared to non-lethal 
infection, however TNFa'7' mice were not protected from death [292]. TNFa induced 
upregulation of the adhesion molecule ICAM-1 has been suggested to correlate better with 
the development of cerebral malaria [292]. Earlier work, however, did not differentiate 
between the cytokines TNFa and LTa, and many of the effects originally attributed to 
TNFa are now thought to be caused by LTa [172].
The anti-inflammatory cytokines IL-10 and TGF0 downregulate the production of TNFa 
and thereby ameliorate pathology in P.chabaudi infection [110,279, 293,294]. In human 
malaria infections, reduced levels of IL-12 and TGFp are associated with severe disease 
[295,296], however TGFp has also been associated with the pathogenesis of cerebral
malaria [297,298], possibly through a synergistic mechanism with TNFa [297]. Low 
levels of IL-10 in P.falciparum infections, particularly a low IL-10:TNFa ratio, have been 
associated with severe malarial anaemia [130,299].
Production of an appropriate immune response to malaria is therefore thought to involve a 
fine balance between pro and anti-inflammatory responses. Indeed, there is evidence that 
the ratio of pro to anti-inflammatory cytokines may be more important than the absolute 
level of those cytokines (review [300-302]).
B cells and antibody responses to malaria infection
Antibody responses to malaria antigens in humans are detectable after the first infection, 
and are associated with resistance to clinical disease [128,184,293,303-312] (review 
[262]). However many anti-malaria antibodies do not last long after the end of the 
transmission season and are unable to protect against re-infection with P falciparum [177, 
306, 311, 313, 314]. In vitro, antibodies to specific P falciparum antigens have been shown 
to prevent parasite invasion [306, 315,316].
B cells are more important for final clearance of blood-stage P.chabaudi parasitaemia than 
in the control of acute parasitaemia, as pMT mice lacking B cells can control the acute 
infection but develop a chronic, persistant infection that remains for life [287, 317, 318]. 
JhD mice, however, which are also deficient in B cells, were able to control the acute 
parasitaemia in P.chabaudi and P.vinckei infection, but suffered a lethal infection with 
P.yoelii [319], indicating that B cells are more important in infection with P.yoelii than in 
infections with other malaria species. B cells and antibody responses are continually 
dependent on T cells, however, as transfer of immune B cells to T cell deficient mice could 
not protect them against death from secondary malaria infection [261].
The importance of B cells in immunity to malaria is due to their production of antibodies.
In human infections, and in infections of monkey with P.falciparum, transfer of serum 
antibodies can reduce parasitaemia in a stage-specific manner [320, 321] (review [262, 322, 
323]). Protection against human malaria infection has been associated with antibodies of 
the IgGl and lgG3 isotypes [324,325]. Although antibodies can prevent invasion of red 
blood cells by parasites; their main effect seems to be antibody-dependent cellular 
inhibition (ADCI) of invasion in co-operation with blood monocytes [326], with antibodies 
binding FcyRII on monocytes, causing the release of soluble factors responsible for parasite 
killing [213]. Antibodies may also be responsible for parasite clearance in an Fc receptor 
independent mechanism [327]. In mice, transfer of immune serum can protect against 
challenge infection from P. yoelii but not P. vinckei [99,258], effectivity of the serum 
increasing with the number of infections of the donor. This protection has been shown to 
be mediated by IgG, not IgM [17], and is associated with IgGl, IgG2a, IgG2b and IgG3 
isotypes [327-329].
Despite the importance of antibodies in immunity to malaria, veiy little is known about the 
malaria B cell response in humans or mice (review [262]). Inappropriate antibody 
responses may contribute to disease, as elevated IgE levels have been associated with 
cerebral malaria [330]. Whilst some vaccination strategies have been successful in mice 
[328, 331-334], transfer of these strategies to clinical application has proved problematic 
[306, 335-338] (review [339-341]).
The spleen in immune responses to malaria
The spleen has three distinct roles during malaria infection. It is a site of haematopoisis 
and erythropoiesis, particularly in the mouse [184,342, 343], it is a major site for the
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removal of pRBC from the circulation [306,344] and it is a site for the generation of 
immune responses (review [172]). The spleen increases several fold in size during acute 
malaria infection [184,345], and undergoes extensive, yet temporary, alterations in its 
microarchitecture [345-348]. The significance of these alterations is unclear, and has been 
hypothesised to be a protective mechanism to prevent infection of the erythropoietic beds 
of the spleen [347]. Despite these alterations, clearance of the parasite and development of 
antibody responses still occurs [346]. The trigger for these alterations in the splenic 
microarchitecture is also unknown. It has been suggested to be an over-reaction of the host 
immune response (review [172]), however it may also be caused by parasite antigens 
activating TLRs, as TLR4 activation by LPS can induce some of the same changes that are 
seen in the immune response to malaria [349] and parasite antigens have been shown to 
stimulate TLRs [350]. Replacement of the spleen by a splenic cell suspension has the same 
effect as splenectomy and increases susceptibility to malaria infection, indicating a role for 
splenic stromal cells in the immune response [258,351].
Immunity to re-infection
Malaria has been studied for many years, however we still know relatively little about how 
the body reacts to it. There are different views of what effective immunity to malaria 
consists of (immunity to parasitaemia or immunity to symptoms of disease), and why it 
takes so long to develop, which are not mutually exclusive (review [352]). The first view is 
that much of the pathology caused by malaria infection is due to an over-reaction of the 
immune response (review [353]) or an inappropriate immune response [110]. Immunity to 
disease is acquired slowly and in stages, the first being resistance to the most severe forms 
of disease, then over time a lessening of other symptoms (review [354]). This would
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suggest that “immunity to malaria” is perhaps not sterile immunity to infection, but only the 
body learning how to produce an appropriate response, the memory of which is short-lived. 
Even after many years of living in an endemic area, resistance to disease can be lost by 
moving to a non-malarious area for approximately 12 months [18].
The second view is that immunity is very strain-specific, and that only after infection with 
many different strains is a sufficient memory repertoire built up to protect against most 
infections. Indeed, analysis of strains infecting children showed that some strains were 
found only in younger children, presumably the prevalent strains in that area, and that 
patients did not have antibodies to the strain they were currently infected with ([355-357]). 
Specific, more prevalent, isolates were also associated with more severe malaria, indicating 
that immunity to severe disease may be the immunity to those isolates which cause severe 
disease [358, 359]. This would suggest that cross-isotype immune responses would be 
beneficial to the host, however it has been suggested that cross-reactive immune responses 
would be weaker and more likely to cause chronic infection [360]. It has also been 
suggested that immunity to malaria may be associated with the ability to maintain chronic, 
asymptomatic infections [361]. Such contradictions emphasise that acquisition of 
immunity to malaria is a complex process, thus only by fully understanding the interaction 
between the parasite and the immune system, and what constitutes an effective immune 
response, can we hope to eliminate this disease.
It has been hypothesised that the malaria parasite has the ability to downmodulate the 
immune response, suppressing the ability of dendritic cells to present antigens and 
preventing the development of T and B cell memory [348,362]. Whilst there is evidence to 
suggest that the immune system cannot mount an effective response to unrelated antigens
79
during the first 21 days of an acute malaria infection, and that this is mediated by dendritic 
cell uptake of haemozoin [363], there is also evidence to suggest that the induction of 
immunity to the parasite itself is fully functional [265,364]. Mice that have cleared 
primary infections are largely resistant to infection with homologous, and to varying 
degrees heterologous, parasites. Whilst it takes many infections for people to develop 
immunity to malaria this may well be due to the fine specificity of immunity to particular 
isolates. In short, immunity to isolates is acquired with a single infection but immunity to 
the whole species is built up over many infections. This may be one of the reasons why 
producing an effective vaccine against blood-stage malaria has so far been difficult. An 
alternative hypothesis is that the malaria parasite produces a large number of strongly 
immunogenic antigens that are not essential to its survival, creating a smokescreen to hide 
those molecules that are essential (review [365]).
Chronic malaria infection has a depressive effect on the immune responses to other 
antigens including experimental antigens such as sheep erythrocytes [40]. Malaria 
infection can also alter the antibody isotype to non-malaria antigens, to IgM instead of IgG 
[366]. There could therefore be a short optimal time period between transmission seasons 
when vaccination in endemic areas would be most effective. Additionally, if malaria 
infection inhibits the development of T and B cell memory, it may suppress the efficacy of 
any vaccines to blood-stage malaria [367].
Clearance of parasitaemia of infection in humans is complicated by continual re-infection, 
resulting in chronic infection. This persistence of infection may be due to the 
predominance of strain-specific immunity particularly in P.falciparum infections [360, 
368], the recrudescence of infection from hypnozoites [19] or to the concurrent infections
protecting the host from infection with other, perhaps more virulent, strains [369]. In other 
parasitic infections, such as L. donovani, low-level chronic infection is essential for the 
establishment of concomitant immunity [107], however low-level infection of Brugia 
pahangi and Toxoplasma gondii does not seem to protect hosts against re-challenge [213, 
370]. The effect of chronic malaria on the development of a new malaria infection is 
unknown.
In order to investigate persistent infections, secondary infections and memory responses, it 
is first necessary to determine when primary infection is naturally cleared. This is an 
important aspect of the infection, which has not been investigated in any rodent model.
The reasons for persistence of some strains of parasites and not others are unknown, 
however they are likely to include variation of parasite antigens to avoid the hosts’ immune 
system [365] and a trade-off between the fitness cost to the host and the virulence and 
replication rate of the parasite [31]. Ultimately, parasite persistence increases the 
likelihood of transmission.
Aims o f the thesis
This introduction has shown that despite the importance of the spleen in immunity to 
malaria, and the demonstrated changes in splenic architecture, the mechanism of these 
changes is still unknown. The extent, order and timing of these changes has also not been 
fully characterised. Immunity to malaria does occur in the field and B cells are known to 
be important in that immunity. However, the development and maintenance of good B cell 
and antibody responses has still not been well characterised, and it has been debated 
whether or not they form. The mechanism of B cell memory maintenance, whether by 
production of long-lived cells or by continuous turnover of short-lived cells, is also
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controversial, yet despite investigations into B cell responses in malaria the chronicity of 
infection in model systems has not been determined.
This thesis aims to pinpoint the order and timing of changes in splenic microarchitecture 
during acute P. c. chabaudi infection, follow the development and maintenance of memory 
B cells and plasma cells during and after chronic infection, and to determine the natural 
clearance point of chronic infection.
Objectives:
1) To determine the duration of a chronic P. c. chabaudi infection
2) To conduct a detailed analysis of splenic microarchitecture and cellular composition 
during the acute infection
3) To assess longevity and turnover of B cells and plasma cells in relation to antibody 
titres
4) To assess longevity and turnover of B cells and plasma cells during chronic 
infection
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Chapter 2
Buffers
Alkaline phosphate substrate buffer
lOOmM Tris-HCl (Sigma-Aldrich Inc; T3253)
lOOmM NaCl (Fisher; 7647-14-5)
5mM MgCl2 (Sigma-Aldrich Inc; M8266)
pH 9.5
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) stock
BCIP 1 OOmg (Promega; S381C)
Add 2ml of 100% dimethylformamide (Sigma-Aldrich Inc; D4254)
(Sigma-Aldrich Inc; B-0149)
(Fisher; E/0560DF/17)
(BDH; 10002)
Make up to final volume with deionised H20  
Coomassie blue destain
45% ethanol (Fisher; E/0560DF/17)
Coomassie blue
0.25% w/v Coomassie 
Brilliant Blue 
45% ethanol 
10% acetic acid
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10% acetic acid (BDH; 10002)
Make up to final volume with deionised H2O
DNA extraction buffer
50mM Tris-HCI 
50mM EDTA 
lOOmM NaCl 
pH7.5
FACS bufTer 
500ml PBS 
1% BSA 
0.005M EDTA 
Sterile filter before use
Giemsa buffer
0.09% w/v NaCl 
0.02mM KH2PO4 
0.08mM K2HPO4 
pH 7.0-7.2
(Sigma-Aldrich Inc; T3253) 
(Sigma-Aldrich Inc; E5134) 
(Fisher; 7647-14-5)
(T/C grade; Gibco/Life Technologies; 20012-019) 
(Sigma-Aldrich Inc; A9647)
(Sigma-Aldrich Inc; E5134)
(Fisher; 7647-14-5) 
(BDH; 102034B) 
(BDH; 296194X)
Giemsa stain
Giemsa R66 solution (BDH; 352603R)
Dilute 1 in 10 in Giemsa buffer
Histology buffer
Tris pH 7.6 (0.05M Tris) 1.6 parts saline stock, 1 part Tris stock, 1.4 parts water with
1%HC1 (BDH; 101254H)
Tris stock (0.2M)
Saline stock
Kreb’s glucose saline
55mM NaCl 
4.6mM KC1 
2.4mM MgS04.7 H20  
Buffer pH7.4
26mM NaH2P04
NHC1
dH20
dH20
llmM Glucose
121.14g Trizma base (Sigma-Aldrich Inc; T6066) in 5L 
deionised water
42.5g NaCl (Fisher; 7647-14-5) in 5L deionised water
(Fisher; 7647-14-5) 
(Sigma-Aldrich Inc; P3911)
222.2ml
(BDH; 102454R) 
4.36ml 
217.86ml 
777.8ml
MSP-1 purification -  elution buffer
500ml PBS (T/C grade; Gibco/Life Technologies; 20012-019)
50mM NaH2P04 (BDH; 102454R)
300mM NaCl (Fisher; 7647-14-5)
250mM imidazole (Sigma-Aldrich Inc; 10250)
pH 8.0
MSP-1 purification -  lysis buffer
500ml PBS (T/C grade; Gibco/Life Technologies; 20012-019)
50mMNaH2PO4 6.9g/l (BDH; 102454R)
300mM NaCl 17.54g/l (Fisher; 7647-14-5)
lOmM imidazole 0.68g/l (Sigma-Aldrich Inc; 10250)
pH 8.0
MSP-1 purification -  wash buffer
500ml PBS (T/C grade; Gibco/Life Technologies; 20012-019)
50mMNaH2PO4 6.9g/l (BDH; 102454R)
300mM NaCl 17.54g/l (Fisher; 7647-14-5)
20mM imidazole 1.36g/l (Sigma-Aldrich Inc; 10250)
pH 8.0
Nitro-Blue Tetrazolium (NBT) stock
NBT 1 OOmg (Promega; S381C)
Add 2ml of 70% dimethylformamide (Sigma-Aldrich Inc; D4254)
Parasite freezing medium
40% glycerol (Sigma-Aldrich Inc; G5516)
0.14M Sodium lactate (Sigma-Aldrich Inc; L7022)
0.005M KC1 (Sigma-Aldrich Inc; P3911)
pH 7.4
SDS-PAGE reducing loading buffer
1M Tris-HCl 8ml (Sigma-Aldrich Inc; T3253)
10% w/v SDS 20ml (BioRad; 161-0418)
20mM dithiothreitol (DTT) 154.2mg 
Glycerol 10ml (Sigma-Aldrich Inc; G5516)
0.2% w/v bromophenol 0.6ml (Sigma-Aldrich Inc; B5525) 
in ethanol
Make up to 50ml with deionised H2O
SDS-PAGE running buffer
NuPAGE MES SDS (Invitrogen; NP0002)
running buffer (20x)
Dilute 1:20 in MilliQ H2O
Semi-supplemented HBSS
500ml Hank’s balanced salt (Gibco; 24020-091) 
solution
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12mM Hepes (Gibco; 15630-056)
Supplemented HBSS
500ml Hank’s balanced salt (Gibco; 24020-091)
solution
5% FCS
12mM Hepes (Gibco; 15630-056)
Tris buffer pH 9.2
0.02M Tris (Sigma-Aldrich Inc; T6066)
0.12M NaCl (Fisher; 7647-14-5)
0.03M HC1 (BDH; 101254H)
Western blot alkaline phosphatase substrate
5ml Alkaline Phosphatase substrate buffer 
33 pi NBT stock 
17pl BCIP stock
Western blot transfer buffer
24mM Tris (Sigma-Aldrich Inc; T6066)
0.19M Glycine (BDH; 28458)
Methanol 200ml (Romil; H410)
Make up to 1L with dH20
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Suppliers
Amersham Biosciences -  GE Healthcare UK Ltd., Amersham Place, Little Chalfont, 
Buckinghamshire HP7 9NA 
Am icon -  Millipore UK Ltd., Units 3 & 5 The Courtyards, Hatters Lane, Watford WD18 
8YH
Animalcare Ltd.. Common Road, Dunnington, York Y019 5RU 
Applied Biosvstems. 850 Lincoln Centre Drive, Foster City CA 94404 USA
Avid Identification Systems Inc., 3185 Hamner Ave, Norco CA 92860
Axxora (UK) Ltd., PO Box 6757, Bingham, Nottingham NG13 8LS
BD, 21 Between Towns Road, Cowley, Oxford 0X4 3LY
BDH -  VWR International bvba, Haasrode Research Park, Zone 3, Geldenaaksebaan 464, 
B-3001 Leuven
BioRad Laboratories Ltd., Bio-Rad House, Maxted Road, Hemel Hempstead, Hertfordshire 
HP2 7DX
Bright Instruments Co. Ltd., St. Margarets Way, Huntingdon, Cambridgeshire PE29 6EU
Coming. One Riverfront Plaza, Coming, NY 14831 USA
Dako Cytomation, 6392 Via Real, Carpinteria, CA 93013 USA
Euro-Diagnostica BV, Beijerinckweg 18, NL-6827 BN Arnhem, The Netherlands
Falcon -  BD, 21 Between Towns Road, Cowley, Oxford 0X4 3LY
Fisher Scientific Ltd., Bishop Meadow Road, Loughborough, Leicstershire LEI 1 5RG
Gibco -  Invitrogen Ltd., 3 Fountain Drive, Inchinnan Business Park, Paisley PA4 9RF
Harlan UK Ltd., Shaw’s Farm, Blackthorn, Bicester, Oxon 0X25 1TP
Hawkslev. Marlborough Road, Lancing Business Park, Lancing, Sussex BN 15 8TN
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CA Hendley (Essex) Ltd., Oakwood Hill Industrial Estate, Loughton, Essex
Hvbaid -  Thermo Electron, 171 Industry Drive, Pittsburgh PA 15275
Invitrogen Ltd., 3, Fountain Drive, Inchinnan Business Park, Paisley PA4 9RF
Kendall. 15 Hampshire Street, Mansfield MA 02048
Leo Labs. Princes Risborough, Buckinghamshire HP27 9RR 
Miltenvi Biotec Ltd., Almac house, Surrey GU24 9DR
Molecular Probes -  Invitrogen Ltd., 3, Fountain Drive, Inchinnan Business Park, Paisley 
PA4 9RF
Nalge Nunc Int., 75 Panorama Creek Drive, Rochester NY 14625
PMI Nutrition Int.. PO Box 19798, Brentwood, MO 63144 USA
Pierce -  Perbio Science UK Ltd., Unit 9, Atley Way, North Nelson Industrial Estate,
Cramlington, Northumberland NE23 1WA
Promega. Delta House, Southampton Science Park, Southampton SO 16 7NS
Oiagen Ltd., Qiagen House, Fleming Way, Crawley, West Sussex RH10 9NQ
Raymond A Lamb Ltd., Units 4 & 5, Parkview Industrial Estate, Alder Close, Lottbridge
Drove, Eastbourne, East Sussex BN23 6QE
Rhone-Mdrieux Ltd., Spire Green Centre, Harlow, Essex CM 19 5TS
Romil Ltd., The Source, Convent Drive, Waterbeach, Cambridge CB5 9QT
Rotring GmbH, PO Box 54,10 60 D-22510, Hamburg 
Sigma-Aldrich Inc.. 3050 Spruce St., St. Louis, MO 63103 USA
Thermo Electron. 171 Industry Drive, Pittsburgh PA 15275 USA
Treestar Inc., 340 A Street Bdl #203, Ashland, OR 97520
Vericore Ltd.. Kinnoull Road, Dunsinane Industrial Estate, Dundee DD2 3XR
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Materials and Methods
Mice
Female C57BL/6, BALB/c, Rag V1' mice on a C57BL/10 background [371] and male Rag 
2~a mice on a BALB/c background [372] bred in the SPF unit at the National Institute for 
Medical Research were used at 6-12 weeks of age. All mice were conventionally housed 
on sterile bedding, food and water. The food was autoclaved CRM rodent diet (Harlan) 
until 2004 and was then changed to Lab diet 5021-3 (PMI Nutrition Int.). For short-term 
experiments, animals were identified by tail marking with a waterproof Edding pen. For 
long-term experiments, 12-mm microchips (Avid) were implanted for identification. The 
light cycle consisted of 12 h light and 12 h dark to mimic conditions in malaria-endemic 
regions. For schizont enrichment, mice were kept on a reverse light cycle where daylight 
occurred from 8pm to 8am. For identification of cells dividing at specific time-points, mice 
were given 5-Bromo-2'-deoxyuridine (BrdU) 0.8mg/ml in drinking water, changed daily 
for 14 or 28 days. Mice were checked daily to identify gross health problems and cages 
were cleaned once a week.
Parasites
Plasmodium chabaudi chabaudi (AS) was originally isolated from an African thicket rat 
(Thamnomys rutilans) by Dr. D. Walliker and cloned in vivo by passaging in mice [373]. A 
stock of this was obtained from Dr. K. N. Brown, NIMR. Frozen stocks were negative for 
mycoplasma and for common mouse pathogens such as Hepatitis, Pasteurella and Lactate 
Dehydrogenase Virus. To make a new stock, one vial was thawed, diluted with 0.9% saline 
(Sigma-Aldrich Inc) and injected into several (e.g. between 6 and 10) two to three month
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old C57BL/6 female mice. Such amplification of stock reduces mutation and genetic drift 
to a minimum, ensuring that each infection is as similar as possible to each other, and to the 
starting stabilate. One to two days before the peak of parasitaemia (approximately 10-15% 
parasitaemia), mice were anaesthetised by injection of 0.1-0.15ml Sagatal (pentobarbitone 
sodium BP; Rhone-M6rieux; 7SA005; 60mg/ml), 0.05ml Euthanal (pentobarbital sodium 
Ph.Eur; Vericore Ltd; 05327/4112; 200mg/ml) or Pentoject (pentobarbitone sodium Ph.Eur; 
Animalcare Ltd.; XUD132; 200mg/ml). Blood was taken after cardiac puncture with a 
syringe and transferred to a 15ml tube (Falcon) containing 50pl heparin per mouse (Leo 
Lab; 9860; 5000U/ml) on ice. Blood was centrifuged (10 mins, 1064 x g, 4°C), plasma 
removed and the pellet diluted with two pellet volumes sterile parasite freezing medium. 
Blood was aliquoted into cryotubes, frozen quickly at -80°C then transferred to liquid 
nitrogen for long-term storage. For initiation of infection, parasitised red blood cells 
(pRBC) were routinely injected intra-peritoneally (i.p.) from stabilate stocks kept in liquid 
nitrogen, thawed and diluted 1:1 with 0.9% saline. All injections were performed with 
sterile 1 ml syringes (BD) and 27G x V2" needles (Kendall). Parasites were passaged up to 
four times in mice by i.p. injection of 106, 105 or 104 pRBC diluted in lOOpl 0.9% saline 
(Sigma Aldrich Inc.) or Kreb’s glucose saline [41]. Inoculum sizes were calculated by 
determining the percentage of parasitaemia in the infected mice and assuming an 
erythrocyte density of 6 x 109 / ml blood. pRBC were obtained from infected mice before 
the peak of parasitaemia, with parasitaemia determined by Rapi-Diff II stain (Raymond 
Lamb) of thin blood films made with blood from a small tail nick. For experimental 
infection, mice were injected with 105 pRBC diluted in lOOpl 0.9% saline or Kreb’s
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glucose saline. For secondary infections, mice were injected with 10s pRBC diluted in 
lOOpl 0.9% saline 3 months after the start of the primary infection.
Giemsa staining o f thin blood films
Thin blood films were air dried and fixed with 100% methanol (BDH). Giemsa R66 
solution (BDH) was diluted 1:10 in Giemsa buffer. Slides were immersed in staining 
solution for 20 minutes, rinsed with water and air dried. Slides were analysed under oil 
immersion on a Zeiss Axioskop light microscope with a lOOx objective (final magnification 
1200x). For high parasitaemia (over 1%) at least 10 fields, defined by a grid in the 
eyepiece, were counted. For low parasitaemias (less than 1%) at least 50 fields were 
counted.
% parasitaemia = ____________Total number pRBC___________________ xlOO
Number RBC in a representative field x Number of fields counted
Schizont purification and CFSE labelling o f schizont-infected red blood cells 
Mice just before the peak of parasitaemia were anaesthetised with 100pl Sagatal. Blood 
was taken from the peritoneal cavity after cardiac puncture with a syringe containing 50pl 
heparin and kept on ice. A MACS column (Miltenyi; Type D; 130-041-201) and stop-cock 
were assembled on a clamp stand. A 50ml syringe was used to wash the column with 
dH20 2-3 times, then with RPMI (Gibco) 2-3 times. The column was placed in the column 
holder on a SuperMACS II magnetic separator. Mature malaria parasites containing the 
iron-rich molecule haemazoin are attracted by the magnet and remain on the column whilst 
uninfected red blood cells pass through the column [314,374]. Blood samples (~20ml)
were made up to at least 30ml with RPMI, then loaded onto the top of the column. The 
column flow rate was adjusted to a steady drip (approx. 1 drip in 2 seconds) and flow­
through was collected into 50ml tubes (Falcon). 1-2 x 50mls RPMI was also loaded onto 
the column to rinse it. The flow was stopped and the column removed from the magnet. 
The lid was placed on the column and a 50ml syringe used to flush the schizont-enriched 
blood into a 50ml tube. The column was then washed with RPMI, dFbO and 100% ethanol 
before storing in 100% ethanol (BDH; 10107). The schizonts were centrifuged at 804 x g 
for 5 mins at 4°C, the supernatant was removed, the pellet resuspended and a thin blood 
film made to check the purification. Erythrocytes were counted using a haemocytometer, 
then schizonts were diluted to approximately 6.667 x 106/ml in PBS. lpl CFSE (Molecular 
Probes) per ml of schizont solution was added from a 5mM stock in dimethyl sulphoxide 
(DMSO, Sigma-Aldrich Inc) and the cells incubated for 5 mins at room temperature. Cells 
were washed 3 x in RPMI then resuspended in RPMI and injected i.v. into C57BL/6 mice. 
Sub inoculation o f blood
1-6 months after primary infection mice were anaesthetised by injection of 0.1-0.15ml 
Sagatal. Mice were exsanguinated by cardiac puncture with a syringe containing 200U/ml 
heparin in 250pl Kreb’s glucose saline. Blood from one donor animal was injected i.p. into 
two immunodeficient (C57BL/10 Rag V1' or BALB/c Rag 2'A) mice, which were then 
monitored for parasitaemia by microscope analysis of Giemsa stained thin blood films as 
above, and killed by cervical dislocation once parasitaemia was ascertained. Mice not 
developing parasitaemia after 3 weeks were assumed not to have received viable parasites, 
and were culled.
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Limiting dilution o f parasites
pRBC were taken from a mouse before the peak of infection and serially diluted in 0.9% 
saline to a final concentration of 1, 10, 100 or 1,000 pRBC per 100p.l, then injected i.p. into 
Rag 2‘a mice, which were monitored for parasitaemia as above.
Administration o f Indian Ink
Mice were injected intravenously (i.v.) with 200pl 5% Indian Ink (Rotring) in 0.9% saline. 
Immunisation and blood sampling
Purified protein (MSP-1, CGG and pMCKl 10) at a concentration of 1 mg/ml was diluted 
1:1 with 9% potassium aluminium sulphate (Alum) and precipitated with 1M sodium 
hydroxide solution added dropwise until maximum precipitation was reached, as judged by 
eye. The precipitate was centrifuged for 5 mins at 289 x g, washed twice with PBS and 
resuspended in 0.9% saline to a final concentration of250pg/ml. Mice were injected i.p. 
with lOOpl of this solution. Mice immunised with MSP-1 and pMCKl 10 were boosted 
twice at two week intervals.
Treatment o f mice with agonistic anti-lymphotoxin ft antibody
Mice were infected with 10s pRBC in 100pl Kreb’s glucose saline. On day 4 of infection, 
one third were injected with 50pg anti-lymphotoxin p receptor agonist antibody (Axxora) 
and one third with 50pg control rat IgG (Sigma-Aldrich Inc) in 0.9% saline. Parasitaemia 
was monitored by Giemsa-stained thin blood films as above. Half the mice from each 
group were killed by cervical dislocation for spleen harvesting (see below) on day 10 of 
primary infection. Remaining mice were given a secondary infection of 105 pRBC in lOOpl 
Kreb’s glucose saline 3 months after primary infection, parasitaemia was monitored by
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Giemsa-stained thin blood films and mice were killed for spleen harvesting on day 10 of 
secondary infection.
Organ harvesting and freezing
Mice were killed by cervical dislocation. Spleens were extracted, all fat was carefully 
removed and the tips cut off to give flat ends to make sectioning easier. Spleens were 
placed on strips of aluminium foil, which was repeatedly dipped in liquid nitrogen to freeze 
the organs. Frozen organs were stored at -70°C.
Cryosectioning
A circle of Whatman filter paper was wetted and frozen onto the cryostat chuck. OCT 
compound (BDH) was placed on the filter paper and spleens mounted in, but not covered 
by, the OCT. 5pm thick sections were cut with a cryostat (Bright) and mounted on 4-spot 
slides (Hendley). Slides were air dried for 1 hour, fixed in cold (4°C) 90% acetone (BDH) 
for 20 mins and stored at -20°C.
Immunofluorescence histology
Slides were defrosted and rehydrated for 5 mins in histology buffer. Primary antibodies 
were diluted in histology buffer and centrifuged (10,000 x g, 10 mins) to remove 
aggregates. Slides were wiped dry around sections after each washing step and 75 pi of 
diluted antibody added for each incubation step. Slides were incubated for 1 hour in the 
dark at room temperature, during which time secondary antibodies were pre-incubated with 
equal volume of normal mouse serum, diluted in histology buffer for at least 30 mins to 
prevent secondary antibodies cross-reacting with mouse immunoglobulin. All incubation 
steps were carried out in a box containing damp tissue to maintain humidity and prevent 
sections from drying out. Slides were washed 2 x 5  mins in histology buffer then incubated
with secondary antibody for 1 hour in the dark at room temperature. During this time 
Neutravidin Texas Red (if used) was pre-incubated with equal volume of normal mouse 
serum, diluted in histology buffer for 30 mins. Slides were washed again for 2 x 5 mins, 
then incubated with Neutravidin Texas Red for 2 hours in the dark at room temperature. 
Slides were washed for 2 x 5 mins in histology buffer and 1 x 5 mins in (IH2O, then 
mounted with fluorescence mounting medium (Dako). Antibodies used are listed in Table 
3. Normal mouse serum was obtained by exsanguination of naTve CS7BL/6 mice and 
serum extraction.
Immunohistology
For horseradish peroxidase (HRP) staining, slides were blocked with 2% H2O2 for 1 hour. 
Slides were incubated with primary antibodies as described above, washed and incubated 
with secondary antibodies for 45 mins. During this time Streptavidin ABComplex alkaline 
phosphatase (AP) (Dako) components were pre-incubated with an equal amount of normal 
mouse serum, diluted in histology buffer. Slides were washed, then incubated with 
Streptavidin ABComplex for 30 mins. For HRP staining, one tablet of 3,3- 
diaminobenzadine tetrachloride (DAB) (Sigma-Aldrich Inc) was dissolved in 15ml Tris 
buffer pH 9.2, then filtered through Whatman filter paper before use, 10ml were collected 
and 0.1% H2O2 added. Slides were washed (2x5 mins in histology buffer, and two drops 
of DAB solution added to each section. Sections were incubated until staining became 
visible under a light microscope, then slides were washed for 2 x 5 mins in histology 
buffer. For AP staining, 8mg levamisole (Sigma-Aldrich Inc) was dissolved in 10ml Tris 
buffer pH 9.2. 3.5-4mg napthol AS-MX phosphate (Sigma-Aldrich Inc) was dissolved in 
380pl N,N-dimethylformamide (DMF, Sigma-Aldrich Inc), then added to the levamisole
solution, followed by lOmg Fast Blue (Sigma-Aldrich Inc). The solution was filtered 
through Whatman filter paper before use, and two drops added to each section. Sections 
were incubated until staining became visible under a light microscope, then slides were 
washed for 2 x 5 mins in histology buffer and 1 x 5 mins in dFfeO. Slides were mounted 
with Immunomount (Thermo Electron).
Colour analysis o f immunohistology images
Immunofluorescence images were acquired on a Leica confocal microscope and prepared 
for presentation using Adobe Photoshop. Colour spectrum analysis was done in ImageJ 
using the colour picker plugin (Daan Zhu, NIMR). Parameters for the colour spectrums 
were confirmed with the colour masker produced by the plugin during analysis.
MSP-1 protein production and purification
Recombinant MSP-119 was expressed in Pichia pastoris SMD1168 strain with a His-tag by 
Dr. M. Hensmann as described [375]. 25pl glycerol stock of this construct was cultured 
overnight at 30°C in 5ml Yeast Extract Peptone Dextrose (YEPD) medium, plated out on 
YEPD agarose plates with Geneticin antibiotic (Gibco) at concentrations from 0.5-4 mg/ml 
and incubated for 4 days at 30°C. Once colonies had formed, a 10 or 20 litre culture was 
grown up in 1% glycerol stock for 24 hours, then protein expression was induced by 
switching to 0.5% methanol for 48 hours. The culture supernatant was harvested, 
concentrated to 450ml, aliquoted into 50ml tubes (Falcon) and stored at -20°C.
For MSP-1 purification, the supernatant was defrosted, adjusted to pH 7.0 and filtered 
through Whatman filter paper. Glass columns were loaded with Ni-NTA agarose (Qiagen), 
approximately 3ml agarose per 50ml supernatant. The column was washed with 3-5x 
column volume of wash buffer, then the supernatant was passed through the column and
the flow-through collected. The column was washed with 3-5x column volume of wash 
buffer and 3-5x column volume of lysis buffer until the OD280 of the flow-through was the 
same as the OD280 of the lysis buffer. The protein was eluted with 2x column volume of 
elution buffer, then the eluate was concentrated with a Centricon YM3 (Amicon) at 3,000 x 
g and dialysed against PBS. Final protein concentration was measured 
spectrophotometrically at OD280.
Recombinant MSP-1 protein pMCKl 10 (Figure 9) was expressed in Escherichia coli 
(E.coli) as a fusion protein with maltose binding protein (MBP), extracted and purified as 
described [376].
Protein gels and Western blots
Denaturing SDS-PAGE was performed under reducing conditions according to the 
Laemmli method as described in Current Protocols in Immunology (John Wiley and Sons 
Inc., 1995). Pre-made 10% Bis-Tris polyacrylamide gels (Nunc) were removed from their 
packaging, rinsed with dFfcO and placed in an electrophoresis tank with running buffer. 
10pl protein was diluted 1:1 with SDS-PAGE reducing loading buffer and heated for 5 
mins at 95°C to denature the proteins. Samples were loaded into wells in the gel and a 
prestained protein molecular weight standard with a range of approximately 10-250kDa 
(Biorad) was included. A constant voltage of 120 V was applied to the gel and progress of 
the proteins was monitored by the location of the bromophenol blue band. Proteins were 
visualised by staining with Coomassie blue. The gel was covered with Coomassie staining 
solution and placed on shaker for 1 h at room temperature or until the gel was fully stained. 
After this, the gel was rinsed in deionised water followed by incubation with destain 
solution. The gel was placed on a shaker until the protein bands became visible in blue and
the background was clear or only moderately stained. The destaining solution was then 
replaced by deionised water. Gels were photographed, then dried onto Whatman filter 
paper with a Scie-Plas gel drier (model GD4534) for long-term storage.
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Figure 9. Full length P . c h a b a u d i  MSP-1 molecule and recombinant proteins.
Full length protein (□), and two recombinant proteins [375, 376], that were labelled with 
fluorescent probes for detection of antigen-specific B cells and plasma cells (□). Numbers 
underlined indicate location of natural proteolytic cleavage sites. Figure adapted from
For Western blotting, gels were placed on a piece of nitrocellulose protein transfer 
membrane (Hybond-C extra; Amersham Biosciences). Gels and paper were sandwiched 
between pieces of Whatman filter paper (4 pieces each side) and sponge pads. These were 
placed in a clamp in a transfer tank with transfer buffer, with the
nitrocellulose membrane closest to the positive terminal. All pieces of filter paper, sponge 
and nitrocellulose paper were pre-soaked in transfer buffer before touching gels. A
[377]
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constant voltage of 40V was applied for 1 hour. The clamp was removed and the gel and 
filter paper discarded. The nitrocellulose membrane was blocked in PBS (5% BSA) 
overnight. The membrane was washed for 6 x 5 mins with PBS 0.05% Tween and 
incubated with antibody diluted in PBS 0.05% Tween 1% BSA for 1 hour, then washed 6 x 
5 minutes with PBS 0.05% Tween. The membrane was then incubated with a secondary 
antibody diluted in PBS 0.05% Tween for one hour with shaking, washed 6x10 minutes 
and 30 minutes with PBS 0.05% Tween, then developed with alkaline phosphatase 
substrate.
Protein labelling
Alexa 647 labelling was carried out, and fluorophore to protein ratio measured, according 
to the manufacturer’s (Molecular Probes) instructions. 1/ioth volume of 1M sodium 
bicarbonate was added to the (l-2mg/ml) protein solution, which was then transferred to the 
vial of reactive dye. The protein and dye were incubated for 1 hour at room temperature 
then excess dye was removed by passing the solution over a spin column, which retains free 
dye on the column. The absorbance of the solution was measured at 280nm and 650nm by 
a spectrophotometer, and the fluorophore to protein ratio was calculated as follows:
Protein concentration (M) = (O D ^ - IQD^n x 0.0311 x dilution factor
203,000
Moles dye per mole protein =  O D ^ x dilution factor_____
239,000 x protein concentration (M)
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Flow cytometry
Mice were killed by cervical dislocation, spleens and bones extracted and placed in 
supplemented Hank’s Buffered Salt Solution (HBSS). For collagenase treatment, spleens 
were placed in a Petri dish (Coming) with 3ml semi-supplemented HBSS, 1.65ml 
collagenase and 0.5ml DNase, cut into small pieces and incubated at 37°C, 7% CO2 for 30 
mins. For preparation without collagenase, spleens were mashed through a 0.7pm sieve 
(Falcon) into supplemented HBSS using the plunger of a sterile 5ml syringe (BD). Spleen 
cell suspensions were centrifuged at 289 x g for 10 mins at 4°C, washed with HBSS and 
centrifuged again. Bone marrow was flushed out with supplemented HBSS and centrifuged 
at 289 x g for 10 mins at 4°C. The supernatant was removed, the pellet resuspended and 
red blood cell lysis buffer (Sigma-Aldrich Inc.) was added, 2ml for suspensions from small 
spleens or bone marrow and 5ml for suspensions from large infected spleens, and cells 
were incubated at room temperature for lOmins. Supplemented HBSS was added to 20ml 
to stop the reaction, cells were centrifuged (289 x g, lOmins, 4°C) and resuspended in 
FACS buffer. Live cells were counted using a haemocytometer (Hawksley) and trypan 
blue (Sigma-Aldrich Inc.) exclusion, or on a Coulter Counter (lOpl cell suspension in 10ml 
isotonic buffer). 1 x 106 cells per well were added to 96-well V-bottom microtitre plates 
(Nunc) and incubated for 10 mins with 25p.l/well Fc receptor blocking antibody (24G2;
[378]). Antibodies were diluted in FACS buffer, 25pl added to each well and incubated for 
30 mins on ice in the dark. Plates were centrifuged for 5 mins at 289 x g, 4°C and washed 
twice with 150p,l/well FACS buffer. Cells were fixed with 2% paraformaldehyde (Sigma- 
Aldrich Inc.) for 30 mins to 1 hour on ice in the dark, washed and resuspended in FACS 
buffer. For intracellular staining, after fixation cells were washed, permeabilised with 0.1%
NP-40 (nonylphenyl-polyethyleneglycol acetate; Sigma Aldrich Inc.) for 3 mins, 
centrifuged and incubated with 20pl/well anti-BrdU antibody with DNase (BD) or control 
antibody for 1 hour at room temperature, washed and resuspended in FACS buffer. 
Antibodies used are listed in Table 4. Cells were collected on a FACSCalibur (BD) and 
analysed with FlowJo (Treestar), Microsoft Excel and Graphpad Prism 4. Statistical 
significance was tested with a non-parametric, two-tailed Mann Whitney test.
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Table 3. Reagents used for immunohistology
Reagent Source Catalogue
no.
Clone Isotype Concentration/ 
dilution for use
Rat anti-mouse 
CD3 IgG
Serotec MCA5006 KT3 IgG2a 1.25pg/ml
Rat anti-mouse 
IgM heavy 
chain
Serotec MCA 199 0.42pg/ml
Rat anti-mouse 
CD8a
BD 553029 53-6.7 IgG2a 5pg/ml
Hamster anti­
mouse CDllc 
Alexa 488
Caltag MCD1 lc20 N418 IgG lpg/ml
Biotinylated 
hamster anti­
mouse CD1 lc
BD 553800 HL3 IgGl 5pg/ml
Sheep anti­
mouse IgD
Binding Site PC283 IgG 0.135mg/ml
Anti-mouse
CD138
(syndecan-1)
BD 09342D 281-2 IgG2a 0.255jxg/ml
Biotinylated
peanut
agglutinin
Vector Labs B-1075 50pg/ml
Rat anti-mouse 
ER-TR9
BMA T-2010 ER-TR9 IgM 2.5ug/ml
Rat anti-mouse 
MAdCAM-1
Serotec MCA 1551 MECA-367 IgG2a 2.5ug/ml
Rat anti-mouse 
MOMA-1
Serotec MCA947 MOMA-1 IgG2a 1/10
Rat anti-mouse 
CD169
Serotec MCA884 3d6.112 IgG2a 2.5pg/ml
Rat anti-mouse 
F4/80 FITC
eBioscience 11-4801 BM8 IgG2a 1.25pg/ml
Donkey anti­
sheep IgG HRP
Binding Site AP360 1/100
Biotinylated 
rabbit anti-rat 
IgG
Dako E0468 1/600
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Reagent Source Catalogue
no.
Clone Isotype Concentration/ 
dilution for use
Donkey anti­
sheep IgG 
Alexa 647
Molecular
Probes
A-21448 IgG lOpg/ml
Donkey anti­
sheep IgG 
Alexa 568
Molecular
Probes
A-21099 IgG
Goat anti-rat 
IgG Alexa 488
Molecular
Probes
A-11006 IgG 6.67pg/ml
Goat anti-rat 
IgM Alexa 488
Molecular
Probes
A-21212 IgG 6.67pg/ml
Chicken anti­
rat IgG Alexa 
647
Molecular
Probes
A-21472 IgG 6.67pg/ml
Rat anti-mouse 
Fc receptor
NIMR 24G2 IgGl 1:5
Rat anti-mouse 
pDC Alexa 488
G.Trinchieri 120G8 IgGl 2pg/ml
Goat anti­
mouse IgM (p 
chain) FITC
Sigma F-9259 1:400
Goat anti­
mouse IgG (y 
chain) FITC
Sigma F-8264 1:400
Rat anti-mouse 
ER-TR7
BMA T-2109 ER-TR7 IgG2a 1.33pg/ml
Rat anti-mouse 
CD31 FITC
BD 553372 MEC 13.3 IgG2a 0.83pg/ml
Hamster anti­
mouse LT{3
BD 552938 BB.F6.F6.BF2 Arm
hamster
lpg/ml
Hamster anti­
mouse LT0R
BD 552939 AC.H6 Arm
hamster
lpg/ml
Mouse anti­
hamster IgG 
biotinylated
BD 554010 G70-204 & 
G94-56
IgGl & 
IgG2b
1:100
Tyramide
signal
amplification
kit
Molecular
Probes
T20932
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Table 4. Antibodies and labelled antigens used for flow cytometry
Reagent Source Catalogue
no.
Clone Isotype Concentration/ 
dilution for use
Rat anti-mouse 
CD 19 biotinylated
BD 553784 1D3 IgG2a 0.5pg/ml
Rat anti-mouse 
CD138 PE
BD 553714 281-2 IgG2a lpg/ml
Rat IgG2a isotype 
control biotinylated
BD 553928 R35-95 IgG2a 0.5pg/ml
Rat IgG2a isotype 
control PE
BD 553930 R35-95 IgG2a lpg/ml
Mouse anti-BrdU 
FITC with DNase
BD 350649 IgGl 20pl per well
Mouse IgGl isotype 
control FITC
BD 550616 MOPC-31C IgGl 5pg/ml
pMCKl 10 Alexa 
647
NIMR 200pg/well
CGG Alexa 647 NIMR 200pg/well
pMCKl 10 FITC NIMR 200pg/well
CGG FITC NIMR 200pg/well
Rat anti-mouse Fc 
receptor
NIMR 24G2 IgGl 1:5
Rat anti-mouse IgM 
(p chain) APC
BD 550676 11/41 IgG2a 1:400
Goat anti-mouse 
IgG ( y chain) FITC
Sigma F-8264 1:400
Streptavidin
Tricolour
BD SA1006 1:100
Rat anti-mouse IgD 
FITC
BD 553439 ll-26c.2a IgG2a lOpg/ml
Goat anti-hamster 
IgG FITC
Jackson 127-095-160 1:400
Rat anti-mouse 
CD19APC
BD 550992 1D3 IgG2a 2pg/ml
Rat anti-mouse 
CD19PE
BD 553786 1D3 IgG2a 2pg/ml
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Chapter 3
Determining the duration of a primary infection of Plasmodium chabaudi chabaudi 
(AS)
Introduction
Malaria is a chronic infection in its natural host. A single infection with either Plasmodium 
falciparum or Plasmodium vivax causes a long-term recrudescing infection that can persist 
for several years in the absence of re-infection [379], although in endemic areas this pattern 
of infection is often complicated by many re-infections over the course of the transmission 
season [380]. Such multiplicity of infection is associated with a reduced risk of clinical 
disease [369]. Once the infection is cleared, however, immunity to re-infection wanes, so 
much so that absence from endemic areas for a long period of time results in loss of 
immunity [18]. The reasons for the existence of this concomitant immunity, and the lack of 
sterile immunity to malaria, are unknown. It is thought that the expression of variant 
antigens is a major contributor to this effect [360], however other mechanisms of immune 
evasion such activation of regulatory T cells [112] are also thought to have roles in the 
parasite's escape from immune responses (review [365]).
It is sometimes difficult to distinguish direct effects of the parasite from inadequate or 
inappropriate host responses. Nevertheless, it is clear that alterations in the function of the 
immune system do occur in malaria infection. For example, the high degree of alteration in
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the splenic microarchitectuie [345,346] is likely to affect the development of immune 
responses to both malarial and other antigens. Alteration of immune responses can be seen 
in both the acute and chronic phases of malaria infection [40, 366,381-384]. Defective 
antigen-processing caused by parasite-produced haemazoin has been suggested to play a 
role in immunosuppression [385], and alterations of dendritic cell function have also been 
suggested to contribute to malarial immunosuppression, although this is somewhat 
controversial (review [91]). These immunosuppressive effects of malaria have major 
implications for the development and severity of human infections, as well as for the 
efficacy of vaccination, as the majority of people in endemic areas will be infected with at 
least one other pathogen, more likely several different pathogens.
Plasmodium chabaudi, as well as P.falciparum and P. vivax, can produce a long-term 
recrudescing infection in its natural host [17]. Infection in laboratory mice does not exactly 
mimic the course of human infection, although it does have defined acute and chronic 
phases of disease, and the duration of laboratory infection has not been established.
Malaria infection is often thought of as cured once parasitaemia can no longer be detected 
by Giemsa-stained thin blood film. It is possible, however, that the infection persists below 
this detection limit for many weeks.
In order to study responses to secondary infection, and also the effects of chronic malaria 
on the immune system, it is necessary to determine the exact time limit when live parasites 
are no longer present in the host. This chapter establishes the duration of primary infection 
in two common strains of laboratory mice, C57BL/6 and BALB/c, by sub-inoculation of 
blood from chronically infected mice to immunodeficient hosts.
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Results
A typical course of parasitaemia in an infection of 1 x 10s P.chabaudi pRBC in C57BL/6 
mice as described previously [265,276,293, 318,346] is shown in Figure 10. The 
infection becomes patent, or detectable, usually at day 3, increases to a peak at day 8 then 
drops to less than 1% at around day 15. There is a slight recrudescence around day 20, then 
by day 30 the infection becomes subpatent -  i.e. cannot be detected by thin blood film 
(detection limit approximately 0.001% or 5 parasites per pi blood).
In order to determine how long parasitaemia remains subpatent, infected mice were 
exsanguinated at different times after primary infection was initiated. The recipient mice 
chosen were immunodeficient Rag 2'/_ or Rag Y1' mice, which have no acquired immune 
system, as small numbers of parasites are more likely to grow in an immunodeficient than 
in a wild-type host. This was likely to detect low parasitaemias, since a single parasite can 
theoretically give rise to a full infection. The experimental plan is shown in Figure 11. 
Theoretically, a single parasite can give rise to a full infection, however parasite viability 
within the inoculum, even in immunodeficient hosts, is unknown. The route of infection is 
likely to affect efficacy; experimental infections are commonly given intra-peritoneally, 
which is likely to decrease parasite viability more than intra-venous infection. Therefore, 
the sensitivity of this method was tested by injecting known numbers of parasites (1-1,000) 
into immunodeficient mice, which were then monitored until the recipient mice became 
parasitaemic by Giemsa stained thin blood films. If parasitaemia was not detected within 
three weeks it was assumed that no parasitaemia would develop and the mice were culled. 
Time to detection of parasitaemia varied, however no parasitaemia was ever detected more
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Figure 10. Representative course of primary parasitaemia in three 
C57BL/6 mice infected with 1 x 105 parasitised red blood cells. Error 
bars indicate standard error of the mean (SEM). Where error bars are 
not present, SEM is less than 10% of the mean.
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▼ Detection
1 2 3 4 5 6 limit with
Giemsa 
Months post infection stained thin- 
blood film 
BALB/c or 
C57BL/6 donor
Exsanguinate
Approximately 300 pi Approximately 300 pi
Rag V1 or Rag 2 /_ 
recipients
Monitor parasitaemia by Giemsa blood slides 3 x per week for 3 weeks
Figure 11. Experimental plan for sub-inoculation of blood from chronically infected mice 
to immunodeficient mice.
than 14 days after infection or sub-inoculation. The results of this limiting dilution 
experiment indicate that an infection of only 1 parasite can be reliably detected in 25% of 
recipients (Table 5). Parasites were not micro-manipulated, but were serially diluted in 
saline, and according to the zero order term of the Poisson distribution, with an average of 1 
parasite per inoculum 66% of mice should develop parasitaemia, assuming that all parasites 
are viable and can grow in the new host. Therefore, out of 20 mice injected, 12 should 
develop parasitaemia if there is 100% efficacy. As only 5 of these mice became 
parasitaemic efficacy is <50%, nevertheless an inoculum of only 1 parasite can be 
reproducibly detected. In the sub-inoculation experiment, mice were given between 200 
and 300pl of blood. The total blood volume of a laboratory mouse is approximately 2ml, 
therefore if we can detect a single parasite in Vio* this volume, we can detect a minimum of 
10 parasites in the entire blood volume of a mouse. The sensitivity of this assay is therefore 
very high.
The results of the sub-inoculation of blood from chronically infected donors to 
immunodeficient recipients are shown in Table 6. From these results it appears that 
BALB/c mice clear their infection faster than C57BL/6 mice. The first time this result was 
obtained it was unexpected, therefore a second experiment was performed to test the 
validity of the results. The second experiment gave the same results as the first, 
demonstrating both the validity and reproducibility of these results.
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Table 5. Limiting dilution of parasites
Number of parasites injected % mice developing parasitaemia
1* 25% (5/20 mice)
10 80% (16/20 mice)
100 100% (10/10 mice)
1,000 100% (13/13 mice)
* Parasites from BALB/c were serially diluted in 0.9% saline to give an average of 1-1,000 parasites per lOOpl 
injected volume, and injected into Rag 2'/' mice
Table 6. Detection of residual parasitaemia by sub-inoculation of blood from chronically 
infected hosts to immunodeficient recipients
Time of blood 
transfer after primary 
infection
% of recipients developing detectable parasitaemia
Experiment 1 Experiment 2 Combined results
BALB/c C57BL/6 BALB/c C57BL/6 BALB/c C57BL/6
1 month
100%
(6/6)*
75%
(6/8)
90%
(9/10)
100%
(6/6)
100% 86%
2 months
0%
(0/6)
33%
(2/6)
0%
(0/10)
27%
(3/11)
0% 29%
3 months
0%
(0/6)
0%
(0/6)
0%
(0/10)
0% (0/8)
0% 0%
* (x/y) indicates the number of mice developing parasitaemia (x) out of the total number of recipient mice (y)
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Discussion
This study has established that the chronic phase of P. chabaudi infection can persist for up 
to 3 months, depending on the host mouse strain; and that sub-inoculation of blood from 
chronically infected mice to immunodeficient hosts is a sensitive method for determining 
subpatent infection, able to detect a single parasite in 300pl of blood. It has also shown that 
BALB/c mice clear residual parasitaemia faster than C57BL/6 mice.
Different immune responses to infection are well documented in BALB/c and C57BL/6 
mice in response to Leishmania infection, where the Th2 response of BALB/c mice 
corresponds to susceptibility to disease, whilst the Thl response of C57BL/6 mice 
corresponds to resistance to disease (review [386,387]). These two mouse strains also 
differ in susceptibility to other infections (e.g. Burkholderia, Trypanosoma, ocular 
toxoplasmosis and viral infection) (review [388]) [262, 389-391]. This has been associated 
with higher levels of TNFa, nitrate and sometimes IFN-y in C57BL/6 mice [389, 391], and 
decreased IL-12 and IL-12Rp2 with increased IL-4 production in BALB/c mice [388], 
although higher levels of IFN-y mRNA were found in BALB/c than in C57BL/6 mice in 
Burkholderia pseudomallei infection [390].
The difference in clearance of P.chabaudi parasites between BALB/c mice and C57BL/6 
mice might be a consequence of a genetic predisposition of BALB/c mice towards a faster 
switch to Th2 responses, which might also mean faster and better antibody responses 
compared to C57BL/6 mice. Earlier production of antibody could be expected to correlate 
with faster clearance of parasites, since antibodies have been shown to be crucial for 
parasite clearance [287, 317, 318]. Higher IL-4 secretion from splenocytes of BALB/c
mice in response to P.chabaudi antigens has been observed [392], however a faster switch 
to a Th2 response in BALB/c mice may lead to increased susceptibility to higher acute 
parasitaemia, due to premature downregulation of the pro-inflammatory response before 
Th2 effector functions can be fully activated. In P.falciparum endemic areas, a 
polymorphism in the IL-4 promoter is associated with elevated anti-malaria IgG antibodies 
and decreased susceptibility to clinical infection [393]. In mice, the IgG2a isotype is 
associated with increased protection against P.chabaudi infection [329], however IL-4 non- 
responsive mice produce marginally lower levels of IgGl switch transcripts and higher 
levels of IgG2a transcripts [394] . The effect of the timing and magnitude of the Th2 
response on immune responses to malaria infection is, therefore, still unclear.
Chronic infection can allow the development of concomitant immunity (i.e. a low-level 
infection preventing the establishment of an acute infection from new exposure to the same 
pathogen), for example, maintenance of low-level infection of Leishmania is required for 
the persistence of immunity to re-infection [107]. Chronic infection can also affect the 
development of memory responses to the same pathogen, and can influence the amplitude 
and type of responses to other pathogens. Clearance of subpatent parasitaemia within 3 
months in C57BL/6 mice is substantiated by other work done in our laboratory during the 
time of this thesis. C57BL/6 mice re-infected 2.5 months after primary infection (i.e. in the 
presence of chronic infection) had a lower peak parasitaemia than mice re-infected 4.5 
months after primary infection (i.e. after clearance of chronic infection). Those mice re­
challenged at 4.5 months after primary infection had higher parasitaemias, and also clear 
their parasites faster, whereas mice with lower secondary infection parasitaemias take 
longer to clear the infection to subpatent levels [395, 396] (Figure 12). This suggests the
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Figure 12. Variations in parasitaemia during primary infection ( A ) ,  
and in secondary infection in the presence ( • )  or absence (O) of 
chronic parasitaemia.
A. Achtman, R. Stephens, E. Cadman, V. Harrison & J. Langhome, 
manuscript submitted
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existence of concomitant immunity in the C57BL/6 model of malaria. Malaria infections 
outside the laboratory often persist for the life of the host [17,361,397], although it is not 
clear to what degree this is due to continuous re-infection rather than persistence of a single 
infection. The precise effects of chronic infection on the development of memory 
responses are unclear, and the presence of memory T cells, memory B cells and long-lived 
plasma cells in malaria infection has not been demonstrated, but would be important to 
investigate.
Immunological memory is defined as the ability of the immune system to mount a more 
rapid and heightened response to antigens which have been encountered previously [43], 
and is thought to be mediated by a pool of antigen-specific cells that are more numerous 
than those present during primary exposure, which in the case of B cells may have a higher 
affinity for the antigen, and both B and T cells that may have a lower threshold for 
activation. One model of immunological memory maintenance is that memory cells 
proliferate during primary antigen exposure, then persist in a non-proliferating state, or 
turnover homeostatically, in the blood, secondary lymphoid organs and bone marrow until 
secondary antigen exposure. An alternative model is that memory cells are not long-lived, 
but that they divide and replenish themselves to maintain the memory cell population long­
term [235] (review [210,244, 398]). This second model may or may not require the 
persistence of antigen in order to retain the memory cell pool.
Requirements for antigen persistence in order to maintain immunological memory are 
controversial [210,248,399]. Zinkemagel [210] argues that immunological memory -  i.e. 
a faster response, is antigen-independent, but that protective immunity is antigen- 
dependent. Antigen may be maintained on follicular dendritic cells in secondary lymphoid
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organs for weeks after the live infection has been eliminated, however it has been argued 
that antigen does not persist after the end of an infection (review [192]). If this is the case 
then establishing the length of infection is important in order to allow us to study whether 
longevity of immune responses is due to long-lived memory, concomitant immunity or to 
continuous turnover of antigen-experienced cells.
Arguably, as long as immunological memory is maintained, the method of its maintenance 
is less important. Determining the presence of residual antigen after pathogen clearance is 
difficult, the presence of small amounts of antigen somewhere in the body can rarely be 
ruled out, and the question of persistence of antigen that is not live parasites has not been 
addressed here. Nevertheless, if immune responses wane soon after the clearance of 
chronic infection, a case can be made for the requirement of parasite persistence. This may 
be the appropriate model for human malaria infections, as immune responses drop at the 
end of the transmission season [177, 305,311,313,400]. In the C57BL/6 mouse model, 
antibody titres drop between 1 and 2 months after infection corresponding with the 
clearance of patent infection. There is, however, no obvious decline in antibody titres, 
either to whole parasite extract or to a defined malarial antigen, 3 months after infection 
when the subpatent parasitaemia is cleared [396]. This may indicate that memory B cells 
and long-lived plasma cells develop during the chronic infection, and will be the subject of 
further investigation.
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Chapter 4
Architectural changes and cellular migration in the spleen during acute malaria 
infection
Introduction
The spleen in malaria
The spleen has a central role in the immune response to malaria and splenomegaly, 
although not unique to malaria infection, is nevertheless one of the most striking features of 
the malaria infection. Within the first week of infection it increases in size several fold, 
both in humans and mice [184,345,401-403], and in mice also darkens in colour, so that it 
is easily distinguishable from spleens of naTve mice (Figure 13). Although splenomegaly is 
maximal at peak parasitaemia and reduces thereafter, the spleen never returns to the size (or 
colour) it had pre-infection. Splenomegaly is due in part to increased erythropoiesis in 
mice [183,184, 342-344], and influx of lymphocytes in human and mouse infections [344]. 
It is not caused by the parasite directly, but has been shown to be a T cell dependent 
response [404]. The extreme form of splenomegaly known as hyperreactive malarial 
splenomegaly has also been shown to be, at least partially, hereditary [403].
Splenectomy causes increased susceptibility to malaria in both humans [401] and rodents 
[258, 344, 351], with increased anaemia in splenectomised infected mice due to the greater 
erythropoietic role of the mouse spleen [30]. Injection of a naive splenic cell suspension 
cannot compensate for splenectomy, suggesting a role for splenic microarchitecture or
c . |£ . p ,rl
Figure 13. Photograph of naive and malaria infected mouse spleens 
Infected spleen is at day 20 post-infection
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stromal cells in immune responses to malaria [258,351]. Splenectomy does not, however, 
affect the development of anti-sporozoite immunity in response to immunisation [17]. The 
importance of the spleen in responses to primary infection may also have a genetic 
component, as D2 mice showed no effect of splenectomy on primary P.yoelii infection, 
whereas splenectomised C57BL/6 and BALB/c mice suffered more severe infections [405]. 
Some authors have shown that once immunity to erythrocytic stages has been acquired it 
may be maintained in the absence of the spleen in P.berghei infection [406], however 
splenectomy after the acquisition of immunity has been shown to reduce immunity in 
P.vinckei infection [258], P.chabaudi infection [407], P.berghei infection [408] and 
P.falciparum infection [409]. Splenectomised immune rats can clear a secondary infection, 
although the antibody response is delayed [369]. The spleen is therefore critical for an 
effective immune response against primary malaria infection, and still important for 
immune responses against secondary infection.
Splenic microarchitecture
Analysis of splenic structure in malaria infection shows large changes in both humans [348] 
and mice, particularly around peak parasitaemia [345-347]. These changes are only 
temporary however, and splenic structure returns to normal by day 60 [344, 345, 395]. 
Despite these changes, germinal centres still form and large numbers of plasma cells can be 
seen at the peak of infection [346]. It is not known however, whether these are part of a 
non-specific or malaria-specific immune response. It is also not known whether they 
remain in the spleen as short-lived plasma cells, or migrate to the bone marrow to become 
long-lived plasma cells.
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In P.chabaudi, it has been observed that marginal metallophilic macrophages (MMM) and 
marginal zone B cells (MZ B cells) are lost from the marginal zone during the course of 
infection. MZ B cells have been shown to remain in the spleen [345,346] and gradually 
return to the marginal zone [346], although their numbers remain reduced up to 120 days 
post-infection (R. Stephens, personal communication). Marginal zone macrophages 
(MZM) are also lost from the MZ in a Leishmania donovani infection [172] and after LPS 
treatment [349].
Macrophage depletion by administration of silica renders mice more susceptible to 
P.chabaudi malaria [410], and the effects of loss of macrophages from the MZ have been 
described in several models of systemic infectious disease. Depletion of MZM and MMM 
with low dose clodronate liposomes renders mice more susceptible to Listeria 
monocytogenes infection [411] and lymphocytic choriomeningitis virus (LCMV) infection 
[412], while high dose treatment also affects immunity to re-infection [413]. MZM have 
been shown to be required for the retention of MZ B cells in the MZ [414]. Work in other 
laboratories has demonstrated further changes in splenic microarchitecture, involving 
altered location of dendritic cells [415], macrophages [416] and formation of barrier cells 
[184, 344, 347].
In order to understand what happens in the spleen during acute infection, and to understand 
the differences between changes in mouse and human spleens, we need to thoroughly 
characterise what changes occur in the spleen, when during infection they occur, what 
causes these changes and whether they differ with repeated exposure to the parasite. This 
chapter shows a histological examination of spleens for days 0-10 of the acute infection, 
with two later timepoints at days 14 and 20. The following parameters were investigated
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with respect to extent of changes, chronological order and the time of infection when 
alterations become visible:
1) Location of parasites in the spleen
2) Segregation of T cells zones and B cell follicles
3) Distribution of dendritic cells, CD8+ and CD8‘ subsets and plasmacytoid dendritic 
cells, and their migration within the spleen during the acute infection
4) Distribution of red pulp macrophages
5) Alterations in the structure and composition of the marginal zone
6) Alterations in fibroblasts, reticular cells and expression of cell surface and adhesion 
molecules
7) Formation of germinal centres and plasma cells
8) Possible mechanism of alterations of the splenic microarchitecture
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Results
In order to determine changes in the microarchitecture of the spleen during the first ten 
days of infection and to compare them to later stages of infection, spleens were taken from 
P.chabaudi infected mice as shown in Figure 14.
Controls
One potential problem of multi-colour staining of spleen sections with the available 
antibodies is cross-reactivity of secondary antibodies or reagents. Therefore, all second- 
stage reagents were tested alone, in combination and together with isotype controls for the 
primary antibodies. Representative isotype controls from naive and infected mice for all 
experiments are shown in Figure 15. Cross-reaction of the anti-rat IgM Alexa 488 antibody 
with mouse IgM could not be eliminated by pre-incubating sections with anti-FcR or with 
unlabelled anti-mouse IgM, therefore MZM staining with the ER-TR9 antibody could not 
be transferred to immunofluorescence. All other secondary antibodies used did not cross- 
react with mouse immunoglobulins and no staining was seen with primary antibody isotype 
controls and appropriate secondary antibodies.
Co-staining and colour overlap
Some cell surface molecules are not expressed on the same cells, however confocal 
microscopy at low magnification (x 30.4) cannot always distinguish between the expression 
of such molecules on the same cell and their expression on closely neighbouring cells. In 
this situation, true co-staining can be distinguished by examination of images at higher 
magnification (Figure 16, Figure 17), and can be objectively determined by colour 
percentage analysis of the degree of colour overlap at low and high magnification.
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Spleens taken daily from days 0-10, then days 14 & 20
Figure 14. Experimental plan of histological analysis of spleens during 
the acute malaria infection
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Figure 15. Isotype controls for immunohistology
Black spots on immunocytochemistry sections * (rabbit anti-rat biotin & donkey anti-sheep 
HRP) are Indian Ink taken up by marginal zone macrophages
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Figure 16. False co-staining by expression of cell surface molecules on closely 
neighbouring cells
A) Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 
647 (red) for B cell follicles and rat anti-mouse CD3 & goat anti-rat IgG Alexa 488 
(green) for T cells.
B) Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 
647 (red) for B cell follicles and rat anti-mouse F4/80 & goat anti-rat IgG Alexa 488 
(green) for macrophages.
At higher magnification there is little co-localisation of the two stains. False double 
staining can only be seen at one side of a cell where it is next to one stained with the other 
marker and is seen at the edge of cell populations. Day post-infection of spleen sections is 
indicated to the left of the images.
130
IgD/CD3
A
x 30.4 x 65
dlO
IgD/F4/80
B
d9
- . .  . V  ••• 'j
■ ' /  v ? ,-V  .r-.t .. ** . • x. • i*-s, > c.
- -A  ^ ' •>• 1 ‘ • w l
. ?. ■.. • '■ • • >;
v: •'•••.• • . ;■ '■• .. '•
L . *'• '.i-Jv V . . V • v  1 
-
• h.;: ” v ,  ■ . i  •
; ;
>&;• » i" -
■ . » • ■ ■  . . .• > . , , ,  v ■
-pf
. , V. V?..
J  . . - \ £ ,
. •< / « .  $  •
131
Figure 17. True co-staining of CD8*CD1 lc+ dendritic cells, IgM* and IgG* plasma cells in 
the spleens of mice infected with P.chabaudi
Pixels in the yellow spectrum, as selected by the colour picker plugin for ImageJ, are 
overlayed in white
A) Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 
568 (blue) for B cell follicles, rat anti-mouse CD8 & chicken anti-rat Alexa 647 
(red) and hamster anti-mouse CD1 lc Alexa 488 (green) for dendritic cells.
B) Spleen sections were stained with sheep anti-mouse IgD (blue) for B cell follicles, 
rat anti-mouse CD 138 (red) for plasma cells and rat anti-mouse IgM FITC (green) 
for MZ B cells/IgM* plasma cells
C) Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 
568 (blue) for B cell follicles, rat anti-mouse CD 138 & chicken anti-rat Alexa 647 
(red) for plasma cells and rat anti-mouse IgG FITC (green) for IgG* plasma cells
True co-localisation of antibodies to CD8/CD1 lc, IgM/CD138 and IgG/CD138 can be seen 
all around the cell and in the centre of single stained populations, not just where two 
populations are next to each other. Day post-infection of spleen sections is indicated to the 
left of the images.
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Table 7 shows a colour analysis of the images shown in Figures 16 & 17. The percentage 
of the image area that falls in the yellow spectrum is higher for low magnification images 
than high magnification images from Figure 16. This indicates that the colour overlap is 
due to expression of different cell surface molecules on closely neighbouring cells, which is 
as expected. By comparison, the colour overlap percentage is higher at high magnification 
than low magnification for images from Figure 17, indicating that these cells co-express 
both molecules, also as expected. Higher levels of colour overlap at lower magnification 
than higher magnification therefore indicate false co-staining, while higher levels of colour 
overlap at higher magnification than lower magnification indicate true co-staining.
Location o f parasites
The spleen is the primary site of contact between antigens in the blood and lymphocytes in 
the white pulp of the spleen. It is particularly relevant for malaria infection, where the 
disease-causing phase of the life-cycle is an infection of erythrocytes. The early location of 
parasites in the spleen was identified by injecting CFSE labelled parasites into the mouse 
and harvesting spleens 1 and 4 hours post infection. Confocal microscopy of spleen 
sections shows the majority of the parasites in the red pulp and marginal zone, however 
some have already penetrated into the white pulp as little as 1 hour after injection (Figure 
18 A & B). The location of parasites in relation to CD1 lc+ dendritic cells was also 
determined. Parasites were seen in close proximity to dendritic cells, however there was 
little co-localisation of CFSE and CD1 lc, giving no indication that dendritic cells have 
taken up parasites at this early timepoint (Figure 18 C & D). Further work would be 
required to determine the time and location of the initial uptake of parasites by dendritic 
cells.
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Table 7. Incidence of co-staining in images taken at low and high magnification
Stain Day Magnification (x) % co-staining
IgD/CD3 2 30.4 0.59
IgD/CD3 2 65 0.36
IgD/CD3 10 30.4 0.56
IgD/CD3 10 65 0.26
IgD/F4/80 2 30.4 4.56
IgD/F4/80 2 65 1.27
IgD/F4/80 9 30.4 2.69
IgD/F4/80 9 65 1.63
CD8/CDllc 3 30.4 2.98
CD8/CDllc 3 65 4.78
CD138/IgM 0 30.4 0.25
CD138/IgM 0 65 1.58
CD138/IgG 0 30.4 0.39
CD138/IgG 0 65 0.51
Co-staining was measured using the colour picker plugin (Daan Zhu, NIMR) for ImageJ.
Figure 18. Location of parasitised erythrocytes within the spleen 1 hour after infection 
with 2 x 107 P.chabaudi pRBC
A and B) Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep 
Alexa 568 (red) for B cell follicles. pRBC were labelled with CFSE (green) and 
had been injected i.v. into naiVe mice 1 hour previously 
C and D) Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep 
Alexa 647 (red) for B cell follicles, and hamster anti-mouse CD1 lc biotin & 
neutravidin Texas Red for dendritic cells (blue). pRBC were labelled with CFSE 
(green) and injected i.v. into naive mice.
Images shown are representative of the whole spleen and of two mice. A and C show 
mostly white pulp (WP), B and D show white pulp and red pulp (RP). Magnification x 65
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Segregation o f B and T cell zones
Merging of T and B cell areas during the acute malaria infection is shown in Figure 19. T 
and B cell areas can be clearly defined in the nafve mouse with antibodies to CD3 (T 
cells) and IgD (naTve follicular B cells). These areas remain well segregated until day 5 of 
infection, when increasing numbers of T cells can be observed in the red pulp. Segregation 
of B and T cells continues to lessen as the parasitaemia increases, reaching a minimum at 
day 10 post infection, at the time of peak parasitaemia. At day 14 post infection B cell 
follicles are thinner and more ring-like, as follicular B cells have been pushed out to form a 
follicular mantle around germinal centres. T cells can be seen clustered next to follicles but 
not inside them, and both T and B cells are mostly absent from the red pulp. As the 
parasitaemia is cleared, T and B cell areas re-form, although they have still not regained 
their original locations by day 20. The images shown in Figure 19 are representative of the 
whole spleen, and of three mice. These results confirm what has been previously 
demonstrated by other investigators [345, 346].
Dendritic cells
The cells that initiate the immune response are the antigen-presenting cells, particularly the 
conventional dendritic cells, which express high levels of CD1 lc [55], but also 
plasmacytoid dendritic cells, which are capable of antigen presentation to naive T cells [67] 
(though more efficient at antigen presentation to antigen-experienced cells) and express low 
to intermediate levels of CD1 lc [49,64,67,68]. In naiVe mice, CD1 lc+ cells are present in 
the red pulp, marginal zone and white pulp. Increasing numbers of CD1 lc+ cells can be 
seen throughout the red pulp from day 5 of P.chabaudi infection, however by day 10 post­
infection they have clustered in the red pulp close to the remaining B cell follicles, where
Figure 19. Reduced segregation of B and T cell areas in the spleen during acute 
P.chabaudi infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse CD3 & goat anti-rat IgG Alexa 488 (green) for 
T cells. Images shown are representative of the whole spleen and of three mice. Areas of 
red pulp (RP) and white pulp (WP) are indicated. Magnification x 30.4
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Figure 20. Location of CD1 lc+ dendritic cells in the spleen during acute P.chabaudi 
infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and hamster anti-mouse CD1 lc Alexa 488 (green) for dendritic 
cells. Images shown are representative of the whole spleen and of three mice. 
Magnification x 30.4
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they remain for the next ten days (Figure 20). Colour picker analysis of images shows an 
increase in CD1 lc+ cells from 5% in naive mice to 71% of the image area on day 8 post­
infection. This is an increase not only in numbers of cells,but in density of CD1 lc+ cells in 
the spleen, as the spleen increases several fold in size during the acute malaria infection 
(Figure 13), therefore colour picker analysis of images at the peak of parasitaemia under­
represents cell numbers in comparison to naive mice.
Increasing numbers of dendritic cells in the spleen can also be seen by flow cytometry from 
day 5 post infection, with numbers decreasing after the peak of parasitaemia [61] (Figure 
21 A). It is not known whether this increase is a result of dendritic cell proliferation or 
immigration into the spleen from the blood. Resident splenic dendritic cells are 
CD1 lc+/high, whereas monocytes in the blood are CD1 lc'/int [417]. The majority of the cells 
responsible for the increase in dendritic cell numbers are CD1 lcint cells (Figure 2IB), 
which may suggest that the increase in dendritic cells is mostly due to recruitment of cells 
from the blood.
There is much debate over whether or not the two major subsets of conventional dendritic 
cells, CD8+ and CD8', have different functions. Spleen sections were therefore co-stained 
with antibodies to CD8 and CD1 lc to determine whether the two populations have different 
locations, possibly indicating different roles in the acute P.chabaudi infection. In the naive 
mouse, CD8‘CD1 lc+ DCs are found in the red pulp and marginal zone, while CD8+CD1 lc+ 
DCs are found primarily in the white pulp (Figure 22). In infected mice, there is already an 
increase in the proportions of CD8' CD1 lc+ DC relative to CD8+CD1 lc+ DC by day 5 post 
infection (Figure 21 A). By this time there are increased numbers of CD8*CD1 lc+ DC in 
red pulp (Figure 22). As the B and T cell areas become indistinguishable both DC
Figure 21. Increasing numbers of dendritic numbers in the spleen during acute P.chabaudi 
infection determined by flow cytometry analysis
A) Total CD 1 lc+cells
B) CD llcmttm^ ““  cells
C) CDllchi8h cells
A-M. Sponaas, E. Cadman, C. Voisine, V. Harrison, A. Boonstra, A. O’Garra & J. 
Langhome, J Exp Med 2006 203(6) 1427-33
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Figure 22. Location of CD8+ and CD8~ conventional dendritic cell subsets in the spleen 
during acute P.chabaudi infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 568 
(blue) for B cell follicles, hamster anti-mouse CD1 lc Alexa 488 (green) for CD8* dendritic 
cells and rat anti-mouse CD8 & chicken anti-rat Alexa 647 for CD8+ T cells (red) and 
CD8+ dendritic cells (yellow). Images shown are representative of the whole spleen and of 
three mice. Magnification x 30.4
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populations are spread throughout the spleen, then as B and T cells begin to cluster back 
together around day 14, both CD8CD1 lc+ and CD8+CD1 lc+ DCs can be seen re­
associating with them. The majority of the increase in numbers of dendritic cells is due to 
an increase in numbers of the CD8'CD1 lc+ subsets, however there is also an increase in 
number of CD8+CD1 lc+ DCs. Whether this increase in DC numbers is due to an influx of 
cells from the blood or to proliferation of resident splenic DCs has not been determined. 
Numbers of CD8+CD1 lc+ DCs peak later around day 20, whereas CD8‘CD1 lc+ DC 
numbers peak around the peak of parasitaemia [61] (Figure 21 A). Colour picker analysis 
of images shows similar proportions of CD8+ DCs (3.44%) and CD8' DCs (3%) in naive 
mice, increasing to 5.6% CD8+ DCs and 14% CD8‘ DCs by day 5 post-infection, in 
agreement with flow cytometiy data. CD8‘ DCs further increase to 16.4% on day 8 and 
21.7% on day 14 post-infection. The proportion of CD8+ DCs drops slightly to 4.5% on 
day 8 and 3.4% on day 14, however these numbers refer to the density of CD8+ DCs in the 
images, rather than the absolute number of cells.
Plasmacytoid DCs are found in the red and white pulp in the spleens of naive mice, but not 
in the marginal zone (Figure 23) [80]. They remain mostly in the red pulp during a malaria 
infection and do not migrate into the white pulp, although they increase in number up to 
day 20 post-infection (Figure 24E). Prior to the peak of parasitaemia, days 5-7 post 
infection, they can be seen in the marginal zone as well, moving back out into the red pulp 
at the peak of parasitaemia between days 8 and 10 post-infection.
Macrophages
Macrophages are important in malaria infection for removal of parasites, and macrophage 
depletion renders mice more susceptible to malaria infection [410]. Red pulp macrophages
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Figure 23. Location of plasmacytoid dendritic cells in the spleen during acute P.chabaudi
infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse 120G8 Sc goat anti-rat IgG Alexa 488 (green) 
for plasmacytoid dendritic cells. Images shown are representative of the whole spleen and 
of three mice. Magnification x 65
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Figure 24. Profile of plasmacytoid dendritic cells in the spleen during acute P.chabaudi 
infection. Spleen cell suspensions were made by liberase treating naive and infected 
spleens. Splenocytes were stained with anti-CD 1 lc for dendritic cells and 120G8 for 
pDCs.
A) Naive mouse
B) Day 5 post infection
C) Day 9 post infection
D) Day 20 post infection
E) Changes in pDC number in the spleen during acute P.chabaudi infection 
C. Voisine, E. Cadman, A-M. Sponaas & J. Langhome, in preparation
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are visualised with an antibody to the cell surface molecule F4/80. They are clearly visible 
solely in the red pulp in naTve mice, and remain there throughout the acute infection 
without entering the white pulp or the marginal zone (Figure 25). As the red pulp contains 
the majority of red blood cells, and thereby most likely the majority of parasites, this is 
expected, although the uptake of pRBC by F4/80+ macrophages has not been determined. 
The spleen increases several-fold in size during the acute malaria infection, yet 
macrophages remain at a high concentration in the red pulp, indicating that there is an 
increase in numbers of these cells in the spleen during the acute malaria infection. Colour 
picker analysis of images shows an increase in F4/80+ macrophages from approximately 
11% in naTve mice, to 18% at day 10 post-infection. This increase in numbers is 
particularly striking at day 14 post-infection, when the red pulp appears to be largely 
constituted of F4/80+ macrophages (approximately 24% of image area by colour picker 
analysis). Flow cytometry analysis, however, would be required to confirm an increase in 
macrophage numbers during acute P.chabaudi infection.
CD1 lb (Mac-1) is expressed mainly on phagocytic cells, although it can also be expressed 
on some B, T, and NK cells (review [418]). Splenic red pulp macrophages, however 
express only low levels of CD1 lb and high levels of F4/80 (review [419]), therefore we 
would not expect expression of CD1 lb to correlate directly with expression of F4/80.
CD1 lb+ cells are seen in the red pulp of the spleen in naive mice and remain there 
throughout the acute infection with little increase in density, indicating a possible increase 
in numbers (Figure 26). CD1 lb+ cells are F4/80+ not CD1 lc+ (data not shown), although 
not all F4/80+ cells express levels of CD1 lb detectable by histology. CD1 lc+ cells may 
also express low levels of CD1 lb that are not detectable by this method.
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Figure 25. Location of F4/80+ macrophages in the spleen during acute P.chabaudi
infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse F4/80 & goat anti-rat IgG Alexa 488 (green) for 
red pulp macrophages. Images shown are representative of the whole spleen and of three 
mice. Magnification x 30.4
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Figure 26. Location of CD1 lb+ cells in the spleen during acute P.chabaudi infection 
Spleen sections were stained with sheep anti-mouse IgD (red) & donkey anti-sheep Alexa 
647 for B cell follicles and rat anti-mouse CD1 lb & goat anti-rat IgG Alexa 488 (green) for 
CD1 lb+ cells. Images shown are representative of the whole spleen and of three mice. 
Magnification x 30.4
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The marginal zone
The splenic marginal zone has a specialised structure, which facilitates the interaction of 
antigens in the blood with the cells residing in the marginal zone. There are two distinct 
populations of macrophages in the marginal zone; an inner ring of MMM, and an outer ring 
of MZM [186]. MZ B cells are closely associated with MZM in the outer ring, and 
memory B cells are also thought to be located here [420]. MZM and MMM lie on either 
side of the marginal sinus, which is lined by endothelial cells (Figure 27) [186].
MMM are distinguished by their expression of CD 169 (sialoadhesin/siglec-1) and form a 
complete ring around the white pulp in naive mice, however as the infection progresses 
these are gradually lost from the marginal zone until only a few remain in this location at 
day 10 post infection, the rest being scattered throughout the red pulp (Figure 28A). 
Detection of another cell surface molecule expressed by MMM, MOMA-1, produces the 
same picture (Figure 28B), suggesting that these cells are truly being lost from this location 
and are not just downregulating expression of cell surface molecules.
Marginal zone macrophages (MZM) are visualised with the marker ER-TR9 (SIGNR1 
[44]). They are clearly present in the marginal zone in naTve mice, but begin to be lost from 
this location by day 6, are almost entirely absent from this location by day 10 post­
infection, and are instead scattered throughout the red pulp (Figure 29). An alternative 
method of visualising MZM is to inject mice intravenously with Indian ink, which is taken 
up selectively by MZM, one day prior to infection. MZM which have taken up carbon 
particles can be seen in the marginal zone in naive mice, however these gradually disappear 
as the infection progresses, until they can no longer be seen in the marginal zone by day 10 
post infection (Figure 29). Again this suggests that these cells are being completely lost
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Figure 28. Location of marginal metallophilic macrophages in the spleen during acute
P.chabaudi infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse CD 169 (A) or MOMA-1 (B) & goat anti-rat IgG 
Alexa 488 (green) for marginal metallophilic macrophages. Images shown are 
representative of the whole spleen and of three mice. Magnification x 30.4
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Figure 29. Location of marginal zone macrophages in the spleen during acute P.chabaudi
infection
Spleen sections were stained with sheep anti-mouse IgD, donkey anti-sheep HRP & 
visualised with DAB (brown) for B cell follicles and rat anti-mouse ER-TR9, rabbit anti-rat 
biotin, streptavidin ABComplex AP & visualised with Fast Blue (blue) for marginal zone 
macrophages (A). Mice were injected intravenously with 5% Indian Ink in saline, which is 
selectively taken up by marginal zone macrophages (black), one day before infection (B). 
Images shown are representative of the whole spleen and of three mice. Magnification x 
30.4
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from the marginal zone, rather than downregulating cell surface molecules.
Marginal zone B cells are closely associated with MZM, and can be clearly seen at the edge 
of the B cell follicle in naTve mice (Figure 30), identified as IgMhigh, IgDlow/' cells. They 
remain closely associated with the follicle until day 5 post infection, when they are no 
longer found in the marginal. Although IgM* cells in the marginal zone may be identified 
as marginal zone B cells, once removed from the marginal zone location, MZ B cells may 
be confused with IgM* plasmablasts/plasma cells in the red pulp. This confirms previous 
work from our laboratory demonstrating the loss of MZ B cells from the marginal zone 
during acute malaria infection [346]. Flow cytometry analysis has previously revealed, 
however, that MZ B cells are still present in the spleen, increasing in number at days 5 and 
6 before the peak of parasitaemia and decreasing in number at, and just after, peak 
parasitaemia [346].
Sinus-lining endothelial cells express the adhesion molecule MAdCAM-1 [186], which 
clearly demarcates the marginal zone in naTve mice. Again beginning around day 5-6 post­
infection, the expression pattern of this adhesion molecule changes, until it can be seen as a 
network pattern encompassing the white pulp just after the peak of infection (Figure 31) 
[345].
Reticular and endothelial cells
Other work has shown similar patterns of staining to that we see with MAdCAM-1 during 
infection, over the white pulp area, with a reticular cell marker, ER-TR7 [421]. In our 
hands however, ER-TR7 expression is restricted to the red pulp and marginal zone (Figure 
32). ER-TR7 is an antigen produced by fibroblastic reticular cells that may have a role in 
chemotaxis of lymphocytes, by forming part of a reticular meshwork making up the
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Figure 30. Location of marginal zone B cells and IgM* plasma cells in the spleen during
acute P.chabaudi infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and goat anti-mouse IgM FITC (green) for marginal zone B 
cells/IgM+ plasma cells. Images shown are representative of the whole spleen and of three 
mice. Magnification x 30.4
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Figure 31. Expression of MAdCAM-1 on endothelial cells in the spleen during acute 
P.chabaudi infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse MAdCAM-1 & goat anti-rat IgG Alexa 488 
(green) for sinus-lining endothelial cells. Images shown are representative of the whole 
spleen and of three mice. Magnification x 30.4
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Figure 32. Location of ER-TR7+ reticular cells in the spleen during acute P.chabaudi
infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse ER-TR7 & goat anti-rat IgG Alexa 488 (green) 
for reticular cells. Images shown are representative of the whole spleen and of three mice. 
Magnification x 61
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extracellular matrix that is the “scaffolding” for organ formation [422]. ER-TR7 
expression is altered in malaria infected spleens, with the strongest staining in the marginal 
zone and surrounding central arterioles. Colour picker analysis of ER-TR7 staining shows 
an increase in expression from approximately 34% in naTve mice, to approximately 54% on 
day 8 post-infection, indicating either an increase in number of reticular cells or induction 
of ER-TR7 expression on cells not previously expressing this molecule. Although the 
spleen increases in size up to 15-fold during acute malaria infection [184], colour picker 
analysis was conducted on the same area of splenic tissue, indicating an increase in density 
of ER-TR7 expression as well as in total amount of expression. Further work, however, 
would be required to confirm this.
As the increased MAdCAM-1 expression does not co-localise with ER-TR7+ reticular cells, 
other endothelial cell markers were studied. CD31 (PECAM-1) is another adhesion 
molecule expressed on endothelial cells in the spleen, although not those lining the 
marginal sinus [423]. It is important for transendothelial migration of lymphocytes, in 
particular the migration of neutrophils into the peritoneal cavity [424]. Expression of this 
molecule does not alter in location during the malaria infection. It is found in the red pulp, 
bridging channels and a little in the T cell zone in naTve mice, and remains mostly in the red 
pulp throughout the acute infection (Figure 33). As with ER-TR7 expression, the degree of 
CD31 expression increases from approximately 25% in naTve mice, to approximately 60% 
by day 8 of infection over the same area of the spleen, indicating an increase in density of 
CD31 expression, and a possible increase in either number of endothelial cells, or induction 
of expression of this adhesion molecule, although further work would be required to detail 
changes in endothelial cell populations during acute malaria infection.
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Figure 33. Location of CD31+ endothelial cells in the spleen during acute P.chabaudi 
infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse CD31 & goat anti-rat IgG Alexa 488 (green) for 
endothelial cells. Images shown are representative of the whole spleen and of three mice. 
Magnification x 61
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Germinal centres
Despite the transiently altered splenic structure and lack of defined T, B and marginal 
zones, a B cell response still occurs. Mice were not kept in a germ-free environment, 
therefore some germinal centres (1-2 per B cell follicle) can be seen in uninfected mice. 
These increase in number and size during the malaria infection, reaching their maximum 
after the peak of parasitaemia (Figure 34) [346]. There are a few T cells within germinal 
centres in the first few days of infection (0-6), with a larger number of T cells being visible 
in larger germinal centres at later time points (day 10 onwards). T cells are always closely 
associated with germinal centres, even at the peak of parasitaemia when T cells are 
distributed throughout the red and white pulp (Figure 34). Between days 7 and 9 post­
infection, encompassing the period of peak parasitaemia, many germinal centre cells are 
present in the spleen, however they are mostly distributed throughout the red pulp rather 
than forming discrete germinal centres within follicles. By day 10 post-infection, germinal 
centres within B cell follicles can be seen. Germinal centre formation after immunisation 
or viral infection can normally be seen by day 6-10 [151,210], although they can also be 
seen as early as day 4 [151], therefore the scarcity of germinal centres between days 7 and 9 
post-infection points towards a slight delay in germinal centre formation.
Plasma cells
Small foci of extra-follicular plasma cells are present in nai’ve mice and in the first week of 
infection, however from day 8 onwards, larger numbers of plasma cells can be seen in the 
red pulp (Figure 35). By day 10 of infection the plasma cells have spread to the white pulp 
region as well. The peak of plasma cell numbers in the spleen has been shown to be around
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Figure 34. Location of germinal centres, and their location in relation to T cells, in the 
spleen during acute P.chabaudi infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 568 
(blue) for B cell follicles, rat anti-mouse CD3 & chicken anti-rat Alexa 647 (red) for T cells 
and peanut agglutinin biotin & streptavidin FITC (green) for germinal centres. Images 
shown are representative of the whole spleen and of three mice. Areas of red pulp (RP) and 
white pulp (WP) are indicated. Magnification x 30.4
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Figure 35. Location of plasma cells in the spleen during acute P.chabaudi infection 
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 647 
(red) for B cell follicles and rat anti-mouse CD 138 & goat anti-rat IgG Alexa 488 (green) 
for plasma cells. Images shown are representative of the whole spleen and of three mice. 
Magnification x 30.4
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day 10 post infection [346], however large numbers of plasma cells remain in the spleen 
until at least day 20 post-infection. The average lifespan of plasma cells in the spleen is 
approximately 3 days [148]. Long-lived plasma cells may persist for longer, however, from 
these analyses it is not possible to tell whether the plasma cells are long-lived or 
continuously being formed throughout the acute infection. The majority of plasma cells 
present in naYve mice are IgM*, although a few IgG* plasma cells are also present (Figures 
36 & 37). Between days 1 and 4 post-infection, very few IgG+ plasma cells are present, 
and the majority of plasma cells are IgM*. IgM*CD 138' marginal zone B cells are located 
close to extra-follicular foci of plasma cells, suggesting that at least some of these plasma 
cells may be derived from marginal zone, rather than follicular, B cells (Figure 36). Up to 
day 7 of infection, the majority of plasma cells are non-switched, IgM* cells, although IgG* 
plasma cells can be seen in increasing numbers as early as day 5 post-infection. Colour 
picker analysis shows 38% of plasma cells being IgM* on day 7 post-infection, compared 
to only 9% IgG*. As plasma cell numbers increase dramatically, from day 8 post-infection, 
isotype switched IgG* plasma cells constitute the majority of plasma cells, although IgM* 
plasma cells are still visible through to day 20 post-infection. The peak number of IgG* 
plasma cells appears to occur on day 14 post-infection, when 50% of plasma cells are IgG* 
compared to 23% IgM*, although this is a rough analysis of pixel numbers rather than cell 
numbers, using only a single image, and should be backed up by more extensive analysis 
by histology and/or flow cytometry for a full characterisation of antibody isotype switching 
in the spleen during P.chabaudi infection.
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Figure 36. Location of marginal zone B cells and IgM1' plasma cells in the spleen during
acute P.chabaudi infection
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 568 
(blue) for B cell follicles, rat anti-mouse CD 138 & chicken anti-rat Alexa 647 (red) for 
plasma cells and goat anti-mouse IgM FITC (green) for IgM* plasma cells. Images shown 
are representative of the whole spleen and of three mice. Magnification x 30.4
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Figure 37. Location of IgG* plasma cells in the spleen during acute P.chabaudi infection 
Spleen sections were stained with sheep anti-mouse IgD & donkey anti-sheep Alexa 568 
(blue) for B cell follicles, rat anti-mouse CD 138 & chicken anti-rat Alexa 647 (red) for 
plasma cells and goat anti-mouse IgG FITC (green) for IgG+ plasma cells. Images shown 
are representative of the whole spleen and of three mice. Magnification x 30.4
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Lymphotoxin and the splenic microarchitecture
Taken together, all these changes provide a unique phenotype of transient cellular 
reorganisation in the spleen. It has been shown that TNFa, LTa and LTp each have a role 
in the correct formation of splenic microarchitecture [164,171,181,425]. In order to 
investigate the importance of splenic changes in primary malaria infection, we attempted to 
prevent the reorganisation of splenic structure by administration of an agonistic LTpR 
antibody. Changes in splenic microarchitecture become detectable between days 5 and 6 
post-infection, during the exponential growth phase of the blood-stage infection. Day 4 
post-infection was chosen for the administration of the LTpR agonist antibody as being 
prior to the changes in splenic structure becoming visible, but close enough to this critical 
time period to be able to have an effect. Unfortunately, administration of this antibody did 
not have any effect on either splenic structure or parasitaemia in the primary infection 
(Figure 38). T and B cell zones still merge and there is no visible difference in splenic 
microarchitecture between mice treated with anti-lymphotoxin p agonist antibody (Group
C), control antibody (Group B) or untreated mice (Group A). It was hypothesised that 
retention of the correct splenic microarchitecture during primary infection might improve 
immunity to secondary infection, and that if splenic microarchitecture could not be 
preserved during the primary infection, a more subtle effect of the lymphotoxin agonist 
antibody might have a visible effect on immunity and splenic microarchitecture during 
secondary infection. Administration of the agonist lymphotoxin antibody during primary 
infection had no effect on splenic microarchitecture during a secondary infection (Figure 
39), however mice given the lymphotoxin agonist antibody had lower parasitaemia during 
the secondary infection (Figure 3 9A). Although this difference is slight, it suggests that
Figure 38. Effect of lymphotoxin agonist on primary P.chabaudi infection.
Spleen sections were taken at day 10 post-infection and stained with sheep anti-mouse IgD 
& donkey anti-sheep Alexa 647 (red) for B cell follicles and rat anti-mouse CD3 & goat 
anti-rat IgG Alexa 488 (green) for T cells. Images shown are representative of the whole 
spleen. Magnification x 30.4
A) Primary infection parasitaemia in untreated (—— control antibody treated 
(— ) and lymphotoxin agonist antibody treated ( ——) mice 
Red arrow indicates time of agonist lymphotoxin antibody administration
B) Splenic microarchitecture in wild-type mice
C) Splenic microarchitecture in control antibody treated mice
D) Splenic microarchitecture in lymphotoxin agonist antibody treated mice
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Figure 39. Effect of lymphotoxin agonist on secondary P.chabaudi infection.
Spleen sections were taken at day 10 post-infection and stained with sheep anti-mouse IgD 
& donkey anti-sheep Alexa 647 (red) for B cell follicles and rat anti-mouse CD3 & goat 
anti-rat IgG Alexa 488 (green) for T cells. Images shown are representative of the whole 
spleen. Magnification x 30.4
A) Secondary infection parasitaemia in untreated ( —  ), control antibody treated 
( —  ) and lymphotoxin agonist antibody treated (— ) mice
B) Splenic microarchitecture in wild-type mice
C) Splenic microarchitecture in control antibody treated mice
D) Splenic microarchitecture in lymphotoxin agonist antibody treated mice
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more extensive treatment with the agonist antibody may produce a more substantial effect 
on infection. One out of three mice in each group did not develop detectable parasitaemia 
in the secondary infection.
Summary
We have demonstrated the presence of the parasite in both the red and white pulp of the 
spleen as early as 1 hour after infection. The first changes in splenic structure can be seen 
at day 5 post-infection, with changes in location of plasmacytoid dendritic cells, marginal 
zone cells and changes in expression of MAdCAM-1. Daily analysis of splenic structure 
shows that changes in the splenic microarchitecture occur in a linear fashion. As described 
previously [345,346], alterations in splenic structure are maximal between days 8 and 10 of 
infection, around the peak of parasitaemia, when T and B cell zones are merged, CD8'
CD1 lc+ numbers peak, large germinal centres and numerous extra-follicular plasma cells 
are seen. Isotype switching from a majority of IgM+ plasma cells to a majority of IgG+ 
plasma cells occurs on day 8 post-infection. As the parasite is cleared, changes in the 
splenic microarchitecture begin to reverse by day 14 post-infection, with cellular number 
and location becoming similar to that in naive mice, although the spleen remains 
permanently enlarged. These changes were hypothesised to be due to a temporary loss of 
signalling through the LTp pathway, however expression of LTp, LTpR or CXCR5 (Figure 
7) could not be detected by histology in either naTve or infected spleens. Administration of 
a single dose of agonistic LTpR antibody also had no effect on parasitaemia in primary 
infection, little effect on parasitaemia in secondary infection, and no effect on splenic 
structure in either primary or secondary infections.
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Discussion
During malaria infection the spleen increases up to 15>fold in weight [184], and 
approximately 7-fold in lymphocyte numbers (Chapter 5, Figure 43, [346,392]), and 
becomes much darker in colour due to the deposition of haemozoin (malaria pigment). 
Although it has previously been shown that striking but transient changes in location of the 
normal populations of splenic cells occur during acute malaria infection [184,345,346, 
416], the point at which these changes first become evident had not been established. 
Similarly, the order in which different cell populations change location was not known. We 
therefore undertook a detailed analysis of the timing and extent of changes in splenic cell 
populations during the acute phase of malaria infection. The use of immunofluorescence 
rather than conventional histology enabled residual B cell follicles at the peak of 
microarchitecture alterations to be identified more easily (compare Figures 19 & 29).
In naive mice, dendritic cells are found in the red pulp, marginal zone and T cell zone [60], 
with CD8* DCs preferentially found in the red pulp, MZ and bridging channels, and CD8+ 
DCs in the T cell zone (review [55]). They migrate from the MZ and red pulp to the T cell 
zone during infection [45, 62] and in response to LPS [45], for antigen presentation. 
Migration of dendritic cells in the spleen during malaria infection has been demonstrated 
previously [415], however no one has characterised the migration of CD8+and CD8' 
dendritic cell subsets or plasmacytoid DCs in response to malaria. It is possible that the 
large number of DCs seen in acute P.chabaudi infection have proliferated within the spleen 
rather than migrated from the blood. The increase in dendritic cell numbers in the spleen 
could, however, be due to a combination of influx of cells from the blood and development
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from dendritic cell precursors within the spleen [61]. The preferential accumulation of 
CD8‘CD1 lc+ DC over CD8+CD1 lc+ DC has interesting functional implications as the two 
subsets have been shown to express different cell surface molecules [426], may have 
different co-stimulatory requirements during antigen encounter [427] and may perform 
different functions (e.g. CD8+ DC preferentially endocytose apoptotic cells) [63]. They are 
currently thought to be distinct populations rather than the same population at different 
stages of development [69] (review [71]).
The ability of these dendritic cell subsets to present malaria antigens has been investigated, 
and it has been found that CD8' DC present parasite antigens in vivo better than CD8+ DC 
at the peak of infection [61]. In contrast, CD8+ DC present malaria peptide better than 
CD8* DC in vitro, therefore it is possible that the location of CD8‘ DCs in the marginal 
zone and red pulp gives them better access to pRBC, enabling them to present malaria 
antigens better. We have shown that greater numbers of CD8+ DCs undergo apoptosis than 
CD8‘ DC in vivo, and CD8+ DCs are known to have a shorter lifespan than CD8‘ DCs [64], 
which may also affect their antigen presenting capacity [61]. CDS'*' DCs have been 
suggested to be less phagocytic than CD8' DCs (review [55]), although studies showing 
that CD8+ DCs take up and present antigen better than CD8' DCs in vitro [61] would seem 
to contradict this. We have shown that CD8* DCs, not CD8+ DCs, are capable of inducing 
T cells to produce IL-4 and IL-10, indicating a specific role for CD8* DCs in initiating the 
switch towards Th2 responses that occurs between two and three weeks post-infection, after 
the peak of the acute malaria parasitaemia [61,103].
Plasmacytoid DCs are important for immune responses to viral infections, as they produce 
high levels of IFNa [80]. They are not as highly phagocytic as conventional DCs however,
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and therefore do not present antigens as well [67]. Recent work has shown that pDCs may 
be subdivided into two different subsets [68], however for the purposes of this work they 
have been treated as a single population.
This is the first study of pDCs in the spleen during infection. The location of pDCs in the 
spleen does not change dramatically over the course of the acute malaria infection; they 
remain in the red pulp throughout. There is also not the dramatic change in pDC number 
that is seen with conventional DCs at peak parasitaemia, but instead an increase in pDCs 
later between days 9 and 20 (Figure 24). pDCs appear to become more closely associated 
with the marginal zone on days 5 to 7 post infection, at the site of blood (and pRBC) entry 
into the spleen, which may indicate a role for them in taking up parasites and presenting 
malaria antigens to lymphocytes. Studies of antigen presentation by pDCs in malaria have, 
however, shown little presentation of malaria antigens to T cells by pDC, although IFNa is 
produced by pDCs in response to malaria infection and after in vitro culture with pRBC 
(C.Voisine et al, in preparation).
The marker used to identify pDCs, 120G8, can also be expressed on B cells activated by 
IFNa [80]. Expression levels are however lower on B cells (at least one log MFI) [80]. 
There is very little co-staining of 120G8 with the naTve B cell marker IgD, nor does the 
staining pattern resemble that of germinal centre B cells or plasma cells, therefore the 
120G8+ cells shown here are all pDCs.
pDCs may alternatively be activated by the parasite through TLRs, inducing migration into 
the marginal zone and thereby bringing them closer to IFNa-responsive cells. They do not 
appear to increase in numbers in the white pulp, however with the migration of B and T 
cells into the red pulp, interactions may occur in unusual locations. IFNa produced by
pDCs affects B cell responses directly by enhancing isotype switching to IgG [428], can 
promote B cell activation in the absence of T cells [429] and, together with IL-6, induces 
plasma cell differentiation [55]. IFNa can also promote expression of the B cell activating 
molecules BAFF and APRIL on conventional dendritic cells, further enhancing antibody 
isotype switching [428]. It would be interesting to deplete pDCs to determine the extent of 
their role in the B cell and plasma cell response to malaria infection.
We have observed a loss of marginal zone B cells, MZM and MMM from the marginal 
zone during acute malaria infection. Although some MZM and MMM remain in the 
marginal zone, the majority are lost from this location and their fate is unknown. Previous 
work has shown that although MZ B cells are lost from the marginal zone during acute 
malaria infection, they remain in the spleen and do not undergo apoptosis [346]. IgM*"8*1 
cells are found close to plasma cells, indicating that MZ B cells may be responsible for the 
large numbers of extra-follicular plasma cells seen in the spleen around the peak of 
infection.
MZM and MMM may likewise remain in the spleen, spread throughout the red pulp and 
therefore difficult to distinguish by histology. Alternatively, they may phagocytose pRBC 
directly, or phagocytose other cells that are undergoing apoptosis after taking up pRBC 
(e.g. the large proportion of CDS'*' DCs that undergo apoptosis within 5 days post-infection, 
when MZM and MMM begin to be lost from the marginal zone). With the availability of 
fluorescently labelled P.chabaudi, it should be possible to determine whether MZM and 
MMM directly phagocytose parasites, or cells that have phagocytosed parasites. 
Phagocytosis of apoptotic cells has been shown to promote the survival of macrophages 
and inhibit proliferation [430]. Phagocytosis can also trigger the migration of tissue-
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resident macrophages to the draining lymph node in order to present antigen [431], 
however this does not explain the migration of macrophages resident in the spleen away 
from a site ideally suited to antigen presentation. Evidence from other systems [172,174, 
179] indicates that loss of macrophages from the marginal zone is likely to be due to excess 
TNFa causing downregulation of CCL21 expression.
Marginal zone cells are thought to be involved in the early response to blood borne antigens 
and T-cell independent type-2 antigens [432]. Marginal zone B cells, which are lost from 
the marginal zone on macrophage depletion, induce T cell responses better than follicular B 
cells after immunisation with protein antigens [204]. They are also more numerous than 
follicular B cells, 2-3 fold more in the rat [242]. MZ B cells are also thought to be largely 
responsible for the initial burst of IgM production [130], with germinal centre derived 
plasma cells of both MZ and follicular B cell origin being responsible for the later switch to 
IgG isotypes [133]. MZ B cells have been implicated in the transport of antigen into B cell 
follicles and the establishment of germinal centres [133,203]. MZ B cells are capable of 
producing IgG isotypes, which are reduced in the response to TI-II antigens in mice lacking 
MZB cells [131].
MZ B cells are in close contact with MZM in the outer ring of the marginal zone, and it has 
been suggested that they are dependent on MZM and follicular B cells for their location in 
the marginal zone [242,414,433]. Lack of MZM can also affect the location of follicular 
B cells entering the spleen [434]. However, MZ B cells reappear in the spleen 12-16 days 
after macrophage depletion and about 2 weeks before MZM [435], and are not affected by 
elimination of MZM [436], indicating that MZ B cells are not dependent on MZM for their 
location in the marginal zone.
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MZM are thought to be responsive to the chemokine CXCL13, but to be retained in die 
marginal zone by preferential responsiveness to sphingosine 1-phosphate receptor 1 (SIPi), 
a receptor that binds phospholipids present in the blood. Whilst SI Pi signalling occurs, 
MZM remain in the marginal zone, close to the source of this signal in the blood in the 
marginal sinus. If SI Pi signalling is blocked, MZM can then respond to CXCL13 and 
migrate into the B cell follicle [437]. Steiniger and Barth [183] speculate that sialoadhesin- 
positive macrophages in human spleens can leave their position surrounding the sheathed 
capillaries and migrate into the perifollicular region under certain conditions. If CXCL13 
signalling is blocked, MZM may migrate into the blood in response to SIPi signalling, and 
return to the marginal zone only when CXCL13 signalling is sufficiently restored. We 
hypothesise that signalling through the LTp pathway is disrupted during acute malaria 
infection, which would lead to a loss of CXCL13 signalling (Figure 7), and could therefore 
result in the loss of MZM into the blood stream in response to SI Pi signalling. If these 
cells do migrate from the spleen, there are no clues to their destination. MZM can be 
visualised by uptake of fluorescently labelled Ficoll particles [438], and could perhaps be 
tracked during migration this way.
The significance of losing macrophages and MZ B cells from the marginal zone during 
acute P.chabaudi infection is unclear, however macrophages of the marginal zone could 
reasonably be expected to have a role in removal of parasites. Maintaining macrophages in 
the marginal zone during acute infection could potentially increase the removal of parasites 
from the blood. One obvious experiment to investigate the role of these cells during 
malaria infection would be to selectively deplete these cell populations, and observe the 
effect of this depletion on infection.
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It is not possible to deplete a single population of macrophages, however after depletion 
with clodronate liposomes, splenic macrophages repopulate the MZ with different kinetics 
for each subset [435]. Red pulp macrophages reappear one week after depletion, MMM 
and MZ B cells after two weeks. MZM reappear 1 month after depletion, but do not have 
hill functional capacity [435].
Macrophages of the marginal zone have been shown to have a role in the immune response 
to Listeria monocytogenes, but are not essential for this response [411,413]. Lack of 
macrophages of the marginal zone reduces clearance of viral infections [210,412]. 
Similarly, depletion of all macrophages by intravenous injection of silica increases 
susceptibility of C57BL/6 mice to Plasmodium chabaudi (AS) infection [410]. The 
response to a bacterial T-cell dependent antigen also drops sharply after macrophage 
depletion but returns to control levels on repopulation of MMM [439].
In Leishmania donovani infection, MZM are lost from the marginal zone but MMM remain 
[172]. There are also changes in lymphocyte trafficking into the spleen during L. donovani 
infection which have been at least partially attributed to the loss of MZM [172], and other 
authors have also suggested a role for MZM and MMM in lymphocyte trafficking into the 
white pulp [414,434]. We have not studied lymphocyte migration into the spleen in 
malaria infection, however the extent of changes in splenic microarchitecture and the 
closure of splenic circulation [184, 306,416] would suggest that lymphocyte migration is 
almost certainly altered during acute infection. It would, however, be difficult to determine 
the contribution of MZM and MMM to such an effect.
Some changes in splenic microarchitecture can be artificially induced by administration of 
LPS [45,440]. LPS administration causes transient loss of MZM and movement of MMM
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into B cell follicles, reversing within 48 hrs [349]. The receptor for LPS is Toll-like 
receptor 4 (TLR4), which is thought to associate with SIGNR1 (identified with MAb ER- 
TR9) on MZM [62]. This could induce the migration of MZM into follicles in response to 
bacterial infection as an alternative mechanism for transporting antigen into the white pulp. 
On a similar note, haemozoin has been shown to activate DCs through TLR9 [350]. 
Splenomegaly is a thymus-dependent response [404,441], to which CD1+ NK T cells 
partially contribute during malaria infection. However, if the changes in splenic 
microarchitecture are parasite induced, rather than being a consequence of over-reaction of 
the host immune response, then it is possible that haemozoin might be the trigger for this. 
This is unlikely however, as haemozoin deposits remain in the spleen long after clearance 
of parasitaemia and reformation of the splenic microarchitecture. A study of splenic 
microarchitecture after administration of the synthetic molecule p-haematin would be 
informative. Injection of LPS induces some of the same changes in splenic 
microarchitecture that are observed during malaria infection [349], although with only a 
single injection these changes are less extensive and of shorter duration. When 
administered during the acute phase of P.vinckei infection, LPS increases the extent of 
changes in the splenic microarchitecture and enhances the severity of the disease [442]. 
LPS given after day 7 of a P.berghei infection also enhances the severity of disease, 
however it has a protective effect when administered earlier in infection, and has a varying 
protective effect (depending on the time of administration) in a non-lethal P.yoelii infection 
[443]. This indicates that changes in the splenic microarchitecture during acute malaria 
infection may be triggered by activation of TLRs, and that the extent of these changes, as
197
well as their significance for resistance or susceptibility to infection, may depend on the 
species of parasite.
In summary, we have detailed the loss of MZ B cells, MZM and MMM from the marginal 
zone, beginning at day 5 post-infection. We hypothesise that the role of MZM and MMM 
in malaria infection is either the direct removal of parasites or the removal of apoptotic 
cells that have phagocytosed parasites, and that MZ B cells may contribute to the large 
extra-follicular plasma cell response during the acute infection. Whilst these cells may 
contribute to the clearance of parasites, they are unlikely to be critical for the resolution of a 
malaria infection. We also hypothesise that the lack of these cells from the marginal zone 
is a result of downregulation of the LTp signalling pathway, along with many other 
alterations in splenic microarchitecture, that may be triggered by the activation of TLRs.
In P.chabaudi infection, detection of MAdCAM-1 was used as a marker for the splenic 
marginal sinus. Its expression spreads to cover the white pulp area in a network staining 
pattern by day 10 of infection. Despite the extensive changes in splenic microarchitecture, 
it is interesting in itself that the marginal sinus retains its structure, however the increased 
expression of MAdCAM-1 over the white pulp area is an intriguing finding. The 
expression of MAdCAM-1 in the white pulp during infection is similar to the expression 
pattern seen with macrophage depletion [189]. MAdCAM-1 expression is unchanged in 
Ldonovani infection, however, when only MZM are lost from the MZ [172], and may 
therefore be linked to the presence of MMM. This expression pattern is also seen in mice 
lacking the sphingosine-1-phosphate lysophospholipid receptor (SIP3) [444], which is 
required for retention of MZ B cells, MZM and MMM in the marginal zone [437]. Mice 
that do not express LTp on B cells also exhibit this network expression pattern of
MAdCAM-1 in the white pulp, indicating that it is a direct effect of lack of signalling 
through the LTp signalling pathway. Whether lack of LTp itself, or lack of signalling 
downstream of LTp, is responsible for this expression pattern has, however, not been 
determined.
The function of MAdCAM-1 in the splenic MZ is unknown, as administration of blocking 
antibodies in vivo has no discemable effect on lymphocyte migration at this site [189]. 
Increased expression of MAdCAM-1, however, has been suggested to facilitate entry of 
cells into the B cell follicle [444], and it is possible that MAdCAM-1 expression is induced 
to aid the reformation of the white pulp, and to guide B and T cells back into their correct 
locations.
In a study of human spleens, Steiniger et al. [183] observe MAdCAM-1 positive cells in the 
MZ and perifollicular zone, penetrating the white pulp in a reticular pattern, that also stain 
positive for smooth muscle a-actin. They note MAdCAM-1 positive cells ensheathing 
bundles of fibres, and postulate that these cells aid CD4+ T cell immigration into the white 
pulp.
MAdCAM-1 has two known ligands; the integrin a4p7 and L-selectin, which can be 
expressed on a wide variety of lymphocytes [445,446]. L-selectin is an adhesion molecule 
that is expressed on most B cells and naTve T cells, and is upregulated upon activation 
[447]. However, when increased MAdCAM-1 expression is seen, T cells have migrated 
out of the white pulp into the red pulp and would therefore not be binding to MAdCAM-1 
at this time. Analysis of the expression profile of integrin a4p7 during the acute malaria 
infection may help to determine a function of MAdCAM-1 in the spleen.
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MAdCAM-1 expression in P.chabaudi infection is similar to the pattern of splenic conduit 
staining described by Nolte et al [421]. The splenic conduit is a network of reticular 
fibroblasts in the white pulp of the spleen that is thought to be involved in chemokine 
signalling and lymphocyte trafficking. It is logical for adhesion molecules to be induced on 
a network such as the splenic conduit, however MAdCAM-1 expression on the splenic 
conduit is unproven. Staining for ER-TR7, expressed on fibroblasts of the splenic conduit 
[421], in our hands did not produce a staining pattern resembling that seen by Nolte et al. 
We do, however, see an increase in expression of this marker in the red pulp. This could be 
due to either proliferation or expansion of fibroblasts to accommodate the increased volume 
of the spleen, or induction of expression of ER-TR7 on cells not normally expressing this 
molecule. ER-TR7 expression is suggested to be controlled by signalling through the 
lymphotoxin p receptor in combination with the TNF receptors [422], therefore this 
increase in expression could be related to the alterations in LTp and TNFa signalling.
TNFa alone or in combination with LTa is, however, unable to induce formation of the 
reticular network incorporating ER-TR7 expression [422], indicating that there may be 
additional factors controlling expression of this molecule during the acute malaria infection. 
CD31 (PECAM-1) is another adhesion molecule expressed by endothelial cells in the 
spleen [423]. As with ER-TR7, expression of this molecule is seen in the red pulp in naive 
mice, with minor expression in the T cell zone. CD31 expression increases towards the 
peak of infection. Expression of CD31 is enhanced by stimulation of the sphingosine-1- 
phosphate (SiP) receptors [448]. Marginal zone B cells also express SiP receptors, and the 
balance between SiP and CXCL13 is thought to retain MZ B cells in the marginal zone 
[437]. In acute P.chabaudi infection MZ B cells move out of the marginal zone into the red
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pulp, which may be due to decreased expression of CXCL13, but may also (along with 
increased CD31 expression), be due to increased levels of SiP. The expression pattern of 
CD31 is similar to that of ER-TR7 throughout the acute infection, and at no time resembles 
the expression pattern seen for MAdCAM-1.
Therefore, the identity of the cells on which MAdCAM-1 expression is induced in the 
white pulp still cannot be determined, however one possibility is that they are gp38- 
expressing T cell zone stromal cells [449]. We observe an increase in fibroblast and 
endothelial cell surface molecules in the red pulp as the spleen increases in size, however 
the location of these cells does not change.
Acute infection with P.yoelii induces the formation of “barrier cells”, which form a 
branched complex of cells closing off the splenic filtration beds, protecting haematopoietic 
cells from infection and compartmentalising the white pulp [347]. Such closing of the 
splenic circulation has also been described by KrUcken et al [416] in P.chabaudi infection 
and Yadava et al [306] in P.chabaudi adami infection, although they do not speculate 
further as to the cell population which is enabling this closure. Kraal et al [189] concluded 
that the MAdCAM-1 expressing cells were endothelial cells related to those lining the 
marginal sinus, however it is possible that barrier cells and MAdCAM-1 expressing cells 
are in fact the same. The origin of barrier cells has not been determined, and cell surface 
molecules specific to barrier cells have not been described, therefore further work would be 
required to confirm that barrier cells express MAdCAM-1 during acute P.chabaudi 
infection. Infection of MAdCAM-1 knockout mice will help to determine the significance 
of this adhesion molecule in malaria infection.
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Despite the changes occurring in the splenic microarchitecture, germinal centre formation 
still occurs. These germinal centres are larger and more numerous than those induced by 
immunisation [346]. Larger than normal germinal centres can be induced by soluble 
antigens, and have been shown to have impaired affinity maturation [145]. In P.chabaudi 
infection, a larger proportion of antibodies remain low-affinity after primary infection than 
in mice immunised with tetanus toxoid [396].
The presence of PNA+ cells throughout the red pulp between days 7 and 9 post-infection is 
unexpected. This may indicate some delay in the formation of germinal centres, possibly 
due to a lack of appropriate chemokines to allow germinal centre formation [156], but does 
not appear to impede the normal germinal centre functions in any way. Germinal centres 
are in close association with T cells throughout the acute infection, with some T cells 
always found inside them. Even during the period of maximum alteration in the 
microarchitecture, T cells cluster next to germinal centres. Either the association of T cells 
with germinal centre cells requires different signals to those regulating germinal centre 
formation or the lack of defined germinal centres around the peak of infection has another, 
as yet undefined, cause. It would be interesting to determine which malaria antigen 
germinal centre cells are specific for, however attempts to stain antigen-binding B cells 
with fluorescently labelled recombinant malaria antigens by histology were unsuccessful 
(data not shown).
There is also an unusually large number of plasma cells present in the spleen at, and just, 
after the peak of parasitaemia. The peak number of plasma cells in the spleen occurs at day 
10 post infection [346], at the same time as peak numbers of plasma cells are seen after 
immunisation [450], however the number of plasma cells seen at the peak of the malaria
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response is much larger than that seen in immune responses to other infections [231], or 
after immunisation with non-replicating antigens [346]. The antigen specificity of these 
plasma cells has yet to be determined, and it is possible that not all of these plasma cells are 
malaria-specific but may have been non-specifically activated, as polyclonal B cell 
activation in both human [451] and mouse [452,453] malaria infection is well documented. 
In the early stages of infection (up to day 7) most of the splenic plasma cells present are 
IgM*. By contrast, the majority of splenic plasma cells seen at later stages of infection (i.e. 
day 8-20) are IgG*. This indicates that isotype switching from IgM to IgG production is 
taking place around day 7-8 of infection. Further detailed analysis (e.g. antigen specificity, 
IgG isotypes) would be required to fully characterise the malaria-specific B cell response. 
The characteristic changes occurring in splenic microarchitecture described here and 
elsewhere [345, 346,416] point to a disturbance in the lymphotoxin signalling pathway 
(Figure 7). In the spleen of LTa knockout mice, B and T cell segregation is disturbed, 
follicular dendritic cells are absent and germinal centres are not formed [454]. This is due 
to a combination of a lack of signalling through both TNFRI and LT{3R (review [29]). 
Germinal centres are, however, present in LTp knockout mice. LTa and p knockout mice 
lack marginal metallophilic macrophages and do not express the adhesion molecule 
MAdCAM-1 on the sinus endothelium, however mice lacking LTp solely on B cells have 
increased MAdCAM-1 expression in a network pattern over the white pulp area [170]. 
Follicular dendritic cells (FDCs) are absent in mice lacking TNFa, LTa and LTp alone or 
in combination [164], which has particular relevance for the development of B cell 
responses.
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Whilst many of the changes in splenic microarchitecture that we observe in acute 
P.chabaudi infection also occur in the absence of LTa, the distinctive changes in 
MAdCAM-1 expression observed suggest a loss of LTp rather than LTa signalling. In 
order to test our hypothesis, that a defect in LTp signalling is primarily responsible for the 
alterations in splenic microarchitecture, we administered an agonistic LTpR antibody [455]. 
Treatment was given at day 4 post-infection, as this is just before changes in splenic 
microarchitecture become visible, during the period of exponential rise in parasitaemia. 
Unfortunately a single treatment had no effect on either the primary or secondary infection 
as determined by parasitaemia and splenic microarchitecture at day 10 post-infection. This 
does not necessarily indicate that the hypothesis is incorrect, only that the treatment given 
was insufficient to produce a noticeable effect. Repeated doses at 2 day intervals 
throughout the acute infection, certainly for the first two weeks, would be more likely to 
produce a detectable effect. It should also be possible to detect changes in LTp and 
CXCR5 on the surface of splenic lymphocytes, and to detect changes in expression of 
LTpR and CXCL13 by histology [179]. Preliminary experiments have, however, been 
unsuccessful (data not shown). In viral infection, where similar alterations to the splenic 
microarchitecture are seen, reduced expression of CCL21 mRNA in the spleen has been 
described [174].
LTp is a membrane-bound molecule which binds to the LTpR on stromal cells. This 
signals through the alternative NF-kB pathway [456,457] to induce the release of the 
chemokine CXCL13. CXCL13 and its receptor, CXCR5, have been shown to be crucial 
for the proper formation of splenic microarchitecture, particularly the formation of B cell 
follicles [155, 158,454].
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An abundance of TNFa, which has been demonstrated during acute malaria infection [151, 
259], may also contribute to the disruption of splenic microarchitecture. TNFa and/or LTa 
is necessary for CCL19/CCL21 signalling that is responsible for localisation of MZM and 
FDC, germinal centre formation and MAdCAM-1 expression [164,179,181]. An excess 
of TNFa, however, has been shown to downregulate the expression of these cytokines 
[172,179], leading to the loss of MZM.
However, TNFa can also induce the expression of LTp by signalling through NF-kB [458]. 
Whether an excess of TNFa downregulates LTp expression as well as downregulating 
CCL19/21 expression is not known. Reducing TNFa expression during acute malaria may 
therefore help to maintain the splenic microarchitecture.
It would also be interesting to determine the cause of this proposed alteration in LTp 
signalling. As the p subunit anchors LT to the cell surface, it is possible that a specific 
block in expression of the p subunit without alteration of expression of the a  subunit would 
by default cause an increase in secretion of soluble LTa. Although many of the 
immunopathogenic sequelae in acute malaria have been attributed to TNFa, it has recently 
been proposed that these are in fact more due to LTa [172]. The function of LTa in 
maintenance of splenic architecture is difficult to investigate as expression of the a  subunit 
is required for LTp function, and LTa binds the same receptors as TNFa. The expression 
and regulation of expression of lymphotoxin during acute malaria infection certainly bears 
further investigation. Likewise, a potential role for the LTpR ligand LIGHT cannot be 
ruled out, as over-expression of LIGHT has been shown to upregulate expression of 
MAdCAM-1 in tumour tissue, together with expression of CCL21 [174]. It is also possible
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that blockage of the pathway occurs further downstream, at the level of expression of 
CXCL13, CCL19 and CCL21 or their binding to CXCR5 and CCR7.
Many pathogens, particularly viruses, mediate immune escape by mimicking host ligand 
and receptor molecules, including those of the TNFR family [459]. It is possible that the 
parasite expresses a decoy ligand or receptor for LTp that blocks signalling through this 
pathway. TNF and lymphotoxin receptors are expressed on stromal cells, which then 
produce chemokines to attract lymphocytes. Many parasites bind to or infect stromal cells 
and are therefore in a position to alter the function of these cells [172,460,461]. The effect 
of malaria infection on the splenic stroma has not been investigated, and would be an 
interesting topic for future work.
Both germinal centre formation and migration of dendritic cells into the spleen are thought 
to require lymphotoxin-induced chemokine signals [121,152,456]. It is, however, difficult 
to compare data from knockout mice, which have a constitutive lack of signalling, with the 
temporary alterations we see in acute malaria. Other reports have demonstrated a 
reduction, but not absence, of germinal centres in LTp'7' mice [173,462], however we do 
not see a reduction in germinal centres during malaria infection, indicating that either 
signalling through the LTp pathway is not completely abrogated during acute malaria 
infection, that downregulation of the LTp signalling pathway occurs after germinal centre 
formation has progressed sufficiently to no longer require this pathway, or that LTp 
signalling is not a critical requirement for germinal centre formation. DC migration may be 
promoted by other chemokines such as M IP-la/p, which are not dependent on 
lymphotoxin, although only immature DCs are thought to express the receptors for such 
signals [463] (review [55]).
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We have detailed extensive changes to the splenic microarchitecture during the acute 
malaria infection, and have speculated as to the mechanisms that cause these changes. It 
has been hypothesised that such dramatic changes cannot be advantageous to the host, and 
are likely to have a detrimental effect on the generation of an immune response and/or 
memory responses [348]. The fact that similar alterations are found in fatal cases of 
P.falciparum [348] would seem to indicate that such changes are detrimental, although in 
human infections it is possible that the splenic microarchitecture was altered prior to 
infection with malaria. Despite these alterations in the splenic microarchitecture, clearance 
of parasites still occurs in both human and mouse infections. These changes may therefore 
be required for closure of the splenic circulation to protect the haematopoietic beds of the 
mouse spleen from infection [347,416]. Assuming that the changes in splenic 
microarchitecture are caused by downregulation of the LTp signalling pathway, a 
protective effect of these changes is corroborated by the fact that LTpR/7’ mice were less 
susceptible to malaria infection than wild-type mice [416]. Further work is required to 
unravel the contribution and significance of these changes to the pathogenesis of malarial 
disease.
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Chapter 5
Kinetics and lifespan of B cells and plasma cells in the spleen and bone marrow 
during malaria infection
Introduction
There is a large body of evidence, both in animal and human studies, to show that B cells 
and antibodies are required for clearance of a primary malaria infection and are important 
for immunity to subsequent infections (review [262]). pMT mice, which lack B cells, are 
capable of controlling acute P.chabaudi infection, but develop a chronic relapsing 
parasitaemia [255,287, 318], and B cell deficient JhD mice control an acute P.chabaudi or 
P.vinckei infection, but not a P.yoelii 17X infection [319].
Passive transfer of total serum antibodies from immune mice is at least partially protective 
in P.berghei infection [464-466], P.chabaudi infection [466], P.vinckei infection [258], and 
P.yoelii infection [99]. Transfer of immune serum is more fully protective in P.falciparum 
infection of squirrel monkeys [467,468], and transfer of malaria-specific antibodies is 
protective against P.yoelii infection [327].
The strongest evidence that antibodies are important in human malaria infections comes 
from studies on the protective effect of passive transfer of serum antibodies [320, 321] 
(review [322, 323]). Antibody responses to malaria antigens in humans are detectable after 
the first infection [303, 304], and can be associated with resistance to clinical disease [128,
208
184,293,305-312] (review [262]). IgGl and IgG3 antibodies in particular have been 
shown to be the most important isotypes for resistance to disease [324,325]. The presence 
of anti-malaria antibodies can, however, also be evidence of recent or ongoing infection 
[294,311,361,469]. Unfortunately, many antibodies do not last long after the end of the 
transmission season and are therefore unable to protect against reinfection [177,311,313, 
314,470-472].
In addition to malaria-specific antibody responses, hypergammaglobulinaemia, which can 
significantly shorten the half-life of antibodies [473], occurs in both human [451,474] and 
mouse [475,476] malaria infections, and B cell hyperplasia has also been described in both 
human [451,477] and mouse malaria infections with P.chabaudi [452,453] and P.yoelii 
[478], particularly in primary infection [452]. The relationship of these large B cell and 
plasma cell responses to malaria-specific antibody production is unclear, however 
polyclonal B cell activation and hypergammaglobulinaemia have been found in other 
infections where B cell dysfunction occurs [479,480], and in other parasitic infections 
(review [477,481]), suggesting that there may be some dysfunction in the B cell and 
plasma cell response to malaria. Polyclonal B cell activation in T.cruzi infection has been 
shown to be triggered by a parasite antigen, glutamate dehydrogenase, dependent on 
production of B cell stimulatory cytokines by CD1 lb+ cells [482], indicating that such 
responses may be beneficial for the parasite.
Malaria infection produces a good IgG antibody response in mice to both malaria parasite 
lysate and recombinant malaria proteins [265, 377, 396,483,484], however there is also 
some production of malaria non-specific plasma cells [452,453]. In P.chabaudi infection, 
antibodies to malaria antigens drop away quickly as the parasitaemia is cleared.
209
Large numbers of plasma cells are produced in the spleen during acute malaria infection 
(Figure 37), far more than are produced in response to immunisation with chicken gamma 
globulin, however these plasma cells do not seem to persist long in the spleen [346]. Few 
plasma cells can be supported long-term by the spleen, most plasma cells must migrate to 
the bone marrow in order to become long-lived cells [148,228]. The existence of long- 
lived plasma cells in malaria infection has not been established, and the antigen specificity 
of the large number of splenic plasma cells formed during an acute malaria infection is also 
unknown. From immunohistological studies it is clear that most of the plasma cells formed 
during acute infection are gone from the spleen within days [346]. It is likely that most of 
these plasma cells are short-lived, but some may migrate to the bone marrow to become 
long-lived plasma cells.
Very little is known about the generation of memory B cells in response to malaria 
infection in either mice or humans. This is partly because a cell surface marker for memory 
B cells has only recently been identified in humans [237,485], and not yet identified in 
mice. Memory B cells are persistent, long-lived, antigen specific B cells that do not secrete 
antibodies, but can rapidly differentiate into antibody-secreting cells upon secondary 
antigen encounter (review [486]). They are mostly, but not always, isotype switched cells 
that have usually undergone somatic hypermutation [487,488]. Recent work has shown 
that many people with antibodies to malaria antigens do not have detectable numbers of 
memory B cells in the blood [400]. Other work in P.yoelii infection [367] has shown that 
memory B cells and long-lived plasma cells induced by immunisation with P.yoelii MSP- 
119, were ablated by subsequent infection with P.yoelii.
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This chapter investigates the kinetics of B cell and plasma cell formation in the spleen and 
bone marrow, using BrdU labelling to follow cells that divide at specific times during the 
course of infection. In addition, attempts to track malaria antigen specific B cells and 
plasma cells by flow cytometry using fluorescently labelled recombinant proteins are 
detailed. Merozoite surface protein-1 (MSP-1) is a leading candidate for a vaccine against 
the erythrocytic stage of the life cycle (review [339]). It is expressed on the surface of the 
merozoite as a protein complex, which is cleaved off at invasion, leaving a 19kDa fragment 
(MSP-119) on the surface of the invading parasite (review [489]). Antibodies to this 
fragment can protect against parasite invasion [490]. Although the sequence of MSP-119 is 
highly conserved across strains and species, the best protection is still against challenge 
with the homologous strain. The methods used to fluorescently label MSP-1 and detect 
MSP-1 binding cells, degree of success and future directions for investigating malaria- 
specific B cells are discussed.
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Results
Establishment ofparameters fo r FACS analysis
The spleen increases several-fold in size during acute malaria infection [184, 345]. The 
number of lymphocytes in the spleen increases, as does haematopoiesis and apoptosis [184, 
342-344,346, 392]. Far less is known about changes in the cellular composition of the 
bone marrow during malaria infection, as most studies to date have concentrated on 
erythropoietic populations, although decreases in cellularity have been described [342-344]. 
Both the forward light scatter (FSC) and side scatter (SSC) FACS profiles of spleen and 
bone marrow alter during acute malaria infection, but return to a profile similar to that of 
naiVe mice by approximately 12 weeks after primary infection (Figure 40). The 
accumulation of parasite pigment, parasite debris and apoptotic material contributes to an 
increase in autofluorescence in infected spleens and increases the tendency of cells to form 
clumps in suspension, which can interfere with FACS analysis (unpublished observations). 
The first priority was therefore to establish the gates and data analysis techniques to be 
used, and to eliminate dead and autofluorescent cells from the analysis. The live cell gate 
was set to include lymphocytes and blasted cells twice the size of resting lymphocytes, and 
to eliminate dead, autofluorescent and large non-lymphoid cells. Approximately 80% of B 
cells and plasma cells were contained within these gates.
Once the appropriate live cell gate had been established, the problem of autofluorescence 
was addressed. Unstained samples of both spleen and bone marrow cells autofluoresce in 
channels 1, 2 and 3. This produces a characteristic diagonal streak in two colour plots 
(Figure 41 A) that cannot be removed by altering the live cell gate, as autofluorescent cells
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Figure 40. Selection of the live cell gate for flow cytometric analysis of spleen and bone 
marrow cells during primary P.chabaudi infection.
Forward light scatter (FSC) and side scatter (SSC) of single cell suspensions from spleens 
(left panel) and bone marrow (right panel) of naive mice and mice 2,4,6, 8 and 12 weeks 
post-infection are shown as density plots.
A live cell gate including cells with a lymphoid footprint was selected (-). A total of 1 x 
106 cells were analysed, of which approximately 70-90% were contained within the live 
cell gate. The percentage of cells contained within the live cell gate is shown on each 
density plot. These plots are from representative mice (at least 3 mice per time point).
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Figure 41. Elimination of autofluorescence from the analysis of spleen and bone marrow
cells of P.chabaudi infected mice
Splenocytes and bone marrow cells contained within the live cell gate were analysed for 
autofluorescence as follows:
A) Autofluorescence of unstained splenocytes detectable in channels 1,2 and 3
B) Distribution of autofluorescent cells within the FSC, SSC live cell gate
C) Two colour density plot of CD 19 biotin & Streptavidin Tricolour and CD 138 PE 
stained splenocytes. The yellow region (D) was selected for the determination of 
CD19+ cells and the green region (E) was selected for the determination of CD138+ 
cells, thus eliminating the autofluorescent cells in region B
D) Splenocytes in gate D stained with CD 19 biotin & Streptavidin Tricolour and BrdU 
FITC
E) Splenocytes in gate E stained with CD 138 PE and BrdU FITC
F) Single colour controls for CD 19 biotin, CD 138 PE and BrdU FITC and IgG2a 
biotin, IgG2a PE and IgGl FITC isotype controls
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are spread throughout the whole population (Figure 4IB). These cells do not have the 
forward and side scatter profile of dead cells, however it is possible that they are in the 
early stages of apoptosis. This could have been confirmed with an early apoptotic marker, 
however we were already using four-colour analysis, which is the maximum number of 
colours that can be used on the FACSCalibur. This autofluorescence streak made it 
impossible to determine accurate numbers of BrdU positive B cells and plasma cells. 
Therefore, these cells were excluded from the analysis, by gating on CD 138' cells and 
CD 19" cells as shown (Figure 41C, D, E). Removal of this population also reduced the 
probability of including bone marrow pre-B cells in the analysis, as these cells express both 
CD 19 and syndecan (CD 138) [373]. Whilst taking this step may also exclude plasmablasts 
from the analysis, by conducting a timecourse experiment looking at mature plasma cells it 
should still be possible to detect these cells, albeit at a slightly later timepoint. Examples of 
single colour stains and the appropriate isotype controls are shown in Figure 41F.
Detection o f divided cells by BrdU incorporation
5-Bromo-2'-deoxyuridine (BrdU) is a nucleotide analog that is incorporated into DNA 
during cell division and can be detected by specific antibodies [232,247]. Once 
incorporated, BrdU persists in cells for their lifespan, but maybe diluted to undetectable 
levels if labelled cells undergo several cell divisions after BrdU administration has ceased 
(review [491]). To detect cells that divide after infection or immunisation, mice were given 
BrdU in their drinking water for periods of 2-4 weeks. Cells that divided during this 
labelling period were then detected by flow cytometry. BrdU staining was tested first on 
the spleen in otherwise naTve mice, where staining is slightly above that of untreated mice, 
then on the spleen of infected mice where it increases dramatically (Figure 42).
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Figure 42. Cell division in P.chabaudi infected mice detected by incorporation of BrdU 
Spleens were taken from mice that were not BrdU treated, mice treated with BrdU for 37 
days and mice treated with BrdU for the first 7 days of malaria infection.
A) FSC SSC profile indicating the live cell gate (-)
B) Histogram of fluorescence intensity of BrdU staining in untreated (-), BrdU treated 
(-) and infected mice (-)
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Normalisation o f results
For each group of mice, representing a particular BrdU labelling period and timepoint post­
infection, 3 naive mice and 4-5 infected mice were used per group. Five timepoints (weeks 
2,4,6, 8 and 12) were examined, with five labelling periods (0-2,2-4,4-6, 6-8 and 8-12 
weeks) for the 12 week timepoint, 4 labelling periods (0-2,2-4,4-6, 6-8 weeks) for the 8 
week timepoint, 3 labelling periods (0-2,2-4,4-6 weeks) for the 6 week timepoint, 2 
labelling periods (0-2,2-4 weeks) for the 4 week timepoint and 1 for the 2 week timepoint, 
making a total of 15 groups (120 mice). It was not possible to analyse such a large number 
of mice at one time, particularly as both spleen and bone marrow samples were taken. 
Analysing different groups of mice on different days allows the experiment to be 
technically feasible, however it introduces variability in the staining. In the bone marrow 
there is more variation in the number of live cells retrieved, which further adds to the 
variability in staining. The difference in the numbers of live cells retrieved from infected 
and uninfected mice at each time point can be seen in Figure 43 (A, B). There is variation 
in the number of live cells retrieved, particularly from the bone marrow, of uninfected mice 
at the different timepoints, largely due to the technical variability in flushing out cells from 
the bone marrow. There are also age-related changes in numbers of B cells and plasma 
cells in both spleen and bone marrow, as mice in different groups were not of the same age 
at the time of sampling. Therefore, to reduce variability between results because of 
differential recovery and age, total number of lymphocytes, B cells and plasma cells 
obtained from infected mice were normalised to the appropriate naive control mice for that 
time point. (Figure 43 C, D). All subsequent figures show cell numbers expressed as a 
percentage of cell numbers in nai've mice per spleen or per two femurs (12.6% of total
220
Figure 43. Normalisation of live cell numbers in spleens and bone marrow of P.chabaudi
infected mice
The cell numbers shown the means and SEM total numbers of lymphocytes retrieved from 
spleens and bone marrow (2 femurs). Total lymphocyte numbers from each BrdU labelling 
period were pooled for each timepoint, therefore live cell numbers are from a minimum of 
3 mice (week 2, naive) and a maximum of 25 mice (week 12, infected)
A) and B) show a comparison between numbers of lymphocytes from naifve (-) and 
infected (-) mice in the spleen (A) and bone marrow (B) taken at different time points post­
infection with age matched naifve controls.
C) and D) show numbers of lymphocytes from infected mice normalised to the naive 
controls for each time point (absolute cell number for spleen and 2 femurs expressed as a 
percentage of naifve controls) in spleen (C) and bone marrow (D)
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mouse bone marrow is located in two femurs [492]). Where low numbers of cells meanthat 
this normalisation skews the results, absolute cell numbers are also shown as a comparison. 
The spleen increases around 7-fold in size during the acute infection, gradually diminishing 
in size as the infection becomes chronic (Figure 43C). The increase in spleen size is due 
both to an increasing number of lymphocytes and to an increase in erythropoiesis in the 
spleen [342-344]. Although the spleen itself remains permanently larger than that of a 
naTve mouse, the number of lymphocytes retrieved is similar for naTve and infected spleens 
from 6 weeks post-infection (Figure 43C). The number of lymphocytes retrieved from 
bone marrow, however, is similar to the naTve at all timepoints (Figure 43D).
B cells in spleen and bone marrow
Despite recovering a relatively similar total number of lymphocytes from the bone marrow 
of naive and infected mice at all time points, the total number of B cells in the bone marrow 
of mice 2 and 4 weeks post-infection is much lower than the total number of B cells in the 
bone marrow of naive mice, however at 4 weeks post-infection, this difference is not 
significant (p = 0.1564). The difference at 2 weeks post-infection is also not significant (p 
= 0.0571 at 2 weeks), however the test at this timepoint is not very powerful as only 3 naive 
and 4 infected mice were used, compared to 6 naTve and 9 infected mice at 4 weeks post­
infection. The total number of B cells in the bone marrow does not fully return to normal 
levels until 6 weeks post-infection (Figure 44A). This may be because of increased export 
of B cells into the circulation, and to other lymphoid organs such as the spleen. In line with 
this possibility, there are approximately 50% more B cells in the spleen at 2 weeks post­
infection than in naTve mice.
The number of B cells in the spleen continues to increase up to 4 weeks post-infection,
Figure 44. Reduction of B cell numbers in the bone marrow at 2 weeks post-infection
A) Total numbers of CD19+ B cells in spleen (-) and bone marrow ( ) relative to 
naive controls (-)
B) Experimental plan to show the period of BrdU labelling ( H I ) and sampling time 
points ( for spleen and bone marrow during infection
C) Total numbers of BrdU labelled CD19+ B cells that divided in the first two weeks of 
infection in spleen (-) and bone marrow (-) relative to naive controls (-)
D) Absolute numbers of BrdU labelled B cells in naive (■ ) and infected ( ■ ) spleen
E) Absolute numbers of BrdU labelled B cells in naive ( □ )  and infected ( O ) bone 
marrow (2 femurs)
F) Experimental plan to show period of BrdU labelling; 0-2 weeks ( HU), 2-4 weeks 
( ■ ■  ), 4-6 weeks ( W M  ), 6-8 weeks ( ) & 8-12 weeks ( ■ ■ ) post-infection; 
and sampling time points ( ^ )  for spleen and bone marrow during infection
G) Kinetics of B cell incorporation of BrdU in spleen ( ■ ) and bone marrow ( □ ) 
throughout acute and chronic infection
Points and bars represent the mean value +/- SEM of 3 age matched naive controls and 4-5 
infected mice per time point, and the horizontal black line indicates the normalised naive 
controls (100%)
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however the number of B cells in the bone marrow also increases at this time. We therefore 
investigated the longevity and location of the B cells dividing within the first 2 weeks of 
infection (see experimental plan Figure 44B). B cells that divided in the first two weeks of 
infection were almost completely lost from the spleen by 4 weeks post-infection, but were 
not observed in the bone marrow (Figure 44C). We also looked at the generation of new B 
cells at all time points throughout infection to see how B cell generation was affected by 
malaria infection. Mice were given BrdU in their drinking water between 0 and 2 weeks 
post-infection, 2-4 weeks, 4-6 weeks, 6-8 weeks and 8-12 weeks post-infection, and spleens 
and bone marrow taken for analysis at the end of each labelling period (see experimental 
plan Figure 44D). The greatest difference in B cell production between spleen and bone 
marrow is at 2 weeks post-infection, when numbers of recently divided B cells are 5-fold 
higher in the spleen than naiVe mice. By contrast, the numbers of divided B cells was 10- 
fold lower in the bone marrow at that time. At other timepoints B cell production fluctuates 
between 50 and 200% of B cell production in naiVe mice (Figure 44E).
There are four possible explanations for the loss of B cells produced during the first two 
weeks of infection from the spleen.
1) B cells may migrate back to the bone marrow.
2) B cells undergo several cycles of cell division, which dilutes their 
incorporated BrdU beyond detection.
3) B cells differentiate into plasma cells.
4) B cells undergo apoptosis.
Looking at B cells labelled in the first two weeks of infection (experimental plan Figure 
45 A) in the bone marrow, it can be seen that although the number of labelled B cells does
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Figure 45. The majority of B cells lost between 2 and 4 weeks post-infection do not 
migrate to the bone marrow and do not dilute their BrdU label through cell division
A) Experimental plan to show the period of BrdU labelling ( ■ ■ ) and sampling time
B) Total number of BrdU labelled B cells in bone marrow (-) relative to naive controls
(-)
C) Experimental plan to show the period of BrdU labelling; 0-2 weeks ( Hi), 2-4 
weeks (^H) post-infection; and sampling time points ( \  ) for spleen and bone 
marrow during infection
D) Total number of BrdU labelled B cells in spleen ( ■ ) and bone marrow ( □ )  relative 
to naive controls (-)
Points and bars represent the mean value +/- SEM of 3 age matched naive controls and 4-5 
infected mice per time point, and the horizontal black line indicates the normalised naive 
controls (100%)
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increase between 2 and 4 weeks post-infection (Figure 45B), it is only a slight increase and 
insufficient to account for the number of B cells lost from the spleen. We therefore 
compared the number of labelled B cells lost between 2 and 4 weeks post-infection ( ■■ 2 
weeks to 4 weeks) to the number of new B cells formed at this time (H I  )(experimental 
plan Figure 45C). B cell division between 2 and 4 weeks post-infection is much less than 
during the first 2 weeks of infection, and is similar to that in naive mice in both spleen and 
bone marrow. This suggests that cell division is insufficient to have resulted in loss of the 
BrdU label (Figure 45D, E).
Approximately 2 x 106 BrdU labelled B cells are lost from the spleen between 2 and 4 
weeks post infection (data not shown). During the same time period, approximately 2 x 105 
plasma cells are formed (data not shown). Therefore the number of plasma cells produced 
also cannot completely account for the number of B cells lost from the spleen between 2 
and 4 weeks post-infection. It is therefore likely that the majority of B cells that divided in 
the first two weeks of infection, and are lost between 2 and 4 weeks post-infection, have 
died. Previous investigations of apoptosis in P . c h a b a u d i  infection have shown that 
approximately 30% of apoptotic cells in the spleen at 12 days post-infection were B cells 
[392].
Since the majority of B cells that divide in the first two weeks of infection do not become 
long-lived cells, we looked at those cells that are present at 12 weeks post-infection to see 
when they were produced (experimental plan Figure 46A). The greatest proportion of B 
cells present at 12 weeks post-infection in the spleen were those recently formed, i.e. 
divided between 8 and 12 weeks post-infection (Figure 46B), however the contributions 
from cells dividing at all time points except 2-4 weeks post-infection were similar to each
229
Figure 46. B cells present at 12 weeks post-infection are mostly recently produced cells
A) Experimental plan to show the period of BrdU labelling; 0-2 weeks ( ■■), 2-4 
weeks (M i), 4-6 weeks ( ■ 1 ), 6-8 weeks ( ) & 8-12 weeks QM ) post­
infection; and sampling time point ( ^ ) for spleen and bone marrow at 12 weeks 
post-infection
B) Total number of BrdU labelled B cells in spleen ( ■ ) and bone marrow ( □ )  relative 
to naive controls (-)
Points and bars represent the mean value +/- SEM of 3 age matched naive controls and 4-5 
infected mice per time point, and the horizontal black line indicates the normalised naive 
controls (100%)
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other. In the bone marrow, the contribution of cells dividing at different time points is 
always similar to that in naYve mice (Figure 46B), although the greatest absolute number of 
B cells were those that divided between 8 and 12 weeks post-infection (data not shown). 
Plasma cells in spleen and bone marrow
Analysis of the spleen by immunohistology at the peak of infection shows a large number 
of extra-follicular plasma cells at 10-14 days post infection (Chapter 4, Figure 37; [346]. 
We have shown above that the majority of B cells generated during this time probably die, 
and only a minority differentiate into long-lived plasma cells. Similarly, anti-malaria 
antibody titres contain a large short-lived component; the IgG response to both P.chabaudi 
parasite extract [396] and recombinant P.chabaudi MSP-119 increases up to 4 weeks post­
infection, then decreases between 4 and 8 weeks post-infection at the time of clearance of 
detectable parasitaemia (Figure 47; [396]). After this time, although parasites are not fully 
cleared until 12 weeks post infection, low levels of IgG anti-malaria antibodies remain 
stable up to 24 weeks post-infection (Figure 47; [396]). In line with these observations of 
the anti-malaria antibody response, the total number of plasma cells in the spleen was 
greatest during the first two weeks of infection, then steadily declined until 6 weeks post­
infection, when it stabilised (Figure 48A). By contrast, the number of plasma cells in the 
bone marrow was similar to that in naYve mice at all time points.
The majority of plasma cells lost from the spleen between 2 and 4 weeks post-infection did 
not appear in the bone marrow (Figure 48C), indicating that these are short-lived cells. 
Plasma cells are terminally differentiated cells that do not undergo further cell division 
[493], therefore the loss of BrdU labelled cells from the spleen can only be due to either 
migration or cell death.
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Figure 47. Parasitaemia and anti-MSP-119 IgG antibody titres during 
primary P.chabaudi infection
A) Diagrammatic representation of primary P.chabaudi infection
B) Anti-MSP-119 IgG antibody during primary P.chabaudi infection 
Points represent mean value and SEM of 4-8 mice per timepoint
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Figure 48. Majority of plasma cells produced during P.chabaudi infection are short lived
A) Total number of plasma cells in spleen (-) and bone marrow (--) relative to naive 
controls
B) Experimental plan to show the period of BrdU labelling ( ■ ■ ) and sampling time 
points ( for spleen and bone marrow during infection
C) Total number of BrdU labelled plasma cells in spleen (-) and bone marrow (~) 
relative to naive controls
D) Experimental plan to show the period of BrdU labelling ( W M )  and sampling time 
points ( for spleen and bone marrow during infection
E) Total number of BrdU labelled plasma cells in spleen (-) and bone marrow (—) 
relative to naive controls
Points and bars represent the mean value +/- SEM of 3 age matched naive controls and 4-5 
infected mice per time point, and the horizontal black line indicates the normalised naive 
controls (100%)
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Due to changes in the splenic microarchitecture during the acute infection (Chapter 4, 
[346]), it is possible that plasma cells produced during the first two weeks of infection are 
unable to migrate out of the spleen to the bone marrow. We therefore looked at plasma 
cells that were produced between 2 and 4 weeks post-infection (experimental plan Figure 
48D). Similarly, large numbers of plasma cells were produced in the spleen between 2 and 
4 weeks post-infection, though slightly less than were produced during the first two weeks 
of infection. Those plasma cells that are produced at this time also do not remain in the 
spleen, and only a few migrate to the bone marrow (Figure 48E).
There are two possible mechanisms for maintenance of antibody responses -  production of 
long-lived plasma cells or continual turnover of short-lived plasma cells. The production of 
new plasma cells throughout the acute and chronic infection was investigated, by analysing 
spleens and bone marrow at the end of each BrdU labelling period (Figure 49A). Plasma 
cell production in the spleen was maximal during the first 4 weeks of infection, and similar 
to that in naYve mice thereafter (Figure 49B). Plasma cell production in the spleen at 12 
weeks post-infection remains higher in infected mice compared with that in naive mice, 
indicating that turnover of plasma cells continues at an elevated level throughout the 
chronic infection. However, this elevated production is more a reflection of small numbers 
of plasma cells in the naYve mice than large numbers in infected mice (approx. 9,000 in 
naYve cf. approx. 35,000 in infected mice) (Figure 49C). Plasma cell production is minimal 
during the chronic infection compared to plasma cell production during the acute infection 
(Figure 49B).
Plasma cell migration to the bone marrow is consistently at a similar or slightly lower level 
of that in naYve mice (Figure 49B, D), possibly indicating that fewer plasma cells
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Figure 49. Turnover of plasma cells during P . c h a b a u d i  infection and contribution of 
plasma cells formed throughout infection to plasma cell pool at 12 weeks post-infection
A) Experimental plan to show the period of BrdU labelling; 0-2 weeks ( ■■), 2-4 
weeks OHO, 4-6 weeks ( ■ ■  ), 6-8 weeks ( ) & 8-12 weeks (Mi ) Post-
infection; and sampling time points (^) for spleen and bone marrow during infection
B) Relative number of BrdU labelled plasma cells in spleen (■ ) and bone marrow 
(CD as a percentage of plasma cell numbers in naive controls
C) Absolute number of BrdU labelled plasma cells in naive (■ ) and infected ( ■ ) 
spleen
D) Absolute number of BrdU labelled plasma cells in naive ( □ )  and infected ( D ) 
bone marrow (2 femurs)
E) Experimental plan to show the period of BrdU labelling; 0-2 weeks ( W M ), 2-4 
weeks (■■), 4-6 weeks ( ■ ■  ), 6-8 weeks ( ) & 8-12 weeks (M l) Post- 
infection; and sampling time point ( J r) for spleen and bone marrow at 12 weeks 
post-infection
F) Relative number of BrdU labelled plasma cells in spleen (■ ) and bone marrow 
(CD as a percentage of plasma cell numbers in naive controls
G) Absolute number of BrdU labelled plasma cells in naive (■ ) and infected ( ■ ) 
spleen
H) Absolute number of BrdU labelled plasma cells in naive (Q) and infected ( □ )  
bone marrow (2 femurs)
Bars represent the mean value +/- SEM of 3 age matched naive controls and 4-5 infected 
mice per time point, the horizontal black line indicates normalised naive controls (100%)
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migrate to the bone marrow in infected mice in comparison to naTve mice, however plasma 
cell migration to the bone marrow does not differ between acute and chronic infection 
(Figure 49B).
Finally, we looked at plasma cells present in the spleen and bone marrow at 12 weeks post­
infection to see when they were produced (Figure 49E). The apparent peak in the number 
of plasma cells labelled between 4 and 6 weeks post-infection (Figure 49F) is due to half 
the samples from naTve spleens for this time point containing <1 plasma cell per 106 
splenocytes, and therefore being below our detection threshold. Absolute numbers of 
plasma cells not normalised to naTve mice are therefore shown (Figure 49G, H). Whilst a 
large proportion of plasma cells produced between 4 and 6 weeks post-infection are present 
in the spleen of infected mice compared to naTve mice (Figure 49F), the absolute number of 
these plasma cells is similar to the number produced between 8 and 12 weeks post-infection 
(Figure 49G).
The majority of plasma cells present in the spleen at 12 weeks post-infection are recently 
produced cells (between 6 and 8 weeks post-infection) (Figure 49F, G), again indicating 
elevated turnover of plasma cells in infected mice throughout the chronic infection and 
suggesting that continuous turnover of plasma cells maintains long-term antibody 
production. However, the second largest contribution to the pool of splenic plasma cells 
present at 12 week post-infection comes from plasma cells formed between 0 and 2 weeks 
post-infection (Figure 49F, G). This may indicate the production of some long-lived 
plasma cells in the spleen. The contribution of plasma cells produced at different time 
points to the bone marrow plasma cell pool does not differ much from that of nai've mice 
(Figure 49F, H), suggesting that long-lived plasma cells are not present in the bone marrow
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at 12 weeks post-infection, although we cannot exclude the possibility that the small 
number of plasma cells that do persist in the bone marrow are responsible, and sufficient, 
for long-term antibody production or that the anti-malaria serum antibody titre is not 
reflected by the number of long-lived plasma cells in the bone marrow.
F l u o r e s c e n t  l a b e l l i n g  o f  r e c o m b i n a n t  m a l a r i a  p r o t e i n s
In order to compare the kinetics and longevity of malaria-specific cells to total B cells and 
plasma cells, attempts were made to detect malaria antigen-specific B cells and plasma cells 
by flow cytometry. To visualise malaria-specific cells, recombinant malaria proteins were 
labelled with fluorescent moieities. The recombinant MSP-1 proteins and their location in 
the intact MSP-1 molecule are shown in Figure 50.
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Figure 50. Full length P . c h a b a u d i  MSP-1 molecule and recombinant proteins.
Full length protein ( □ ) ,  and two recombinant proteins [375, 376], that were labelled with 
fluorescent probes for detection of antigen-specific B cells and plasma cells ( □  ). 
Numbers underlined indicate location of natural proteolytic cleavage sites.
Figure adapted from [377]
Firstly, recombinant P . c h a b a u d i  MSP-119 was expressed in P i c h i a p a s t o r i s  with a histidine 
tag for purification [375], and was labelled with Alexa Fluor 647. The ideal fluorescent
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dye to protein (F:P) ratio for flow cytometry analysis is thought to be approximately 5-6:1 
[494], in order to obtain a good signal above background. This is especially important 
when dealing with low numbers of cells, such as expected for antigen-specific cells [495]. 
Alexa Fluor 647 labelling of MSP-119 gave an F:P ratio of no greater than 1:1, and we were 
unable to detect MSP-119 specific cells in flow cytometry analysis of MSP-119 immunised 
mice. The low labelling efficiency may be due to the structure of the C-terminus of MSP-1. 
Structural analysis has shown that MSP-119 is made of up two epidermal growth factor 
(EGF)-like domains with a C-terminal glycosyl phosphatidyl inositol (GPI) membrane 
anchor [358]. Unfortunately this means that there is a scarcity of lysine residues available 
on the surface, which provide the amine group that is essential for succinimidyl ester 
linkage of fluorescent moieties [494].
Therefore, a recombinant protein from the 38kDa portion of the MSP-1 protein complex 
that is shed on invasion was chosen, which is expressed in E.coli as a fusion protein with 
maltose binding protein (MBP) [376]. This protein, pMCKl 10, is more soluble than MSP- 
119, has a more open structure and is also more immunogenic [377]. Crucially, maltose 
binding protein provides more available lysine residues on the surface, which should 
provide a vehicle for better fluorescent labelling.
The F:P ratio obtained for Alexa Fluor 647 labelling of pMCKl 10 was approximately twice 
that obtained with MSP-119, at 1.8:1, which, although not ideal, is the highest degree of 
labelling that could be obtained with the recombinant MSP-1 proteins available. Chicken 
gammaglobulin (CGG) was used as a control protein, and labelled with an F:P ratio of 3:1.
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Detection o f antigen-specific cells
In order to test the feasibility of detecting antigen-specific cells, splenic B cells and plasma 
cells were analysed by flow cytometry 10-14 days after primary (CGG) or tertiary 
(pMCKl 10) immunisation. A low frequency of antigen-specific cells could be detected 
(Figure 51), however this was barely above that in naYve mice, and antigen-specific staining 
was not always greater than staining with the irrelevant control antigen. Double staining of 
antigen-specific cells with the same protein labelled with two different fluorophores, known 
as single epitope multi-staining (SEMS) [495], and pre-incubation of biotinylated protein 
with streptavidin to form biotin-streptavidin tetramers [268], have been reported to reduce 
background staining and allow clearer visualisation of antigen-specific B cells. Neither of 
these methods, however, were successful in allowing clear and reproducible identification 
of antigen-specific B cells and plasma cells in our hands.
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Figure 51. Feasibility of detecting antigen-specific cells by flow cytometry 
Spleens were taken from mice 10 days after primary immunisation with CGG or 14 days 
after tertiary immunisation with pMCKl 10. Approximately 5 x 10s cells were collected per 
sample.
A) FSC SSC profile showing live cell gate (-)
B) Single colour histogram showing CD19+ B cells
C) Single colour histogram of viable CD19+ B cells from CGG immunised mice 
stained with CGG-Alexa 647 (-) or with irrelevant Alexa 647 labelled protein 
(pMCKl 10) (-)
D) Single colour histogram of viable CD19+ B cells from pMCKl 10 immunised mice 
stained with pMCKl 10-Alexa 647 (-) or with irrelevant Alexa 647 labelled protein 
(CGG) (-)
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Discussion
This is the first study looking at the lifespan of B cells and plasma cells during a primary 
malaria infection in mice. The work in this chapter has shown that large numbers of B cells 
and plasma cells are found in the spleen during the acute infection. However, these cells 
are lost from the spleen during the chronic infection, and are probably short-lived as they 
do not appear in the bone marrow. There is a decrease in the B cell population of the bone 
marrow during the first 4 weeks of infection; plasma cell migration to the bone marrow is 
also consistently lower in infected than naYve mice, although the difference is much smaller 
than the difference in bone marrow B cell numbers during the acute infection. B cell and 
plasma cell production up to 12 weeks post-infection is still elevated in infected mice in 
comparison to naYve controls, indicating continuous turnover of B cells and plasma cells 
throughout the chronic infection.
The peak of B cell formation is during the first 2 weeks of infection, which is as expected 
with the increase in spleen size and number of splenic B cells at this time. After the peak of 
infection, the production of new B cells and plasma cells rapidly stabilises, fluctuating 
close to normal levels of production from 6 weeks post infection. We interpret this as B 
cell production returning to a normal level, and predict that these fluctuations would 
diminish after the clearance of chronic infection, until there is no difference between naYve 
and infected mice. It is interesting to note, however, that the alterations in B cell formation 
occur mostly during the acute infection, and that the homeostatic situation is mostly 
regained before residual parasitaemia is completely cleared.
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The majority of B cells that undergo cell division during the first 2 weeks of infection do 
not persist long as CD19+ B cells. Large numbers of these cells have been shown to 
undergo apoptosis [392], however others may have undergone further cell division, forming 
germinal centres and more plasma cells. We have shown that the loss of those B cells that 
divided during the first two weeks of infection from the spleen cannot be accounted for by 
migration of B cells to the bone marrow, by further cell division or by differentiation into 
plasma cells, indicating that the majority of these cells are indeed lost. Staining with an 
early apoptotic marker would confirm whether a large fraction of these B cells have died. 
For the majority of the period of observation, B cell production in the spleen remained 
elevated above the level of production in naive mice. It is also clear that the majority of 
splenic B cells present at 12 weeks post-infection were recently produced cells, that divided 
between 6 and 12 weeks post-infection. This suggests that B cell turnover may be 
independent of the presence of live parasites, which are eliminated between 8 and 12 weeks 
post-infection, although a stimulatory effect of residual parasite antigen cannot be 
excluded. It will be necessary to look beyond 12 weeks post-infection to determine 
whether B cell production continues at this elevated level for long after the clearance of live 
parasites.
If B cells are continually turning over for the entire 12 weeks of the infection, it raises the 
question of whether long-lived memory B cells are produced, when they may be produced, 
and how they are maintained. The mechanism by which antigen-experienced B cells are 
maintained has been controversial for some time (review [496]). Gray & Skarvall [399] 
showed that after adoptive transfer of memory B cells into an irradiated antigen- 
inexperienced host, no memory response could be elicited after 12 weeks. They concluded
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that the persistence of antigen was essential for the maintenance of memory B cells, and 
that in the absence of antigen, memory B cells have a half-life of 2-3 weeks. Memory cells 
that maintain themselves by continuous turnover would be more likely to require antigen- 
persistence than long-lived, non-cycling, memory B cells, and it is thought that persisting 
antigen would be maintained on follicular dendritic cells, although it is not know long 
antigen can be maintained on FDCs for. Antigen binding memory B cells, however, be 
seen in the marginal zone for up to a year after immunisation [207]. More recent work has 
argued that memory B cells can persist in the absence of antigen [248], and that survival of 
memory B cells does not require the persistence of antigen on FDCs [201].
In P.falciparum exposed humans with antibody responses to specific malarial antigens, 
memory B cells to those malarial antigens are not necessarily detectable in peripheral blood 
[400], suggesting that not all malaria infections resulted in the production of long-lived 
memory B cells. Similar observations have been made in some individuals after 
immunisation with tetanus toxoid [386]. These findings are in line with our experimental 
data on the total B cell pool, however it would be important to extend our work to the 
analysis of malaria-specific B cells.
A study of malaria-specific memory B cell responses [367] induced by vaccination of mice 
concluded that subsequent infection with P.yoelii induced deletion of malaria-specific 
memory B cells and long-lived plasma cells. However, the cell surface molecule, CD27, 
was used to identify memory B cells in this study. Whilst this has been shown to be a 
memory B cells marker in humans [237,485] it is not clear whether it similarly detects 
memory B cells in mice [240]. Further functional studies would be needed to verify these 
findings.
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The study of memory B cell production is hampered by the lack of a definitive cell surface 
molecule specific for memory B cells. We had hoped to bypass this by using fluorescently 
labelled antigen to identify malaria-specific B cells. Two major problems were 
encountered with this method. Firstly, the recombinant protein originally used, the C- 
terminal fragment of MSP-1 (MSP-119), was difficult to label with any fluorescent probe. 
This was probably due to its highly disulphide bonded globular structure [358], with few 
lysine residues available for succinimidyl ester linkage to the fluorescent probe. The 
second recombinant protein, from another part of MSP-1 (MSP-138, encoded by the 
plasmid pMCKl 10), was a fusion protein with maltose binding protein that had a more 
open structure with more lysine residues available. This protein was more readily labelled, 
however we were unable to obtain reliable, repeatable staining of plasma cells or memory 
B cells. The reason for the lack of visualisation of MSP-1 specific cells is likely to be the 
relatively low frequency of cells specific for any surface antigen of P.chabaudi. Previous 
studies from this lab have shown by limiting dilution assays that B cells specific for a crude 
mixture of malaria antigens was approximately 1 in 7,000 in the spleen [497], and 
ELISPOT analysis indicates that the frequency of MSP-119-specific memory B cells is 
approximately 1 in 80,000 during a primary infection (F. Ndungu, personal 
communication). At such a low frequency it would be very difficult to detect these cells by 
flow cytometry. The majority of reports describing flow cytometry analysis of antigen- 
specific B cells are from BCR transgenic mice which have a higher frequency of antigen- 
specific B cells [495], or in the response to NP ((4-hydroxy-5-nitrophenyl) acetyl) [498- 
500] where the frequency of NP-specific B cells is approximately 1 in 15-20,000 [501], 
compared to 1 in 80,000 for MSP-119, rendering FACS analysis of these cells more
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feasible. A malaria-specific BCR transgenic mouse would be an ideal tool for the 
measurement of antigen-specific B cell responses during P.chabaudi infection.
Given the low number of malaria-specific memory B cells present in the spleen, and the 
improbability of detecting these by flow cytometry, we can say little about the production 
and maintenance of malaria-specific B cells. Although we have not been able to 
definitively identify malaria-specific memory B cells, our work on total B cell production 
and turnover suggests that continual turnover of B cells is a more likely mechanism for 
maintenance of memory B cells than the production of long-lived memory B cells during 
the 12 weeks of primary P.chabaudi infection. Further work, however, would be required 
to give a more definitive answer to this question.
The low level of B cell production in the bone marrow of infected mice compared with 
naive mice during the first 2 weeks of infection was unexpected. B cell production in the 
bone marrow recovers quickly, however, and has returned to normal levels by 6 weeks 
post-infection. Previous studies have documented a decrease in cellularity in the bone 
marrow during acute malaria infection [342-344], although most studies on the composition 
of the bone marrow during malaria infection have focused on erythropoietic cells rather 
than on lymphoid cells.
There are two possible explanations for the lower numbers of B cells in the bone marrow 
during acute infection. The first is that all newly produced B cells may be quickly exported 
from the bone marrow to the spleen in response to the infection. This hypothesis assumes 
that export of B cells from the bone marrow can be increased, which is supported by the 
increased number of B cells observed in the spleen at this time. Regulation of B cell 
production in the bone marrow appears to be independent of feedback from the mature B
cell pool -  i.e. proliferation of B cell progenitors is not affected by the number of mature B 
cells [502], therefore B cell production in the bone marrow should not be reduced as a 
consequence of large numbers of B cells in the spleen. B cell proliferation can, however, 
be prevented by elimination of macrophages by silica injection and by splenectomy [502], 
therefore the loss of macrophages from the marginal zone (Chapter 4) may be directly 
related to the reduction in the number of bone marrow B cells. It would be interesting to 
discover whether the presence of macrophages in the marginal zone and the level of B cell 
production in the bone marrow are causally related, or whether they are both symptoms of 
an unknown underlying cause.
The second possibility is that the high levels of pro-inflammatory cytokines in the blood 
during the initial stages of malaria infection suppress B cell production in the bone marrow. 
Levels of IL-1 in particular have been shown to suppress B cell production in the bone 
marrow [503], which may be worth investigating further. In agreement with this, bone 
marrow cellularity has been shown to decrease by up to 80% during acute malaria infection 
(D. Brown et al, in preparation) [342-344]. These two possibilities are not mutually 
exclusive, and the decline in the number of B cells in the bone marrow at 2 weeks post­
infection could be due to a combination of increased export and decreased production of B 
cells.
Suppression of B cell production in the bone marrow has been demonstrated in several 
bacterial, viral and parasitic infection [504-506], and in influenza infection was shown to be 
due to apoptosis of early B cells mediated by TNFa/LTa [507]. This has been 
hypothesised to be responsible for the poor development of immunity to subsequent 
heterologous infections (e.g. influenza) [504]. Large amounts of TNFa/LTa are produced
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during acute malaria infection [151, 172,259], therefore suppression of B cell production 
by TNFa/LTa may be an important mechanism in malaria-induced immunosuppression 
during acute infection. This would, however, probably affect only immune responses to 
antigens encountered during the acute infection, and should not affect immune responses to 
antigens encountered at other times (e.g. to vaccination). TNFa/LTa is, however, 
important for memory responses, as mice lacking the TNFRI undergo a similar course of 
infection during secondary malaria infection as in primary infection [147]. A balance is 
therefore necessary, between the levels of TNFa/LTa required for the production of 
memory responses, and over-production of TNFa/LTa that causes suppression of B cell 
production in the bone marrow. Interestingly, bone marrow B cell production is also 
suppressed during pregnancy [508], which may be one reason for the increased 
susceptibility of pregnant women to malaria infection [509].
In addition to short-lived B cells in P.chabaudi infection, the majority of plasma cells 
produced during the first 4 weeks of infection are also short-lived. This result was 
expected, as it is highly unlikely that either the spleen or the bone marrow would have the 
capacity to support such a large number of plasma cells for long. It is not known, however, 
how many plasma cells the bone marrow is capable of supporting. Despite the increase in 
plasma cell numbers, there is little change in migration of plasma cells to the bone marrow 
at any of the time points investigated, suggesting that plasma cell migration to the bone 
marrow may be inhibited during malaria infection. Expansion of plasma cells in the 
P.chabaudi infection co-incides with a large inflammatory response in the spleen [151, 
259], which may help to retain plasma cells in the spleen, as it has been shown that plasma 
cells produced in an inflammation-associated immune response remain at the site of
inflammation rather than migrating to the bone marrow [510]. Alternatively, the extent of 
changes observed in the splenic microarchitecture during the acute malaria infection 
(Chapter 4) may prevent plasma cells from migrating to the bone marrow. Although the 
changes in the splenic microarchitecture are reversed by 8 weeks post-infection [346], 
plasma cells are only responsive to migratory chemokines for 2 weeks after formation 
[488].
Previous work in our laboratory has shown that the total number of plasma cells resident in 
the spleen during acute P.chabaudi infection is much greater than that produced after 
immunisation with CGG [346]. Here we show that plasma cell numbers in the bone 
marrow are somewhat lower during acute malaria infection than in naTve mice. There is 
very little information available on total plasma cell numbers in other infections or 
immunisations, however there are reports on antigen-specific plasma cell responses in the 
spleen and bone marrow.
Total numbers of plasma cells per two femurs range from 2-4 x 105 cells in naive mice, 
consistently slightly lower in malaria infected mice. In a study of virus-specific plasma 
cells, [231] showed that approximately 2,500 virus-specific plasma cells per two femurs 
could be seen in total bone marrow by day 15 post-infection, and that the number of virus- 
specific plasma cells in the bone marrow remained between 2,500-3,800 per two femurs up 
to day 103. This indicates that approximately 1% of bone marrow plasma cells are specific 
for one particular antigen. If we therefore assume that antigen-specific plasma cells 
constitute 1% of the total number of plasma cells in infection or immunisation, it is possible 
to compare our data with other studies (Table 8).
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Table 8. Comparison of estimated number of total plasma cells produced in response to 
infection or immunisation
Infection/ Immunisation
Total number of plasma cells
Spleen Bone marrow (2 femurs)
Naive mice 1x10s 2-4 x 105
P.chabaudi day 14 5 x 106 2 x10s
CGG day 10a) 3.75 x 105 ND
LCMVday 8 b) lx lO 6 4-5 x 104
Tetanus toxoid (2° imm. day 10)c) 3-4 x 10s 1.5-2 xlO4
Ovalbumin ~ day 7 * 1.5 x 107 7x10s
NP - d a y 7 e) 5x 106 2x  10s
ND = not done
With the exception of the response to OVA immunisation, the numbers of plasma cells 
detected during acute malaria infection are within the range described by others during 
infection and immunisation.
Migration of newly formed plasma cells to the bone marrow does not appear to alter 
throughout acute and chronic infection, and is consistently lower than that in naive mice. 
This contrasts with observations of LCMV-specific plasma cells, where it was shown that 
80% of LCMV-specific plasma cells were present in the bone marrow by day 30 post­
infection, and the the number of antigen-specific plasma cells in the bone marrow remained
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at a relatively high level for up to 103 days [231]. Therefore, it seems that the situation in 
P.chabaudi infection is different, and our observations indicate that plasma cell migration 
to the bone marrow is defective in the malaria infection. Inhibition of plasma cell 
migration to the bone marrow could explain the lack of long-lived antibody responses seen 
to many malaria antigens in humans [177, 311,313,314,470-472], and the drop in 
antibody titre at 4 weeks in P.chabaudi infection [396] (Figure 49).
The decay in the number of plasma cells in the spleen slightly precedes the reduction of 
anti-malaria IgG antibody responses between 1 and 2 months post-infection. Short-lived 
plasma cells in extrafollicular antibody responses been shown to have a half-life of 3-5 days 
[148], therefore between 2 and 4 weeks post-infection (discounting production of new 
plasma cells), plasma cell numbers would be reduced to between 3% and 12.5% of those 
present at 2 weeks post-infection. The decay of serum antibody titre lags behind that of 
plasma cell numbers, as serum y-globulin has a half life of approximately 4 days at normal 
concentration [473]. Catabolism of y-globulin is increased at the peak of infection and 
returns to normal by day 12-18 post-infection [476], therefore the anti-malaria IgG titre 
should mirror the reduction in numbers of plasma cells with a delay of approximately 4 
days. Splenic plasma cell numbers return to numbers similar to that of naive mice between 
4 and 6 weeks post-infection. Likewise, the anti-malaria serum antibody titre drops linearly 
from 4 weeks post-infection, and continues to drop as the number of plasma cells in the 
spleen stabilises. This indicates that there is a large short-lived plasma cell and antibody 
response.
During the chronic phase of infection (4-12 weeks), it appears that no long-lived plasma 
cells are generated, as most of the plasma cells present in both the spleen and bone marrow
at 12 weeks post-infection are those that were produced from cells dividing between 6 and 
12 weeks post infection. Plasma cell production in the spleen is also elevated above that 
seen in naive animals at 12 weeks post-infection, therefore the low level long-lived 
antibody response observed in P.chabaudi infection could be the product of short-lived 
plasma cells continously turning over throughout the chronic infection. Whether the 
antibody response subsequent to clearance of chronic infection at 8-12 weeks post-infection 
is due to these short-lived plasma cells, or to long-lived plasma cells generated after 
clearance of parasitaemia, remains to be determined. The threshold number of plasma cells 
required to maintain a protective serum antibody response is not known, however the 
number of plasma cells and the low level of long-lived malaria-specific antibody is 
sufficient to provide protection against challenge infection, at least up to 6.5 months after 
primary infection, as mice exhibit good immunity to secondary P.chabaudi infection [396, 
512].
Maintenance of the long-lived antibody response by continuous production of plasma cells 
could be verified by treating mice with cyclophosphamide, an alkylating agent and potent 
suppressor of B cell activity and antibody production [513] during the chronic infection. 
This treatment would prevent production of new plasma cells, but would not eliminate 
long-lived plasma cells that had already been formed [514]. If anti-malaria serum antibody 
titres drop after this treatment, this would demonstrate a requirement for continued 
production of plasma cells in order to maintain anti-malaria antibody production.
Antibody responses to immunisation commonly last for many years. In humans, antibodies 
and memory B cells to vaccines composed of attenuated viruses such as smallpox have 
been detected up to 75 years after immunisation [249,250]. Not all responses to
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vaccination are this long-lived, however, and some decay to low or pre-immunisation levels 
within 4 years (review [262]). Antibody responses in mice can also persist for long periods 
of time (review [515]). This contrasts with antibody responses of humans to malaria 
antigens, where some responses decay within months of infection [177,311,313,314,470- 
472].
The maintenance of serum antibody levels has been hypothesised to be due to either 
continual production of short-lived plasma cells from antigen-experienced B cells, or 
production of long-lived plasma cells. One mechanism for maintaining low levels of serum 
antibodies for a lifetime has been suggested to be polyclonal activation of memory B cells 
to produce plasma cells [516]. Whether or not a low level of plasma cell turnover is 
required for the maintenance of antibody responses is still under debate [515]. Our data so 
far provide no evidence that long-lived B cells or plasma cells are generated the first 12 
weeks of primary P.chabaudi infection, contrary to observations in other infections [231]. 
In summary, we have shown that large numbers of short-lived B cells and plasma cells are 
produced during acute malaria infection, that there may be some defect in plasma cell 
migration to the bone marrow, that kinetics of plasma cell formation agree with kinetics of 
anti-malaria serum antibody titres, and that the likely mechanism for maintenance of long­
term anti-malaria serum antibody titres is continuous turnover of B cells and plasma cells. 
Future directions for this work should include the development of a transgenic system to 
investigate antigen-specific B cells and plasma cells, the extension of these studies to later 
timepoints in the primary infection and to include an investigation of B cell and plasma cell 
responses in secondary infection. ELISPOTs are a more sensitive assay for detecting small 
numbers of memory B cells and plasma cells, both total numbers of antigen-producing cells
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and numbers of antigen-specific cells. These also have the advantage that they require no 
genetic modification of mice. Whilst a transgenic mouse with malaria-specific B cells has 
the advantage of greater numbers of antigen-specific cells for flow cytometry analysis, it is 
nevertheless not a natural situation and therefore care must be taken when drawing 
conclusions from such work. A study of plasma cell migration would also be useful, to 
determine if migration to the bone marrow is inhibited during primary malaria infection, as 
well as further investigation of suppression of B cell production during acute infection. A 
comparison of both total and antigen-specific B cell and plasma cell responses in malaria 
infection to other infections and to immunisation would also be informative, as the 
migration of long-lived plasma cells to the bone marrow in response to infection has not 
been investigated. We need to understand why long-lived B cells and plasma cell do not 
appear to be generated in response to malaria infection if we hope to be able to induce long- 
lived responses to malaria by vaccination.
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Conclusions
After decades of research into immune responses to malaria infection, we still do not know 
how immunity to malaria is formed, or why it takes so long to develop in humans. Changes 
in the splenic microarchitecture have been observed previously [345,346, 517], however as 
the first step in relating these changes to the development of the immune response, the 
alterations in the splenic microarchitecture during the acute infection were documented in 
detail.
Changes in the microarchitecture of the spleen are extensive, yet die significance of them in 
terms of benefit or harm to the host, and whether they are part of a normal or dysregulated 
immune response, is still unclear. It is entirely possible that the merging of the T and B 
cells zones is a normal physiological response to infection, allowing the cognate interaction 
between T and B cells, that is required for T-dependent antibody responses, to occur. This 
would agree with the observations that germinal centres are formed in response to malaria 
infection, and a strong anti-malaria IgG antibody response is produced. Whilst germinal 
centers are formed, it is however possible that they may not have formed the division 
between dark and light zones, as this division is dependent on the appropriate production of 
chemokines that are also required for maintenance of the splenic microarchitecture [156]. 
The correct formation of germinal centres in acute malaria infection, and the interactions 
between T, B and dendritic cells, should be investigated to determine whether these 
alterations are part of a normal physiological response to infection, or part of an 
inappropriate, dysregulated response.
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The spleen is the main secondary lymphoid organ involved in the immune response to 
malaria infection, as because of the large amount of blood flowing through the spleen, the 
cells of the spleen are in close contact with the parasite in the blood. However, lymph 
nodes are also secondary lymphoid organs, yet little work has been done on their role in 
immune responses to malaria infection. We do not know what effect the absence on lymph 
nodes in the presence on the spleen would have on susceptibility to infection, and we also 
do not know how, or if, the lymph node architecture is altered during malaria infection, or 
if this phenomenon is unique to the spleen. Whilst it would be technically difficult to 
perform the surgery necessary to remove all lymph nodes from a mouse, an investigation of 
lymph node microarchitecture during acute malaria infection should be carried out.
The cause of rearrangement of the splenic microarchitecture, whether or not it is caused by 
a parasite antigen and is related to the level of parasitaemia, and the signalling pathways 
involved have also not been determined. A single injection of the TLR ligand LPS causes 
some of the same alterations in architecture seen in malaria infection [349]. Repeated 
injections of LPS or other TLR ligands, to mimic the proliferation of a replicating antigen, 
may cause changes in the splenic microarchitecture that further resemble those seen in 
malaria infection. Alternatively, infection of mice lacking TLRs may fail to produce these 
alterations in the microarchitecture, and such a result would indicate a direct role for TLRs 
in the mechanism of these changes. A study of splenic microarchitecture in a secondary 
malaria infection, where the parasitaemia and pathology are reduced, might also indicate 
whether these changes are related to parasite numbers.
We have hypothesised that the alterations in splenic microarchitecture are caused by lack of 
signalling through the LTfS signalling pathway, as our observations agree with many
observations made of splenic microarchitecture in LT(5 KO mice [170]. We therefore 
treated mice with a lymphotoxin-p receptor agonist antibody to try and prevent the 
alterations in splenic microarchitecture from occurring. Although this was unsuccessful, 
the problem may have been due to technical difficulties such as insufficient antibody dose, 
and this hypothesis would therefore benefit from further investigation. Reduction of LTp 
signalling has also been associated with increased susceptibility to Ldonovani and viral 
infection, secondary to alterations in the lymphoid microarchitecture [518].
One key observation was that large numbers of plasma cells were found in the spleen 
shortly after the peak of infection, which did not persist long-term [346]. We wanted to 
know whether these cells were short-lived, or whether they migrated to the bone marrow to 
become long-lived plasma cells. We hypothesised that the majority of these plasma cells 
would be short-lived, with a small number of long-lived plasma cells colonising the bone 
marrow.
Our results agreed with this hypothesis, with some plasma cells produced during the 
malaria infection migrating to the bone marrow, and a few becoming long-lived plasma 
cells. However, this number is less than the number of plasma cells establishing in naTve 
mice, and also less than the optimal number of plasma cells calculated to be required to 
maintain long-term protective antibody responses [519]. This indicates that there may be 
some defect in plasma cell migration to the bone marrow, either in trapping plasmablasts in 
the spleen during their migration window, in production of bone marrow homing 
chemokines, or in plasmablast responsiveness to chemokines. Of these three possibilities, 
the first is most likely, as reorganisation of the spleen has already been demonstrated, and 
may well make it difficult for plasma cells to migrate out. As blood flows through the bone
marrow, pRBC may also be found in the bone marrow, and may thereby interfere with the 
production of chemokines by bone marrow stromal cells. Alternatively, the unusual 
environment of the reorganised spleen may either interfere with the appropriate expression 
of receptors for bone marrow chemokines, or may favour the production of splenic, rather 
than migratory, plasma cells. Future work on this could include a study of the 
responsiveness of plasma cells to migratory chemokines, the expression of chemokines by 
bone marrow stromal cells and of chemokine receptors by plasma cells.
The increased turnover of B cells and plasma cells in chronically infected mice in 
comparison to naive mice was unexpected. Whether this turnover is dependent on live 
parasites or on antigen retained on FDC is an important question that should be addressed. 
This could be done by extending these experiments to later timepoints post-infection, and 
by cyclophosphamide treatment of mice (to eliminate plasmablasts but not mature plasma 
cells) after clearance of chronic infection [513], thereby establishing whether long-term 
antibody titres are maintained by mature plasma cells, or by continual cycling of 
plasmablasts. If continual, antigen dependent, cycling of B cells and plasmablasts is 
necessary to maintain long-term antibody titres against malaria antigens, any vaccine would 
need to be able to provide a stable, long-term repository of antigen in order to maintain 
protective antibody titres.
In order to study the effects of chronic infection, and the presence or absence of chronic 
infection, on the development of the immune response, we first needed to establish how 
long the chronic infection persists for, and this was done successfully. As many infections 
in malaria endemic areas are cleared early by drug treatment, it would be useful to 
investigate the differences in the development of the immune response in hosts that
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undergo chronic infection compared to those which are drug cured. This could have major 
significance for the management of malaria infection, if elimination of infection by drug 
treatment adversely affects the development of the immune response.
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Summary
The extent of chronic P.chabaudi infection has now been established in two mouse strains. 
This is an important step to allow us to study the development of memory responses, the 
impact of chronic infection on the development of memory responses, the effect of chronic 
infection on immune responses to secondary malaria infection and the impact of chronic 
infection on immune responses to unrelated antigens. The difference in clearance of the 
chronic infection between the two mouse strains was unexpected, and raises interesting 
questions about how the speed of clearance of low-level infection is regulated, and about 
which response is better for the host. A comparison of the development of memory B cells, 
memory T cells and long-lived plasma cells between the two strains could be very 
informative.
The detailed analysis of the splenic microarchitecture allows us to pinpoint the order and 
timing of these changes. Whilst other investigators have previously described some of 
these alterations, we can now for the first time put them in sequence and closely follow 
their development. It is intriguing that whilst infected red blood cells can be seen in the 
spleen as little as 1 hour post-infection, it takes five days for the alterations in splenic 
microarchitecture to become visible. The first populations of cells to change their location 
are the dendritic cells, which is to be expected as these are the initiators of the adaptive 
immune response. This is swiftly followed by the beginning of the breakdown in 
separation between B and T cell zones, which is completed within the next 5 days. 
Marginal zone B cells and macrophages then migrate away from the marginal zone, as the 
expression of the adhesion molecule MAdCAM-1 expands to cover the white pulp area.
Finally, a large number of plasma cells can be seen in the spleen from day 8 post-infection 
(Figure 52). Despite all these alterations, there are some cell populations that are less 
affected. For example, red pulp macrophages do not alter their location, although they may 
increase in number.
The mechanism underlying these changes is an intriguing mystery. There is growing 
evidence that downregulation of chemokines is responsible for these changes [174,179], 
however the initial trigger remains unknown. Such alterations to the splenic 
microarchitecture are not unique to malaria infection, and occur to a greater or lesser extent 
in other parasitic and viral infections [172,174]. The lack of alterations during the first 
four days of infection, despite the presence of parasites in the spleen, indicates a threshold 
for the triggering of these changes, which may be temporarily self-perpetuating once they 
have begun. If parasite triggering of TLRs is responsible for initiating these changes, then 
it is logical that the number of parasites would need to increase before alterations were 
observed. A comparison of alterations in splenic microarchitecture between primary and 
secondary infection, or between low and normal inoculums of primary infection may shed 
some light on this.
It is not surprising that the majority of B cells and plasma cells produced during the acute 
infection are short-lived, however the reduction in B cell numbers in the bone marrow 
during acute infection, and the scarcity of long-lived plasma cells in the bone marrow was 
not predicted. Our results suggest that there may be suppression of B cell production in the 
bone marrow during acute infection, and that there may also be a defect in plasma cell 
migration to the bone marrow at this time. Our results also point towards the continuous 
turnover of B cells and formation of plasma cells throughout the chronic infection as a
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mechanism for the maintenance of long-term antibody titres, although further work is 
required to substantiate this. The inability to detect antigen-specific B cells and plasma 
cells by flow cytometry was disappointing, however future work detailing the antigen- 
specific B cell response to malaria infection should prove to be very interesting.
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